Compounds for targeting and degrading proteins and methods for their preparation and use - Patents.com

PROTAC compounds degrade IRAK4 by combining a small molecule inhibitor with an E3 ubiquitin ligase ligand, addressing drug resistance and effectively targeting IRAK4 in autoimmune and inflammatory diseases, providing a new therapeutic approach for conditions such as cancer.

JP7591301B2Active Publication Date: 2024-11-28LEADING PHARMACEUTICAL (SHAOXING) CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2022573195
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-12-18
Filing Date
2021-08-05
Publication Date
2024-11-28
Estimated Expiration
2041-08-05

AI Technical Summary

Technical Problem

Conventional small molecule inhibitors for IRAK4 are prone to drug resistance due to point mutations, and they do not effectively address the kinase and scaffold functions of IRAK4, limiting their therapeutic efficacy in autoimmune, inflammatory, and neoplastic diseases.

Method used

Development of PROTACs (Proteolysis Targeting Chimera) compounds that combine a small molecule inhibitor of IRAK4 with a ligand for E3 ubiquitin ligase, facilitating the degradation of IRAK4 through the ubiquitin-proteasome pathway, thereby overcoming drug resistance and targeting both kinase and scaffold functions.

Benefits of technology

PROTACs provide efficient degradation of IRAK4 with lower doses, avoiding resistance and effectively targeting IRAK4-mediated diseases by degrading the protein, offering a promising new approach for treating conditions like cancer, immune diseases, and inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591301000001
    Figure 0007591301000001
  • Figure 0007591301000002
    Figure 0007591301000002
  • Figure 0007591301000003
    Figure 0007591301000003
Patent Text Reader

Abstract

The present invention provides bifunctional compounds, pharmaceutical compositions, and methods for preparing the same that target the degradation of IRAK4 kinase protein. The compounds described in the present invention not only effectively inhibit and / or degrade IRAK4 kinase protein in cells, but also effectively inhibit the production of IL-6 by immune cells, demonstrating good degradation selectivity. They can be used to prepare drugs for treating and / or preventing IRAK4-mediated diseases or conditions, such as cancer, immune disorders, and inflammatory diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to the field of medicine, specifically, the present invention relates to compounds that target the degradation of IRAK4 protein, pharmaceutical compositions and methods for their preparation, and their use in the preparation of medicaments for the treatment and / or prevention of IRAK4-mediated related diseases or conditions, such as cancer, immune diseases and inflammatory diseases. [Background technology]

[0002] Interleukin-1 receptor kinase 4 (IRAK4) is a serine / threonine-specific protein kinase with biologically significant kinase activity that plays a key role in immune system activation. Research has shown that IRAK4 is a key downstream factor in the interleukin IL-1β family receptor (including IL-1R, IL-18R, IL-33R, and IL-36R) and Toll-like receptor (TLR) signaling pathways. IRAK4-deficient mice and patients are unresponsive to stimulation by all TLRs (except TLR3) and the IL-1β family.

[0003] Depending on the involvement of MyD88, TLR / IL-1α and IL-1β signaling pathways can be divided into MyD88-dependent and MyD88-independent pathways. The signaling pathways mediated by IL-1R, TLR2, TLR4, TLR7 / 8, and TLR9 all depend on MyD88 as a regulator to activate downstream inflammatory signaling pathways. After TLR / IL-1β binds its ligand, it recruits MyD88 molecules, which further recruit IRAK4 to the TLR / IL-1β complex via its N-terminal death domain. MyD88 then interacts with and activates IRAK1 or IRAK2, transmitting the signal to the downstream E3 ubiquitin ligase TNF receptor-associated factor (TRAF6), which activates the serine / threonine kinase TAK1, which in turn activates the NF-κB and MAPK signaling pathways, resulting in the release of various proinflammatory cytokines and anti-apoptotic molecules. The IRAK4-dependent TLR / IL-1β signaling pathway is involved in a variety of diseases, including multiple sclerosis, atherosclerosis, myocardial infarction, myocarditis, Vogt-Koyanagi-Harada syndrome, systemic lupus erythematosus (SLE), obesity, type 1 diabetes, rheumatoid arthritis, spondyloarthritis (particularly psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, psoriasis, vitiligo, giant cell arteritis, chronic inflammatory bowel disease, viral diseases such as HIV (human immunodeficiency virus) and hepatitis viruses, skin diseases such as psoriasis, atopic dermatitis, Kindler's syndrome, bullous pemphigoid, allergic contact dermatitis, alopecia areata, acne inversa, and acne vulgaris, including allergies, Behçet's disease, gout, and adult-onset Still's disease. Other inflammatory diseases such as ulcerative colitis and Crohn's diseasepericarditis and chronic inflammatory bowel disease such as pericarditis and chronic inflammatory bowel disease, transplant rejection and graft-versus-host reaction, gynecological diseases such as endometriosis, dysmenorrhea, dyspareunia and other symptoms associated with endometriosis, particularly pain associated with endometriosis and other symptoms associated with endometriosis such as dysmenorrhea, dyspareunia, dysuria and difficulty in defecation, eye diseases such as retinal ischemia, keratitis, allergic conjunctivitis, keratoconjunctivitis sicca, macular degeneration and uveitis, fibrotic diseases such as liver fibrosis, myocarditis, primary biliary cirrhosis, cystic fibrosis, chronic liver diseases such as steatohepatitis, particularly non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), myocardial reperfusion injury, myocardial infarction, hypertension, Alzheimer's disease, stroke, traumatic brain injury, muscle atrophy It has been shown to be associated with a variety of diseases, including cardiovascular and neurological disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease; pruritus and pain (including acute, chronic, inflammatory, and neuropathic pain) such as pain hypersensitivity, allodynia, premenstrual pain, pain associated with endometriosis, postoperative pain, interstitial cystitis, CRPS (complex regional pain syndrome), trigeminal neuralgia, prostatitis, pain due to spinal cord injury, pain due to inflammation, lower back pain, cancer pain, chemotherapy-related pain, HIV treatment-induced neuropathy, burn pain, and chronic pain; and oncological diseases such as certain lymphomas: ABC-DLBCL (activated B-cell diffuse large B-cell lymphoma), mantle cell lymphoma, and Waldenstrom's disease, chronic lymphocytic leukemia, melanoma, pancreatic cancer, and hepatocellular carcinoma, ras-dependent tumors, breast cancer, ovarian cancer, colorectal cancer, head and neck cancer, lung cancer, and prostate cancer.

[0004] Regulation of IRAK4-mediated signaling pathways is primarily related to its kinase function; however, there are also reports that IRAK4 regulates downstream processes through its non-kinase functions in certain cell types. Cushing et al. demonstrated that IRAK4 phosphorylation levels were reduced in human skin fibroblasts stimulated with IL-1β, but pharmacological inhibition of IRAK4 did not result in inhibition of IL-6 and TNF-α. Supporting these results, compared with wild-type cells, the scaffolding function of IRAK4 in IRAK4-deficient fibroblasts is crucial for IL-1 signaling, but its kinase activity is redundant. Concurrently, Chiang et al. demonstrated that IRAK4 kinase activity is not essential in human B and T cells, dendritic cells, and monocytes, and siRNA gene ablation also indicates that IRAK4 has a scaffolding function in these cells. Various potent and selective inhibitors of IRAK4, such as CA-4948, BAY-1834845, BMS-986126, and PF-06650833, have been reported. These inhibitors can selectively inhibit IRAK4 kinase activity and are primarily used for the prevention and treatment of autoimmune, inflammatory, and neoplastic diseases. However, because IRAK4 acts as both a scaffolding protein and an active kinase, and traditional small molecule inhibitors are prone to drug resistance, inhibition of IRAK4 kinase activity alone may not be sufficient to produce a therapeutic effect.

[0005] Proteolysis Targeting Chimeras (PROTACs) are a technology that differs from conventional small molecule inhibitors. Conventional small molecule inhibitors typically act on the active site of a target protein to inhibit its activity. In contrast, PROTACs are heterobifunctional molecules, with one end consisting of a small molecule inhibitor that can recognize the target protein and, via a linker chain, an E3 ubiquitin ligase ligand that can recognize the E3 ubiquitin ligase. Such bifunctional molecules recognize the target protein and E3 ubiquitin ligase in vivo, bringing the two together to form a ternary complex that ubiquitinates the target protein and then degrades it via the ubiquitin-proteasome pathway in the body. Compared to traditional small molecule inhibitors, PROTACs degrade substrates simply by bringing the target protein and E3 ubiquitin ligase into close proximity. This mode of operation allows this technology to be used on some undruggable targets. After the target protein is degraded, the PROTAC molecule is released and can continue to participate in the degradation of the next protein. This catalytic degradation action allows for efficient degradation with a lower dose of PROTAC. Traditional small molecule inhibitors are often prone to drug resistance due to point mutations, which can cause small molecule inhibitors to lose their inhibitory effect on the target. PROTACs can directly degrade the target protein, thereby circumventing point mutation-induced drug resistance to some extent. Therefore, compared to traditional small molecule inhibitors, the development of small molecule drugs using PROTAC technology has great merit and feasibility, making them promising new drugs for the next generation. PROTAC technology can also be used to modify various drug targets, such as the androgen receptor, estrogen protein receptor, and BTK. US2019 / 0151295, US2019 / 0192688, WO2019 / 160915 and WO2020 / 113233 disclose degraders that target IRAK4, and further degraders that target IRAK4 remain to be developed. Summary of the Invention

[0006] The present invention provides compounds of formula I, and / or stereoisomers, enantiomers, diastereomers, deuterated forms, hydrates, solvates, prodrugs and / or pharmaceutically acceptable salts thereof, Formula I:PTM-L-ULM where: PTMs are small molecule compounds that can inhibit or bind to the IRAK4 kinase protein. L is a linker chain that covalently connects the PTM and ULM; ULM is a small molecule ligand of an E3 ubiquitin ligase complex, said ULM having the structure of the following formula: [ka] wherein, in the ULM-1, X'' is CH or N; Y″ is CH, N, O or S; Q1, Q2, Q3, Q4, and Q5 are each independently 3 '' or N, each R3" is independently hydrogen, deuterium, hydroxyl, amino, cyano, halogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -O(C1-C6 alkyl), -O-(C3-C8 cycloalkyl), -O-(3- to 8-membered heterocycloalkyl), N(C1-C6 alkyl), NH(C3-C8 cycloalkyl), NH(3- to 8-membered heterocycloalkyl), -O-(6- to 10-membered aryl), or -O-(5- to 10-membered heteroaryl), wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally substituted with 1 to 3 groups independently selected from hydroxyl, halogen, cyano, and amino, or R3" together with the atom to which it is attached forms a cycloalkyl, heterocycloalkyl, heteroaryl, or aryl group; m'' is 1, 2 or 3; R1" each independently represents hydrogen, deuterium, a hydroxyl group, an amino group, a cyano group, a halogen atom, a C1-C6 alkyl group, a C3-C8 cycloalkyl group, a 3- to 8-membered heterocycloalkyl group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group, or -O(C1-C6 alkyl), wherein the alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group, or heteroaryl group is optionally substituted with 1 to 3 groups independently selected from a hydroxyl group, a halogen atom, a cyano group, and an amino group; R2'' is none, hydrogen, deuterium, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group, wherein the C1-C6 alkyl group and the C3-C6 cycloalkyl group are optionally substituted with 1 to 3 groups independently selected from a hydroxyl group, a halogen, -O-(C=O)-(C1-C6 alkyl), a cyano group, or an amino group.

[0007] In some embodiments of the invention, the ULM-1 X'' is CH or N; Y″ is CH, N, O or S; Q1, Q2, Q3, Q4, and Q5 are each independently CR3″ or N; R3'' is independently hydrogen, deuterium, a hydroxyl group, an amino group, a cyano group, a halogen, a C1-C6 alkyl group, a C3-C8 cycloalkyl group, a 3- to 8-membered heterocycloalkyl group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group, -O(C1-C6 alkyl), -O-(C3-C8 cycloalkyl), -O-(3- to 8-membered heterocycloalkyl), or N(C1-C6 alkyl). 1-2 , NH(C3-C8 cycloalkyl), NH(3-8 membered heterocycloalkyl), -O-(6-10 aryl), -O-(5-10 membered heteroaryl), wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted with 1 to 3 groups independently selected from hydroxyl, halogen, and amino groups; m'' is 1, 2 or 3; R1" each independently represents hydrogen, deuterium, a hydroxyl group, an amino group, a cyano group, a halogen atom, a C1-C6 alkyl group, a C3-C8 cycloalkyl group, a 3- to 8-membered heterocycloalkyl group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group, or -O(C1-C6 alkyl), wherein the alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group, or heteroaryl group is optionally substituted with 1 to 3 groups independently selected from a hydroxyl group, a halogen atom, and an amino group; R2'' is hydrogen, deuterium, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group, wherein the C1-C6 alkyl group and the C3-C6 cycloalkyl group are optionally substituted with 1 to 3 groups independently selected from a hydroxyl group, a halogen, or an amino group.

[0008] In some embodiments of the present invention, one or two of Q1, Q2, Q3, Q4, and Q5 in ULM-1 are N, and the remaining are each independently CR3''. In some embodiments of the invention, Q1, Q2, Q3, Q4, and Q5 in the ULM-1 are each independently CR3''.

[0009] In some embodiments of the invention, X'' in the ULM-1 is N. In some embodiments of the invention, X'' in the ULM-1 is CH. In some embodiments of the invention, Y'' in the ULM-1 is N.

[0010] In some embodiments of the present invention, each R1" in the ULM-1 is independently hydrogen, deuterium, -F, -Cl, or a C1-C6 alkyl group, the alkyl group being optionally substituted with 1 to 3 halogens; preferably, R1" is hydrogen. In some embodiments of the present invention, R2″ in the ULM-1 is hydrogen or a C1-C6 alkyl group, the alkyl group being optionally substituted with 1 to 3 halogens, preferably R2″ is hydrogen.

[0011] In some embodiments of the present invention, each R3" in the ULM-1 is independently hydrogen, deuterium, halogen, —O(C1-C6 alkyl), or a C1-C6 alkyl group, the alkyl group being optionally substituted with 1 to 3 halogens, and preferably each R3" is independently hydrogen, deuterium, F, Cl, a methyl group, a methoxy group, an ethoxy group, a trifluoromethoxy group, a 2-hydroxyprop-2yl, or a trifluoromethyl group. In some embodiments of the invention, the ULM-1 is connected to L via Q1, Q2, Q3, Q4 or Q5.

[0012] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein Q1, Q2, Q3, Q4, Q5, R1'', R2'', and m'' are as defined in ULM-1 above. In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R1'', R2'', R3'', and m'' are as defined above in ULM-1.

[0013] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R1'', R2'', and R3'' are as defined above for ULM-1.

[0014] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R3″ is as defined for ULM-1 above. In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein Q1, Q2, Q3, Q5, R1'', R2'', and m'' are as defined above in ULM-1.

[0015] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R1'', R2'', R3'', and m'' are as defined above in ULM-1.

[0016] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R1'', R2'', and R3'' are as defined above for ULM-1.

[0017] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R3″ is as defined for ULM-1 above.

[0018] In some embodiments of the invention, the ULM is [ka] is selected from.

[0019] In some embodiments of the invention, the ULM is [ka] is selected from.

[0020] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein Q1, Q2, Q3, Q4, Q5, R1'', R2'', and m'' are as defined in ULM-1 above.

[0021] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R1'', R2'', R3'', and m'' are as defined above in ULM-1.

[0022] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R1'', R2'', and R3'' are as defined above for ULM-1.

[0023] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R3″ is as defined for ULM-1 above. In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein Q1, Q2, Q3, Q5, R1'', R2'', and m'' are as defined above in ULM-1.

[0024] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R1'', R2'', R3'', and m'' are as defined above in ULM-1.

[0025] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R1'', R2'', and R3'' are as defined above for ULM-1.

[0026] In some embodiments of the invention, the ULM has a structure of the following formula: [ka] wherein R3″ is as defined for ULM-1 above.

[0027] In some embodiments of the invention, the ULM is [ka] is selected from.

[0028] In some embodiments of the invention, the ULM is [ka] is selected from.

[0029] In some embodiments of the invention, the compound of Formula I, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, is a compound of Formula Ia, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, [ka] wherein Q1, Q2, Q3, Q4, Q5, R1'', R2'', m'', X'', and Y'' are as defined for ULM-1, and L and PTM are as defined herein.

[0030] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein in said PTM-1, PTM-1a or PTM-1b: Z1 is hydrogen, deuterium, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocycloalkyl group, or is absent; Z2 is hydrogen, deuterium, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group; R1 is hydrogen, deuterium, an optionally substituted alkyl group, an amino group, a halogen, a cyano group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted (aryl)alkyl- or an optionally substituted (heterocycloalkyl)alkyl-; R2, at each occurrence, is hydrogen, deuterium, halogen, amino, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted (aryl)alkyl- or optionally substituted (heterocycloalkyl)alkyl-; R3, at each occurrence, is a hydroxyl group, a halogen, an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted cycloalkyl group, or -NR a R b and R a and R b is independently at each occurrence hydrogen, deuterium, an optionally substituted alkyl group, an optionally substituted acyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocycloalkyl group, an optionally substituted (aryl)alkyl-, or an optionally substituted (heterocycloalkyl)alkyl-; m is 0, 1, or 2 for each occurrence, and n is 0, 1 or 2 for each occurrence, or

[0031] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein in said PTM-2, PTM-2a, PTM-2b or PTM-2c: Z1 is an optionally substituted heteroaryl group; Z2 is an optionally substituted heterocycloalkyl group, an optionally substituted heteroaryl group, or a bond; R1 is an alkyl group, a cyano group, or -NR a R bor an optionally substituted cycloalkyl group, an optionally substituted aryl group, or an optionally substituted heterocycloalkyl group, wherein each occurrence of said substituent is independently an alkyl group, an alkoxy group, a halogen, a hydroxyl group, a hydroxyalkyl group, an amino group, an aminoalkyl group, a nitro group, a cyano group, a halogenated alkyl group, a halogenated alkoxy group, —OC(O)CHO-alkyl group, —OP(O)(O-alkyl) or —CHOP(O)(O-alkyl); R2 in each occurrence is independently an optionally substituted alkyl group, an optionally substituted cycloalkyl group, wherein said substituents in each occurrence are independently a halogen, an alkoxy group, a hydroxyl group, a hydroxyalkyl group, a halogenated alkyl group, or a halogenated alkoxy group; R3 in each occurrence is independently hydrogen, deuterium, halogen, alkyl, halogenated alkyl, halogenated alkoxy, alkoxy, hydroxyl, hydroxyalkyl, or -NR a R b and R a is hydrogen or an alkyl group, R b is hydrogen, deuterium, an alkyl group, an acyl group, a hydroxyalkyl group, an —S(O)2 alkyl group, or an optionally substituted cycloalkyl group; m or n is independently 1 or 2, or

[0032] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein in said PTM-3, PTM-3', PTM-3a or PTM-3a': X1, X2 and X3 are each independently CR 2 or N, A is O, S, S(O) or S(O)2; Z1 is an optionally substituted heteroaryl group, an optionally substituted heterocycloalkyl group, an optionally substituted aryl group, an optionally substituted cycloalkyl group, an optionally substituted (heterocycloalkyl)alkyl-, an optionally substituted (aryl)alkyl-, an optionally substituted (heteroaryl)alkyl-, an optionally substituted (cycloalkyl)alkyl-, an optionally substituted aryl-O-, an optionally substituted (heteroaryl)alkyl-, an optionally substituted heterocycloalkyl-O-, an optionally substituted cycloalkyl-O-, an optionally substituted aryl-NR'-, an optionally substituted heteroaryl-NR'-, an optionally substituted heteroaryl-S-, an optionally substituted heteroaryl-S-, an optionally substituted heterocycloalkyl-NR'-, an optionally substituted cycloalkyl-NR '-, optionally substituted heterocycloalkyl-S-, optionally substituted cycloalkyl-S-, optionally substituted (cycloalkyl)alkyl-NR'-, optionally substituted (aryl)alkyl-NR'-, optionally substituted (heterocycloalkyl)alkyl-NR'-, optionally substituted (heteroaryl)alkyl-NR'-, optionally substituted (cycloalkyl)alkyl-S-, optionally substituted (aryl)alkyl-S-, optionally substituted (heterocycloalkyl)alkyl-S-, optionally substituted (heteroaryl)alkyl-S-, optionally substituted (cycloalkyl)alkyl-O-, optionally substituted (aryl)alkyl-O-, optionally substituted (heterocycloalkyl)alkyl-O-, optionally substituted (heteroaryl)alkyl-O-, wherein said optional substituents are R x and Z2 is absent or is an optionally substituted heteroaryl group, an optionally substituted heterocycloalkyl group, an optionally substituted aryl group, an optionally substituted cycloalkyl group, an optionally substituted (heterocycloalkyl)alkyl-, an optionally substituted (aryl)alkyl-, an optionally substituted (heteroaryl)alkyl-, an optionally substituted (cycloalkyl)alkyl-, an optionally substituted aryl-O-, an optionally substituted heteroaryl-O-, an optionally substituted heterocycloalkyl-O-, an optionally substituted cycloalkyl-O-, an optionally substituted (cycloalkyl)alkyl-, an optionally substituted (aryl)alkyl-, an optionally substituted (heterocycloalkyl)alkyl-, an optionally substituted (heteroaryl and optionally substituted (cycloalkyl)alkyl-NR''-, optionally substituted (heterocycloalkyl)alkyl-NR''-, optionally substituted (heteroaryl)alkyl-NR''-, optionally substituted (aryl)alkyl-NR''-, optionally substituted (cycloalkyl)alkyl-S-, optionally substituted (aryl)alkyl-S-, optionally substituted (heterocycloalkyl)alkyl-S-, optionally substituted (heteroaryl)alkyl-S-, optionally substituted (cycloalkyl)alkyl-O-, optionally substituted (aryl)alkyl-O-, optionally substituted (heterocycloalkyl)alkyl-O-, optionally substituted (heteroaryl)alkyl-O-, wherein said optional substituents are R y and Z 3is an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted heterocycloalkyl group, optionally substituted aryl-O-, optionally substituted heteroaryl-O-, optionally substituted cycloalkyl-O-, optionally substituted heterocycloalkyl-O-, optionally substituted (cycloalkyl)alkyl-, optionally substituted (aryl)alkyl-, optionally substituted (heterocycloalkyl)alkyl-, optionally substituted (heteroaryl)alkyl-, optionally substituted cycloalkyl-NR'''-, optionally substituted aryl-NR'''-, optionally substituted heteroaryl-NR'''-, optionally substituted heterocycloalkyl-NR'''-, optionally substituted (cycloalkyl)alkyl-NR'''-, optionally substituted (aryl)alkyl-NR'''-, optionally substituted (heteroaryl)alkyl-NR'''-, optionally substituted (heterocycloalkyl)alkyl-NR'''-, optionally substituted cycloalkyl-S-, optionally substituted aryl-S-, optionally substituted heteroaryl-S-, optionally substituted heterocycloalkyl-S-, optionally substituted (cycloalkyl)alkyl-O-, optionally substituted (aryl)alkyl-O-, optionally substituted (heteroaryl)alkyl-O-, optionally substituted (heterocycloalkyl)alkyl-O-, optionally substituted (cycloalkyl)alkyl-S-, optionally substituted (aryl)alkyl-S-, optionally substituted (heteroaryl)alkyl-S-, optionally substituted (heterocycloalkyl)alkyl-S-, wherein said optional substituents are R z and R 2is hydrogen, deuterium, an alkyl group, a halogenated alkyl group, a halogen, a cyano group, an optionally substituted alkoxy group, an optionally substituted cycloalkyl group, an optionally substituted (cycloalkyl)alkyl group, an optionally substituted cycloalkyl-O-, an optionally substituted aryl group, an optionally substituted (aryl)alkyl-, an optionally substituted heterocycloalkyl group, an optionally substituted heteroaryl group, an optionally substituted (heterocycloalkyl)alkyl-, an optionally substituted (heteroaryl)alkyl-, -NR a R b , -OR 3 and -SR 3 wherein said optionally substituted substituents are alkyl, alkoxy, halogenated, halogenated alkyl, hydroxyl, hydroxyalkyl, -SH, -S(alkyl), cyano, amido, amino, carboxylic acid, glycinate, alaninate, oxo, aryl, cycloalkyl, heterocycloalkyl or heteroaryl groups; each R', R'', and R''' is independently selected from hydrogen, deuterium, an alkyl group, a hydroxyl group, a hydroxyalkyl group, an acyl group, and a cycloalkyl group; Each R x , R y and R z are independently an alkyl group, an alkenyl group, an alkynyl group, a halogen, a hydroxyl group, a halogenated alkyl group, a hydroxyalkyl group, an aminoalkyl group, an alkoxy group, -SH, -S(alkyl), a cyano group, an amide group, a carboxylic acid, a carboxylate, an ester, a thioester, an alkoxycarbonyl group, -C(O)NH(alkyl), an oxo group, a cycloalkyl group, a cycloalkyl-O-, a (cycloalkyl)alkyl-, an aryl group, a (aryl)alkyl-, a heterocycloalkyl group, a heteroaryl group, a (heterocycloalkyl)alkyl-, a (heteroaryl)alkyl-, or -NR a R b , -OR 4 and -SR 4wherein the cycloalkyl, aryl, heteroaryl, or heterocycloalkyl group is optionally further substituted with one or more substituents selected from halogen, halogenated alkyl, amino, hydroxyl, alkyl, cyano, nitro, alkenyl, aminoalkyl, hydroxyalkyl, or halogenated alkoxy groups; Each R a and R b are each independently selected from hydrogen, deuterium, an alkyl group, an aminoalkyl group, an acyl group, an aminoacyl group, a halogen, a halogenated alkyl group, a hydroxyl group, a halogenated alkoxy group, a hydroxyalkyl group, a nitro group, a cyano group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, a (cycloalkyl)alkyl-, a (heterocycloalkyl)alkyl group, an (aryl)alkyl-, a (heteroaryl)alkyl-, wherein said cycloalkyl group, heterocycloalkyl group, aryl group and heteroaryl group are optionally further substituted with one or more substituents selected from an alkyl group, a halogen, an alkenyl group, a cyano group, a hydroxyl group, a hydroxyalkyl group, an alkoxy group, an amino group or a nitro group; R a and R b together with the N atom to which it is attached form an optionally substituted 3- to 8-membered ring; Each R 3 and R 4 are each independently selected from hydrogen, deuterium, an alkyl group, an aminoacyl group, a phosphate, a phosphonate, an alkylphosphate, an alkoxycarbonyl group, a cycloalkyl group, a (cycloalkyl)alkyl-, an aryl group, a heteroaryl group, a heterocycloalkyl group, an (aryl)alkyl-, a (heteroaryl)alkyl-, or a (heterocycloalkyl)alkyl-;

[0033] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein in said PTM-4, PTM-4a, PTM-4b, PTM-4c, PTM-4a', PTM-4b', PTM-4c', PTM-4d': A is an optionally substituted heteroaryl group, an optionally substituted aryl group, an optionally substituted heterocycloalkyl group, an optionally substituted cycloalkyl group, an optionally substituted (cycloalkyl)alkyl group, an optionally substituted (heterocycloalkyl)alkyl group, an optionally substituted (aryl)alkyl-, an optionally substituted (heteroaryl)alkyl-, an optionally substituted cycloalkyl-NR x -, optionally substituted heterocycloalkyl-NR x -, optionally substituted aryl-NR x -, optionally substituted heteroaryl-NR x -, optionally substituted cycloalkyl-O-, optionally substituted heterocycloalkyl-O-, optionally substituted aryl-O- or optionally substituted heteroaryl-O-, wherein said optional substituents are selected from the group consisting of R x and B is hydrogen, deuterium, halogen, cyano, optionally substituted alkyl, alkenyl, optionally substituted alkoxy, -NR a R b , optionally substituted cycloalkyl groups, optionally substituted aryl groups, optionally substituted heterocycloalkyl groups, optionally substituted heteroaryl groups, optionally substituted (cycloalkyl)alkyl groups, optionally substituted (heterocycloalkyl)alkyl groups, optionally substituted (aryl)alkyl-, optionally substituted (heteroaryl)alkyl-, optionally substituted cycloalkyl-NR x -, optionally substituted heterocycloalkyl-NR x -, optionally substituted aryl-NR x -, optionally substituted heteroaryl-NR x-, optionally substituted cycloalkyl-O-, optionally substituted heterocycloalkyl-O-, optionally substituted heteroaryl-O-, optionally substituted aryl-O-, wherein said optional substituents are R y and Q is absent or an optionally substituted heterocycloalkyl group, an optionally substituted heteroaryl group, an optionally substituted aryl group, an optionally substituted cycloalkyl group, an optionally substituted (heterocycloalkyl)alkyl group, an optionally substituted (heteroaryl)alkyl group, an optionally substituted (aryl)alkyl-, an optionally substituted (cycloalkyl)alkyl group, -NR 3 R 4 , -OR 3 or -SR 3 wherein the optional substituents are R z and W is N or CH; R1 is hydrogen, deuterium, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted (cycloalkyl)alkyl group, an optionally substituted (heterocycloalkyl)alkyl group, an optionally substituted heterocycloalkyl group, an optionally substituted (aryl)alkyl-, an optionally substituted (heteroaryl)alkyl-, an optionally substituted alkoxyalkyl group, an optionally substituted aminoalkyl group, or -(CH2)mR 2 wherein each of the optional substituents is independently selected from a halogen, a hydroxyl group, an alkoxy group, an amino group, a nitro group, a cycloalkyl group, an aryl group, a heteroaryl group, or a heterocycloalkyl group; R2 is hydrogen, deuterium, -NR a R b , an alkoxy group, a hydroxyl group, an optionally substituted heteroaryl group, or an optionally substituted heterocycloalkyl group, wherein said optional substituents are R y and R3 and R4 are each independently selected from an optionally substituted aryl group, an optionally substituted cycloalkyl group, an optionally substituted heteroaryl group, an optionally substituted heterocycloalkyl group, an optionally substituted (aryl)alkyl-, an optionally substituted (cycloalkyl)alkyl group, an optionally substituted (heteroaryl)alkyl group, or an optionally substituted (heterocycloalkyl)alkyl group, wherein said optional substituents are each independently selected from an alkyl group, a halogenated alkyl group, a hydroxyl group, a hydroxyalkyl group, an alkoxy group, an alkoxyalkyl group, an amino group, a nitro group, a cycloalkyl group, a (cycloalkyl)alkyl group, an aryl group, an (aryl)alkyl-, a (heteroaryl)alkyl-, a (heterocycloalkyl)alkyl group, a heteroaryl group, and a (heteroaryl)alkyl group; R a and R b are each independently selected from hydrogen, deuterium, an alkyl group, an aminoalkyl group, an acyl group, and a heterocycloalkyl group, or R a and R b taken together with the nitrogen to which it is attached form an optionally substituted ring; R x is hydrogen, deuterium, an alkyl group, a hydroxyl group, a hydroxyalkyl group, an acyl group, or a cycloalkyl group; R y and R zare each independently selected from hydroxyl, hydroxyalkyl, halogen, alkyl, oxo, halogenated alkyl, alkoxy, alkenyloxy, amino, nitro, cyano, -SH, -S(alkyl), glycinate, ester, thioester, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, (aryl)alkyl- and (heteroaryl)alkyl groups, wherein said hydroxyl, hydroxyalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally further substituted by one or more substituents selected from alkyl, halogen, alkenyl, amino, nitro, cycloalkyl or (cycloalkyl)alkyl groups; R y and R z together with the atom to which it is attached form an alkyl chain having 1 to 10 carbon atoms, of which 1 to 3 carbon atoms are optionally replaced by O, NH or S; m is 1, 2 or 3 and n is 1 or 2, or

[0034] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a prodrug, nitrogen oxide, stereoisomer, solvate, or pharmaceutically acceptable salt thereof, wherein in PTM-5, PTM-5a, or PTM-5b, X is selected from O, S or NH; A is selected from an aryl or heteroaryl group; R independently represents hydrogen, deuterium, cyano, halogen, hydroxyl, nitro, -NR 3 R 4, optionally substituted alkyl groups, optionally substituted aryl groups, optionally substituted cycloalkyl groups, optionally substituted heterocycloalkyl groups, and optionally substituted heteroaryl groups, wherein the optional substituents are independently selected from halogen, alkyl groups, halogenated alkyl groups, cyano groups, -NR 5 NR 6 or -C(O)OR 7 is selected from R 1 are independently selected from hydrogen, deuterium, halogen, alkyl groups, aryl groups, heterocycloalkyl groups, (heterocycloalkyl)alkyl-, heteroaryl groups, -Y-(aryl)alkyl- or -Y-cycloalkyl groups, wherein said cycloalkyl groups, aryl groups, heterocycloalkyl groups, (heterocycloalkyl)alkyl-, heteroaryl groups or (aryl)alkyl- are optionally substituted by hydroxyl groups, alkyl groups, halogenated alkyl groups, cyano groups or halogens; Y is a bond, -O-, -C(O)-, or -NR 7 - selected from R 2 are independently hydrogen, deuterium, a carboxyl group, a cyano group, a hydroxyl group, a hydroxyalkyl group, an alkyl group, an aryl group, a heteroaryl group, -S(O)R 5 or oxo, R 3 and R 4 are independently selected from hydrogen, deuterium, a hydroxyalkyl group, an aminoalkyl group, an optionally substituted alkyl group, an optionally substituted heterocycloalkyl group, and an optionally substituted aryl group, wherein said optional substituents are independently selected from a halogen, a halogenated alkyl group, or a —C(O)OR 7 is selected from R 5 and R 6 are each independently hydrogen, deuterium, an alkyl group, or -C(O)R 7 or -C(O)OR 7 is selected from R 7is selected from hydrogen and alkyl groups; m, n, and p are each independently selected from 1, 2, or 3;

[0035] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-6, PTM-6a, PTM-6b, and PTM-6c, A is a triazole substituted with 0-2 R, or [ka] and X is N or CR 7 and R is hydrogen, deuterium, R 1 , halogen, cyano group, nitro group, -OR 1 -, -C(O)R 1 , -C(O)OR 1 , -C(O)NR 11 R 1 , -S(O)2R 1 , -NR 11 C(O)R 1 , -NR 11 C(O)NR 11 R 1 , -NR 11 C(O)OR 1 , -NR 11 S(O)2R 1 or -NR 11 R 1 and R 1 is hydrogen, deuterium, 0 to 4 R 1a C1-C6 alkyl group substituted with C1-C6 halogenated alkyl group, 0 to 4 R 1a C2-6 alkenyl group substituted by 0 to 3 R 1a a C2-6 alkynyl group substituted with 0 to 3 R 1aa C3-C10 cycloalkyl group substituted with 0 to 3 R 1a a 6- to 10-membered aryl group substituted with 0 to 3 R 1a a 5-10 membered heteroaryl group containing 1-4 heteroatoms selected from N, O or S substituted by 0-3 R 1a is a 5-10 membered heterocycloalkyl group containing 1-4 heteroatoms selected from N, O or S substituted by R 2 is 0 to 4 R 2a a 6- to 10-membered aryl group substituted by 1 to 4 R 2a a 5-10 membered heterocycloalkyl group containing 1-4 heteroatoms selected from N, O or S substituted by 0-4 R 2a is a 5-10 membered heterocycloalkyl group containing 1-4 heteroatoms selected from N, O or S substituted by R 1a are hydrogen, deuterium, oxo, F, Cl, Br, OCF3, CN, NO2, -(CH2)rOR b , -(CH2)R s R b , -(CH2)R c (O)R b , -(CH2)R c (O)OR b , -(CH2)rOC(O)R b , -(CH2)R n R 11 R 11 , -(CH2)R c (O)NR 11 R 11 , -(CH2)R n R b C(O)R c , -(CH2)R n R b C(O)OR c , -NR b C(O)NR 11 R 11 , -S(O)pNR 11 R 11 , -NR b S(O)pR c , -S(O)2R c, -S(O)R c , 0 to 2 R a C1-C6 alkyl group substituted with C1-C6 halogenated alkyl group, 0 to 3 R a -(CH2)r- 3 to 14-membered carbocyclic ring substituted by 0 to 3 R a -(CH)r- 5-7 membered heterocycloalkyl or heteroaryl group substituted by, wherein said heterocycloalkyl or heteroaryl group contains carbon atoms and 1-4 heteroatoms selected from N, O or S(O)p; R 2a is hydrogen, deuterium, oxo, halogen, OCF3, CN, NO2, -(CH2)rOR b , -(CH2)R s R b , -(CH2)R c (O)R b , -(CH2)R c (O)OR b , -(CH2)rOC(O)R b , -(CH2)R n R 11 R 11 , -(CH2)R c (O)NR 11 R 11 , -(CH2)R n R b C(O)R c , -(CH2)R n R b C(O)OR c , -NR b C(O)NR 11 R 11 , -S(O)pNR 11 R 11 , -NR b S(O)pR c , -S(O)2R c , -S(O)R c , 0 to 2 R a C1-C6 alkyl group substituted with C1-C6 halogenated alkyl group, 0 to 1 R a -(CH2)r- 3 to 14-membered carbocyclic ring substituted by, or 0 to 2 R a-(CH)r- 5-7 membered heterocycloalkyl or heteroaryl group substituted by, wherein said heterocycloalkyl or heteroaryl group each contains carbon atoms and 1-4 heteroatoms selected from N, O or S(O)p; R 3 is 0 to 3 R 3a C1-C6 alkyl group substituted with C1-C6 halogenated alkyl group, 0 to 3 R 3a C2-6 alkenyl group substituted by 0 to 3 R 3a a C2-6 alkynyl group substituted with 0 to 3 R 3a a C3-C10 cycloalkyl group substituted with 0 to 3 R 3a a 6- to 10-membered aryl group substituted with 0 to 3 R 3a a 5-10 membered heteroaryl group containing 1-4 heteroatoms selected from N, O or S substituted by 0-3 R 3a is a 5-10 membered heterocycloalkyl group containing 1-4 heteroatoms selected from N, O or S substituted by R 3a are hydrogen, deuterium, oxo, F, Cl, Br, OCF3, CN, NO2, -(CH2)rOR b , -(CH2)R s R b , -(CH2)R c (O)R b , -(CH2)R c (O)OR b , -(CH2)rOC(O)R b , -(CH2)R n R 11 R 11 , -(CH2)R c (O)NR 11 R 11 , -(CH2)R n R b C(O)R c , -(CH2)R n R b C(O)OR c , -NR b C(O)NR 11 R 11 , -S(O)pNR11 R 11 , -NR b S(O)pR c , -S(O)2R c , -S(O)R c , 0 to 2 R a C1-C6 alkyl group substituted with C1-C6 halogenated alkyl group, 0 to 3 R a -(CH2)r- 3 to 14-membered carbocyclic ring substituted by 0 to 3 R a -(CH)r- 5-7 membered heterocycloalkyl or heteroaryl group substituted by, wherein said heterocycloalkyl or heteroaryl group each contains carbon atoms and 1-4 heteroatoms selected from N, O or S(O)p; R 4 and R 5 are each independently hydrogen, deuterium, or 0 to 1 R f C1-C4 alkyl group substituted with 0-3 R d or a —(CH)-5- to 7-membered heterocycloalkyl group containing a carbon atom and a heteroatom selected from N, O, or S(O)p, substituted by R 6 and R 7 are each independently hydrogen, deuterium, oxo, F, Cl, Br, OCF3, CN, NO2, -(CH2)rOR b , -(CH2)R s R b , -(CH2)R c (O)R b , -(CH2)R c (O)OR b , -(CH2)rOC(O)R b , -(CH2)R n R 11 R 11 , -(CH2)R c (O)NR 11 R 11 , -(CH2)R n R b C(O)R c , -(CH2)R n R b C(O)OR c, -NR b C(O)NR 11 R 11 , -S(O)pNR 11 R 11 , -NR b S(O)pR c , -S(O)2R c , -S(O)R c , 0 to 2 R a C1-C6 alkyl group substituted with C1-C6 halogenated alkyl group, 0 to 3 R a -(CH2)r- 3 to 14-membered carbocyclic ring substituted by 0 to 3 R a and -(CH)r- 5- to 7-membered heterocycloalkyl or heteroaryl groups each containing carbon atoms and 1 to 4 heteroatoms selected from N, O, or S(O)p, provided that R 6 and R 7 are not both hydrogen, R 11 are, in various cases, independently hydrogen, deuterium, R e , 0 to 1 R f C1-C4 alkyl group substituted with 0-3 R d CH2-phenyl group substituted by 0-3 R d and 1 to 4 heteroatoms selected from N, O, or S(O)p, substituted by R 11 is another R on the same nitrogen atom. 11 , R 1 or R 2 together to form an optionally substituted heterocycloalkyl group, R a are hydrogen, deuterium, F, Cl, Br, OCF3, CF3, CHF2, CN, NO2, -(CH2)rOR b , -(CH2)R s R b , -(CH2)R c (O)R b , -(CH2)R c (O)OR b, -(CH2)rOC(O)R b , -(CH2)R n R 11 R 11 , -(CH2)R c (O)NR 11 R 11 , -(CH2)R n R b C(O)R c , -(CH2)R n R b C(O)OR c , -NR b C(O)NR 11 R 11 , -S(O)pNR 11 R 11 , -NR b S(O)pR c , -S(O)2R c , -S(O)R c , 0 to 1 R f and a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a -(CH2)r-3 to 14-membered carbocyclic ring, or a -(CH2)r-5 to 7-membered heterocyclic ring or heteroaryl group, each of which contains a carbon atom and 1 to 4 heteroatoms selected from N, O, or S(O)p, or two R on adjacent carbon atoms or on the same carbon atom, each of which is substituted by a together with the carbon atom to which it is attached form a cyclic acetal of formula -O-(CH2)nO- or -O-CF2-O-, where n is selected from 1 or 2; R b is hydrogen, deuterium, R e , 0 to 2 R d a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C3-C6 cycloalkyl group, or 0 to 3 R d is a (CH)r-phenyl group substituted by R c is 0 to 1 R f a C1-C6 alkyl group, a C3-C6 cycloalkyl group, or 0 to 3 R f is a (CH)r-phenyl group substituted by Rd are hydrogen, deuterium, F, Cl, Br, OCF3, CF3, CN, NO2, -OR e , -(CH2)R c (O)R c , -NR e R e , N.R. e C(O)OR c , a C1-C6 alkyl group, or 0 to 3 R f is a (CH)r-phenyl group substituted by R e is hydrogen, deuterium, C1-C6 alkyl group, C3-C6 cycloalkyl group, and 0 to 3 R f and (CH2)r-phenyl groups substituted by R f is hydrogen, deuterium, halogen, NH2, OH or O(C1-C6 alkyl), p is 0, 1 or 2; r is 0, 1, 2, 3 or 4; or m is 0, 1 or 2, or

[0036] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-7: HET is a heteroaryl group selected from pyrrolo[2,3-b]pyridyl, pyrrolo[2,3-b]pyrimidinyl, pyrazolo[3,4-b]pyridyl, pyrazolo[3,4-b]pyrimidinyl, imidazo[4,5-b]pyridyl, and imidazo[4,5-b]pyrimidinyl, wherein the heteroaryl group is connected to a pyridyl group in the compound through a nitrogen ring atom in the heteroaryl group, and wherein the heteroaryl group contains 0 to 2 R b is replaced by A is a pyrazolyl group, an imidazolyl group, a triazolyl group, an isoxazolyl group, an oxadiazolyl group, or a dihydroisoxazolyl group, each of which is independently R a is replaced by R3 is a cyclic group selected from the group consisting of a C2-C3 alkyl group, a C2-C3 fluoroalkyl group, a C3-C4 hydroxyalkyl group, a C3-C6 cycloalkyl group, an oxetane group, a tetrahydrofuranyl group, a tetrahydropyranyl group, and a pyrazolyl group, wherein the cyclic group is substituted with 0 to 2 substituents independently selected from F, —OH, a C1-C2 alkyl group, and —CH2CHF2; R a is (i) hydrogen, deuterium, F, Cl, -OH, -CN, C1-C6 alkyl group, C1-C6 fluoroalkyl group, C1-C6 cyanoalkyl group, C1-C6 hydroxyalkyl group, C1-C5 hydroxyl-fluoroalkyl group, C2-6 alkenyl group, C1-C6 aminoalkyl group, -(CH2)1-3NHR y , -(CH2)1-3NHR y R y , -CH2CH(OH)(phenyl), -CH2(CH2OH)(phenyl), -CH2CH(OH)CH2(phenyl), -CH2CH(OH)CHO(methoxyphenyl), -CH2CH(NH2)(phenyl), -(CH2CH2O)4H, -(CH2)1-3O(C1-C3 alkyl), -CH2CH(OH)CHO(C1-C3 alkyl), -CH2C(O)(C1-C3 alkyl), -CH2C(O)NR y R y , -(CH2)1-3NR y C(O)(C1-C3 alkyl), -C(O)O(C1-C3 alkyl), -C(O)NH2, -CH2NR y C(O)NH2, -(CH2) 1-2 NR y C(O)O(C1-C2 alkyl), -(CR y R y )1-5OC(O)CH2NR y R y, -CH2CH2S(O)2CH3, -CH2S(O)2(C1-C3 alkyl), -CH2S(O)2(phenyl), or -NH(aminocyclohexane), or (ii)-(CH2)0-3NHR z , or -(CH2)0-1C(O)R z where R z are each independently a C3-C6 cycloalkyl group, azetidine, oxetane, tetrahydrofuranyl group, tetrahydropyranyl group, piperidinyl group, piperazinyl group, pyrrolyl group, pyrrolidone, morpholinyl group, pyrrolidinyl group, phenyl group, pyrazolyl group, imidazolyl group, pyridyl group, pyrimidinyl group, dioxopyrimidinyl group, benzo[d]imidazolyl group, benzo[d]thiazolyl group, 1,3-dioxolane, or 8-azabicyclo[3.2.1]octyl group, each independently selected from F, —OH, —CN, —NR y R y , C1-C3 alkyl group, C1-C3 fluoroalkyl group, C1-C6 hydroxyalkyl group, -CH(phenyl)2, -O(C1-C4 alkyl), -C(O)(C1-C4 alkyl), -C(O)(C1-C4 deuterated alkyl), -C(O)(C1-5 hydroxyalkyl), -C(O)(C1-C3 fluoroalkyl), -C(O)(C3-C6 cycloalkyl), -C(O)O(C1-C4 alkyl), -C(O)NR y R y , -C(O)(phenyl), -C(O)(pyridyl), -C(O)CH2(C3-C6 cycloalkyl), -NH(C1-C4 alkyl), -NH(C1-C3 fluoroalkyl), -NHC(O)CH3, -NHC(O)O(C1-C3 alkyl), -NHC(O)O(CH3)3, -S(O)2(C1-C3 alkyl), -OS(O)2(C1-C3 alkyl), methyloxadiazole, or pyrimidinyl group; R b are each independently selected from hydrogen, deuterium, Cl, —CN, —NH or —C(O)NH, wherein the heteroaryl group is attached to the pyridyl group through a nitrogen atom in the heteroaryl group; Ry are each independently hydrogen or a C1-2 alkyl group; or

[0037] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-8: HET is a heteroaryl group selected from an imidazo[1,2-b]pyridazinyl group or a pyrazolo[1,5-a]pyrimidinyl group, wherein the heteroaryl group is connected to a pyridyl group in the compound through a carbon ring atom in the heteroaryl group, and wherein the heteroaryl group contains 0 to 2 R b is replaced by A is a pyrazolyl group, an imidazolyl group, or a triazolyl group, each of which is selected from 0 to 1 R a is replaced by R3 is (i) -CH2CH3, -CH(CH3)2, -CH2CHF2, -CH(CH3)CH2OH, oxetane, tetrahydrofuranyl group or C3-5 cyclopropyl group substituted by 0 to 2 F; (ii) a pyrazolyl group substituted by 0 to 2 substituents independently selected from a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, a C1-C3 fluoroalkyl group, an oxetane group, a tetrahydrofuranyl group, or a tetrahydropyranyl group; R a is (i) F, Cl, —OH, —CN, a C1-C6 alkyl group, a C1-C4 fluoroalkyl group, a C1-C4 cyanoalkyl group, or a C1-C6 hydroxyalkyl group; (ii) a C3-C6 alkyl group, azetidine, oxetanyl group, tetrahydrofuranyl group, tetrahydropyranyl group, piperidinyl group, piperazinyl group, pyrrolyl group, pyrrolidinone, morpholinyl group, pyrrolidinyl group, phenyl group, pyrazolyl group, imidazolyl group, pyridyl group, or pyrimidinyl group, each of which is independently F, —OH, —CN, —NRy R y , C1-C3 alkyl group, fluoro C1-C3 alkyl group, -CH(phenyl)2, -O(C1-C4 alkyl), -C(O)(C1-C4 alkyl), -C(O)(C1-C4 deuterated alkyl), -C(O)(C3-C6 cycloalkyl), -C(O)O(C1-C4 alkyl), -C(O)NR y R y , -C(O)(phenyl), -C(O)(pyridyl), -C(O)CH2(C3-C6 cycloalkyl), -NHC(O)CH3, -NHC(O)OCH3, -NHC(O)O(CH3)3, -S(O)2(C1-C3 alkyl), or -OS(O)2(C1-C3 alkyl); R b is selected from F, Cl, —CN, —NH2, —CH3, —OCH3 or a cyclopropyl group; R y is hydrogen or a C1-C3 alkyl group, or

[0038] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-9: HET is a heteroaryl group selected from oxazolyl, pyrazolyl, imidazo[1,2-b]pyridazin-3-yl, or pyrazolo[1,5-a]pyrimidin-3-yl, wherein the heteroaryl group is connected to the pyridyl group of the compound through a carbon ring atom in the heteroaryl group, and wherein the heteroaryl group is selected from 0 to 2 R b is replaced by Each R bare independently selected from hydrogen, deuterium, F, Cl, —CN, —NH, a C1-C3 alkyl group, a C1-2 fluoroalkyl group, a C1-C3 alkoxy group, a C3-C6 cycloalkyl group, —NH(C1-C3 alkyl), —NH(C1-C4 hydroxyalkyl), a cyanophenyl group, a pyridyl group, or a hydroxypyrrolidinyl group; R1 is (i) a C3-C6 alkyl group substituted by 1 to 4 substituents independently selected from F, -CN, -OH, -OCH3, -OCD3, -NHC(O)(C1-C3 alkyl), -S(O)2(C1-C3 alkyl), or a C1-C3 fluoroalkoxy group; (ii)-(CR y R y )1-3R x or -(CH2)1-3C(O)R x , where R x is substituted by 0 to 3 substituents independently selected from a phenyl group, an oxetane group, a tetrahydropyranyl group, a morpholinyl group, a piperidinyl group, an imidazolyl group, a pyridyl group, a thienyl group, or a C4-6 cycloalkyl group, F, Cl, —OH, a C1-C3 alkyl group, a C1-2 alkoxy group, or —S(O)2NH2; (iii) a C4-6 cycloalkyl group substituted by 0 to 2 substituents independently selected from -OH, a C1-C4 hydroxyalkyl group, a C1-C3 alkoxy group, -(CH2)1-3O(C1-C3 alkyl), -C(O)NH(C1-C4 alkyl), -C(O)NH(C3-C6 cycloalkyl), -N(C1-C3 alkyl)2, -NHC(O)(C1-C3 alkyl), -NHC(O)O(C1-C3 alkyl), or -NHC(O)(C1-C4 hydroxyalkyl); (iv) a tetrahydrofuranyl group, a tetrahydropyranyl group, a piperidinyl group, a piperazinyl group, a pyrrolyl group, a pyrazolyl group, an imidazolyl group, or a triazolyl group, each independently substituted by 0 to 2 substituents selected from C-C hydroxyalkyl group, —S(O)(C-C alkyl), —CHC(O)NH(C-C alkyl), —CHC(O)NH(C-C hydroxyalkyl), —CHC(O)NH(C-C fluoroalkyl), or —CHC(O)NH(C-C hydroxyl-fluoroalkyl); or (v) a 1-oxa-7-azaspiro[3.5]nonyl group; R y are independently hydrogen, deuterium, F, or —OH; R3 is (i) a C2-5 alkyl group, a C2-5 fluoroalkyl group, a C2-5 hydroxyalkyl group, or —(CH2)1-3R z or -CH(CHOH)CHR z , where R z is substituted by 0 to 1 substituents selected from a C cycloalkyl group, an oxetane group, a tetrahydrofuranyl group, a tetrahydropyranyl group, or a phenyl group, each independently selected from —OH and a methyl group; (ii) a C3-C6 cycloalkyl group substituted by 0 to 3 substituents independently selected from F, Cl, —CN, —OH, a C1-C3 alkyl group, a C1-C3 fluoroalkyl group, a C1-C4 hydroxyalkyl group, a C1-C4 alkoxy group, —C(O)NH2, —C(O)NH(C1-C3 alkyl), or —C(O)NH(C1-C3 fluoroalkyl); (iii) oxetane, tetrahydrofuranyl group, tetrahydropyranyl group, pyrrolidinyl group, piperidinyl group, pyrazolyl group, thiazolyl group, bicyclo[1.1.1]pentyl group, bicyclo[2.2.1]heptyl group, or 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazinyl group, each independently F, —OH, C1-C4 alkyl group, C1-C3 hydroxyalkyl group, C1-C4 fluoroalkyl group, —CH2(C -C(O)(C1-C3 fluoroalkyl), -S(O)2(C1-C3 alkyl), a C3-C6 cycloalkyl group, a C3-C6 fluorocycloalkyl group, an oxetanyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, a pyrimidinyl group, a fluoropyrimidinyl group, or a methoxypyrimidinyl group; or (iv) a phenyl group substituted by 0 to 3 substituents independently selected from F, Cl, —CN, —OH, —C(O)NH, —C(O)NH(C-C alkyl), or —C(O)NH(C-C fluoroalkyl); or

[0039] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt or prodrug thereof, wherein in said PTM-10: X is CR4 or N; Y is CR5 or N, and the premise is that one and only one of X and Y is N, R1 is [ka] and R 1a , R 1b , R 1care each independently hydrogen, deuterium, -OH, F, a C1-C3 alkyl group, a C1-C3 fluoroalkyl group, a C1-C3 alkoxy group, a C1-C3 fluoroalkoxy group, or a C3-C6 cycloalkyl group, or two R 1a can be taken together with the carbon atom to which it is attached to form a 3- to 4-membered spirocycloalkyl ring, or R 1a and R 1b can be taken together with the carbon atom to which it is attached to form a 3- to 4-membered cycloalkyl ring, R 1a and R 1c can be taken together with the carbon atom to which it is attached to form a 3- to 4-membered cycloalkyl ring, R2 is hydrogen, deuterium, halogen, a C1-C3 alkyl group, or a C3-C6 cycloalkyl group; R3 is a C1-C4 alkoxy group, a C1-C4 fluoroalkyl group, or a C3-C6 cycloalkyl group; R4 and R5 are each independently hydrogen, deuterium, halogen, a C1-C4 alkyl group, a C1-C4 fluoroalkyl group, or a C3-C6 cycloalkyl group; or

[0040] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-11 and PTM-11', X is N or CH; m is 1 or 2; Ar is an optionally substituted aryl group or an optionally substituted heteroaryl group; R1 is hydrogen, deuterium, a C1-C6 alkyl group, a C1-C6 alkoxy group, a hydroxyl group, a hydroxyl-C1-C6 alkyl group, a C1-C6 alkyl-amino group, an amino-C1-C6 alkyl group, an amino-C1-C6 alkylamino group, a hydroxyl-C1-C6 alkylamino group, a C3-C6 cycloalkylamino group, an amino-C3-C6 cycloalkylamino group, an amino-C3-C6 heterocycloalkylamino group, an aminocarbonyl group, a halogen, or a hydroxyl-C1-C6 alkoxy group; R 2 is hydrogen or a C1-C6 alkyl group, or

[0041] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein in said PTM-12 or PTM-12′: R 1 is hydrogen or halogen, R 3 represents hydrogen, deuterium, halogen, -CN, -OH, C1-C3 alkyl group, C2-3 alkenyl group, C3-7 cycloalkyl group, C1-C3 alkyl acyl group, -(C0-3 alkyl)C(O)NR 6 R 7 , -(C2-3 alkenyl)C(O)NR 6 R 7 , -S(O) 1-2 NR 6 R 7 , -NR 8 R 9, -OC1-C3 alkyl group, a 3- to 7-membered monocyclic saturated or partially saturated heterocycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group, or a 5- to 6-membered monocyclic aryl group, wherein the alkyl, alkylacyl, or alkenyl group is optionally substituted with halogen, oxo, -CN, -OH, a C1-C3 alkoxy, or a C1-C3 halogenated alkoxy group, and the cycloalkyl, heterocycloalkyl, heteroaryl, or aryl groups are each independently optionally substituted with halogen, oxo, -CN, -OH, a C1-C3 alkyl group, or a C1-C3 halogenated alkyl group; R 4 represents hydrogen, deuterium, halogen, C1-C3 alkyl group, C2-3 alkenyl group, -(C0-3 alkyl)C(O)R 13 , -(C2-3 alkenyl)C(O)NR 10 R 11 , -S(O) 1-2 NR 10 R 11 , 3- to 7-membered monocyclic saturated or partially saturated heterocycloalkyl group, -(C0-3 alkyl)C(O)NR 10 R 11 , -C(O)NR 8 R 9 , -NR 8 R 9 wherein the alkyl group, heterocycloalkyl ring, or alkenyl group is each independently optionally substituted by halogen, oxo, —CN, —OH, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, or a 3- to 7-membered monocyclic saturated or partially saturated heterocycloalkyl ring optionally substituted by oxo; R 5 represents hydrogen, deuterium, -CN, C1-C6 alkyl group, C1-C6 alkoxy group, C3-C10 cycloalkyl group, -NR 8 R 9 , -C(O)NR 8 R 9, -O(C3-7 cycloalkyl), -O(C1-C3 alkyl)-3 to 8-membered cycloalkyl group, -O(C0-3 alkyl)-3 to 8-membered saturated or partially unsaturated heterocycloalkyl group, -O(C1-C3 alkyl)phenyl group, -O(C1-C3 alkyl)-5 to 6-membered heteroaryl group, -3 to 11-membered saturated or partially saturated heterocycloalkyl group, 5 to 6-membered monocyclic heteroaryl group, wherein the alkyl or alkoxy groups are each independently optionally selected from halogen, oxo, and optionally substituted by -CN, -OH, a C3-7 cycloalkyl group, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, or a -C(O)(C1-C3 alkyl) or C1-C3 alkyl group substituted-3 to 11 membered saturated or partially saturated heterocycloalkyl group optionally substituted by halogen, wherein said cycloalkyl group, heterocycloalkyl group, phenyl group or heteroaryl group is optionally substituted by halogen, oxo, -CN, -OH, a C1-C6 alkoxy group, -NR 8 R 9 , -C(O)(C1-C3 alkyl), -(C0-3 alkyl)C(O)NR 10 R 11 , -S(O) 1-2 NR 8 R 9 , -OP(O)(OC1-C3 alkyl)2, a C3-C10 cycloalkyl group optionally substituted by -OH or halogen, a 3- to 11-membered saturated or partially saturated heterocycloalkyl group optionally substituted by oxo or a C1-C3 alkyl group, a 5- to 6-membered monocyclic heteroaryl group optionally substituted by halogen, oxo, -CN, -OH, a C1-C3 alkyl group or a C1-C3 halogenated alkyl group, or optionally halogen, oxo, -CN, -OH, -O(C1-C3 alkyl), -S(C1-C3 alkyl), -S(O)2(C1-C3 alkyl), -NR 8 R 9 , -C(O)NR 8 R 9, a C1-C4 alkyl group substituted by a phenyl group, a C3-C10 cycloalkyl group, a saturated or partially saturated 3- to 11-membered heterocycloalkyl ring optionally substituted by oxo or a C1-C3 alkyl group, or a 5- to 6-membered monocyclic heteroaryl group optionally substituted by oxo, halogen, or a C1-C3 alkyl group; A is a 3- to 11-membered heterocycloalkyl group, which is optionally selected from halogen, oxo, —CN, —OH, a C1-C6 alkyl group, a —(C0-3 alkyl)-C3-C6 cycloalkyl group, a —(C0-3 alkyl)-3- to 11-membered heterocycloalkyl group, —NR 8 R 9 , -NR 12 C(O)R 13 , -NR 12 S(O) 1-2 R 13 , -C(O)(C1-C3 alkyl), -C(O)NR 10 R 11 , -C(O)OR 13 , -S(O) 1-2 NR 10 R 11 or -(C0-3 alkyl)-OP(O)(OC1-C3 alkyl)2, wherein said alkyl, cycloalkyl or heterocycloalkyl groups are each independently optionally substituted with halogen, oxo, -CN, -OR 13 , a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, —C(O)(C1-C3 alkyl), —S(C1-C3 alkyl), or a C1-C3 alkyl group optionally substituted by —OH, halogen, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, or a 3- to 8-membered heterocycloalkyl group; When A is a 5-membered azacycloalkyl group, the nitrogen heteroatom is substituted; R 6 and R 7each occurrence is independently hydrogen, deuterium, a C1-C3 alkyl group, or a C3-C6 cycloalkyl group, wherein said alkyl group or cycloalkane is each independently optionally substituted with halogen, oxo, —CN, —OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, or a C1-C3 halogenated alkoxy group; R 8 , R 9 , R 10 or R 11 each occurrence independently represents hydrogen, deuterium, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a -(C0-3 alkyl)-phenyl group, a 3- to 11-membered saturated heterocycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group, -C(O)R 13 , -C(O)OR 13 , -S(O) 1-2 R 13 or -C(O)NR 6 NR 7 or the R 11 and R 10 together with the atom to which it is attached form a 5- to 8-membered heterocycloalkyl group, wherein said alkyl group, cycloalkyl group, phenyl group, and heterocycloalkyl group each independently optionally contain halogen, oxo, -CN, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, -OR 13 , -NR 6 NR 7 or substituted by a 5- to 8-membered heteroaryl group, R 12 each occurrence is independently hydrogen, deuterium, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group, wherein said alkyl or cycloalkyl group is each independently optionally substituted by halogen, oxo, —CN, —OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, or a C1-C3 halogenated alkoxy group; R 13each occurrence is independently hydrogen, deuterium, a C1-C6 alkyl group, or a C3-C10 cycloalkyl group or a 3- to 11-membered saturated heterocycloalkyl group, wherein said alkyl group, cycloalkyl group, or heterocycloalkyl group is each independently optionally selected from halogen, oxo, -CN, -OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, -OR 12 or -NR 6 NR 7 is replaced by R 16 is hydrogen, deuterium, halogen, -CN or a C1-C3 alkyl group optionally substituted by -NH2, halogen or -CN, or

[0042] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein in said PTM-13: R1 is a C1-C6 alkoxy group, oxetane, -NR x R y , or optionally R z is a 6-membered heteroaryl group substituted by R2 is hydrogen, deuterium, oxo, -CN, -OH, a C1-C6 alkyl group, a -(C0-3 alkyl)-C3-C6 cycloalkyl group, a -(C0-3 alkyl)-3 to 11-membered heterocycloalkyl group, or -NR a R b , -NR e C(O)R f , -NR e S(O) 1-2 R f , -C(O)(C1-C3 alkyl), -C(O)NR c R d , -C(O)OR f , -S(O) 1-2 R c R d, -(C0-3 alkyl)-OP(O)(OC1-C3 alkyl)2, wherein the alkyl, cycloalkyl or heterocycloalkyl groups are each independently optionally selected from halogen, oxo, -CN, -OR f , a C1-C3 halogenated alkoxy group, —C(O)(C1-C3 alkyl), —S(C1-C3 alkyl), or a C1-C3 alkyl group optionally substituted by —OH, halogen, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, or a 3- to 8-membered heterocycloalkyl group; Ring A is a 5- or 6-membered heteroaryl group, a 6-membered saturated or partially saturated heterocycloalkyl group, a 9-membered bicyclic heteroaryl group containing at least two heteroatoms selected from N, O, or S, and said ring A optionally contains R m with the proviso that ring A does not include an optionally substituted 9-membered bicyclic heteroaryl group of the structure: [ka] R a , R b , R c and R d are each independently hydrogen, deuterium, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a -(C0-3 alkyl)-phenyl group, a 3- to 11-membered saturated heterocycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group, or -C(O)R f , -C(O)NR g R h , -C(O)OR f , -S(O) 1-2 R f or R c and R d together with the atom to which it is attached form a 5- to 8-membered heterocycloalkyl group, wherein said alkyl group, cycloalkyl group, phenyl group, heterocycloalkyl group, or heteroaryl group each independently optionally contains one of halogen, oxo, -CN, C1-C3 alkyl group, C1-C3 halogenated alkyl group, C1-C3 alkoxy group, -OR f, C1-C3 halogenated alkoxy group, -NR g R h or a 5- to 6-membered monocyclic heteroaryl group substituted; R e is hydrogen, deuterium, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group, each of said alkyl or cycloalkyl groups independently being optionally substituted with halogen, oxo, —CN, —OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, or a C1-C3 halogenated alkoxy group; R f is hydrogen, deuterium, a C1-6 alkyl group, a C3-C10 cycloalkyl group, or a 3- to 11-membered saturated heterocycloalkyl group, and the alkyl group, cycloalkyl group, or heterocycloalkyl group each independently optionally represents a halogen, oxo, -CN, -OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, or a C1-C3 halogenated alkoxy group, -OR e or -NR g R h is replaced by R g and R h are each independently selected from hydrogen, deuterium, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group, wherein said alkyl or cycloalkyl groups are each independently optionally substituted by halogen, oxo, —CN, —OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, or a C1-C3 halogenated alkoxy group; R m is halogen, oxo, -CN, -OR v , -S(O) 1-2 R v , -OH, C1-C6 alkoxy group, -NR n R p , -C(O)(C1-C3 alkyl), -(C0-3 alkyl)C(O)NR r R s , -S(O) 1-2 NR n R p, -OP(O)(OC1-C3 alkyl), a C3-C10 cycloalkyl group optionally substituted with -OH or halogen, optionally halogen, oxo, -CN, -OH, a C1-C4 alkoxy group, -NR n R p or a 3- to 11-membered saturated or partially saturated heterocycloalkyl group optionally substituted by a C1-C4 alkyl group substituted by halogen or -OH, optionally halogen, oxo, -CN, -OH, -O(C1-C3 alkyl), -S(C1-C3 alkyl), -S(O)2(C1-C3 alkyl), -NR n R p , -C(O)NR n R p , a C1-C4 alkyl group substituted by a phenyl group, a C3-C10 cycloalkyl group, an optional oxo, a C1-C3 alkyl group, or a 3-11 membered saturated or partially saturated heterocycloalkyl group substituted by an optional oxo, a halogen, or a C1-C3 alkyl group; R n , R p , R r and R s are each independently hydrogen, deuterium, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a -(C0-3 alkyl)-phenyl group, a 3- to 11-membered saturated heterocycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group, or -C(O)R v , -C(O)OR v , -C(O)NR t R u , or -S(O) 1-2 R v or R r and R s together with the atom to which it is attached form a heterocycloalkyl group, wherein said alkyl group, cycloalkyl group, phenyl group, heterocycloalkyl group or heteroaryl group each independently optionally contains one or more of halogen, oxo, -CN, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, -OR v , -NR tR u or a 5- to 6-membered monocyclic heteroaryl group; R t and R u are each independently selected from hydrogen, deuterium, a C1-C3 alkyl group, and a C3-C6 cycloalkyl group, wherein said alkyl or cycloalkyl groups are each independently optionally substituted with a substituent selected from halogen, oxo, —CN, —OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, and a C1-C3 halogenated alkoxy group; R v is hydrogen, deuterium, a C1-C3 alkyl group, a C3-C10 cycloalkyl group, or a 3- to 11-membered saturated heterocycloalkyl group, and the alkyl group, cycloalkyl group, or heterocycloalkyl group is each independently optionally selected from halogen, oxo, -CN, -OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, -OR w or -NR t R u is replaced by R w is selected from hydrogen, deuterium, a C1-C6 alkyl group, and a C3-C6 cycloalkyl group, each of which is independently optionally substituted with halogen, oxo, —OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, or a C1-C3 halogenated alkoxy group; R x and R y are each independently selected from a C1-C6 alkyl group, or R x and R y together with the atom to which it is attached, optionally followed by R z forming a 6-membered heterocycloalkyl group substituted by R z is halogen, oxo, -CN, -S(O) 1-2 R v , -OH, C1-C6 alkoxy group, -NR n R p, -C(O)(C1-C3 alkyl), -(C0-3 alkyl)C(O)NR r R s , -S(O) 1-2 NR n R p , -OP(O)(OC1-C3 alkyl)2, a C3-C10 cycloalkyl group optionally substituted with -OH or halogen, a 3- to 11-membered saturated or partially saturated heterocycloalkyl group optionally substituted with oxo or a C1-C3 alkyl group, optionally halogen, oxo, -CN, -OH, a C1-C4 alkyl group, -NR n R p or a 5-6 membered monocyclic heteroaryl group optionally substituted by a C1-C4 alkyl group optionally substituted by halogen or —OH, or optionally halogen, oxo, —CN, —OH, —O(C1-C3 alkyl), —S(C1-C3 alkyl), —S(O)2(C1-C3 alkyl), —NR n R p , -C(O)NR n R p a C1-C4 alkyl group substituted by a phenyl group, a C3-C10 cycloalkyl group, a 3-11 membered saturated or partially saturated heterocycloalkyl group optionally substituted by oxo, a C1-C3 alkyl group, or a 5-6 membered monocyclic heteroaryl group optionally substituted by oxo, a halogen, or a C1-C3 alkyl group; or

[0043] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein in said PTM-14, R 1 represents a C1-C6 alkoxy group, oxetane, -NR a R b or optionally R c is a 6-membered heteroaryl group substituted by R 2is a methyl group, a hydroxymethyl group, or a 2-hydroxypropyl-2-yl group, R 3 is a methyl group, or R 2 and R 3 together with the carbon atom to which it is attached form a 6-membered heterocycloalkyl group optionally substituted by a C1-C3 alkyl group; Ring A is a 5- or 6-membered heteroaryl group, a 6-membered saturated or partially saturated heterocycloalkyl group, a 9-membered bicyclic heteroaryl group containing at least two heteroatoms selected from N, O, or S, and said ring A optionally contains R d with the proviso that ring A does not include an optionally substituted 9-membered bicyclic heteroaryl group of the structure: [ka] R a and R b are each independently a C1-C6 alkyl group, or R a and R b together with the atom to which it is attached, optionally followed by R c forming a 6-membered heterocycloalkyl group substituted by R c is halogen, oxo, -CN, -S(O) 1-2 R n , -OH, C1-C6 alkoxy group, -NR e R f , C(O)(C1-C3 alkyl), -(C0-3 alkyl)C(O)NR g R f , -S(O) 1-2 NR e R f , -OP(O)(OC1-C3 alkyl)2, a C3-C10 cycloalkyl group optionally substituted with -OH or halogen, a 3- to 11-membered saturated or partially saturated heterocycloalkyl group optionally substituted with oxo or a C1-C3 alkyl group, optionally oxo, halogen, -CN, -OH, a C1-C4 alkoxy group, -NR e R for a 5-6 membered monocyclic heteroaryl group optionally substituted by a C1-C4 alkyl group substituted with halogen or —OH, optionally halogen, oxo, —CN, —OH, —O(C1-C3 alkyl), —S(C1-C3 alkyl), —S(O)2(C1-C3 alkyl), —NR e R f , -C(O)NR e R f phenyl group, a C3-C10 cycloalkyl group, a 3- to 11-membered saturated or partially saturated heterocycloalkyl group optionally substituted by oxo, a C1-C3 alkyl group, or a 5- to 6-membered monocyclic heteroaryl group optionally substituted by oxo, a halogen, a C1-C3 alkyl group; R d is halogen, oxo, -CN, -OR n , -S(O)2R n , -OH, C1-C6 alkoxy group, -NR e R f , C(O)(C1-C3 alkyl), -(C0-3 alkyl)C(O)NR g R f , -S(O) 1-2 NR e R f , -OP(O)(OC1-C3 alkyl)2, a C3-C10 cycloalkyl group optionally substituted with -OH or halogen, a 3- to 11-membered saturated or partially saturated heterocycloalkyl group optionally substituted with oxo or a C1-C3 alkyl group, optionally oxo, halogen, -CN, -OH, a C1-C4 alkoxy group, -NR e R f or a 5-6 membered monocyclic heteroaryl group optionally substituted by a C1-C4 alkyl group substituted with halogen or —OH, optionally halogen, oxo, —CN, —OH, —O(C1-C3 alkyl), —S(C1-C3 alkyl), —S(O)2(C1-C3 alkyl), —NR e R f , -C(O)NR e R fa 3- to 11-membered saturated or partially saturated 3- to 11-membered heterocycloalkyl group optionally substituted by a phenyl group, a C3-C10 cycloalkyl group, an oxo, a C1-C3 alkyl group, or a 5- to 6-membered monocyclic heteroaryl group optionally substituted by an oxo, a halogen, or a C1-C3 alkyl group; R e , R f , R g and R h are each independently hydrogen, deuterium, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a -(C0-3 alkyl)-phenyl group, a 3- to 11-membered saturated heterocycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group, or -C(O)R n , -C(O)OR n , -C(O)NRkR m , -S(O) 1-2 R n or R g and R h together with the atom to which it is attached form a 5- to 8-membered heterocycloalkyl group, wherein said alkyl group, cycloalkyl group, phenyl group, heterocycloalkyl group or heteroaryl group each independently optionally contains one of halogen, oxo, -CN, C1-C3 alkyl group, C1-C3 halogenated alkyl group, C1-C3 alkoxy group, halogenated C1-C3 alkoxy group, -OR n , -NRkR m or a 5- to 6-membered monocyclic heteroaryl group; R k and R m are each independently selected from hydrogen, deuterium, a C1-C3 alkyl group, or a C3-C6 cycloalkyl group, wherein said alkyl or cycloalkyl group is each independently optionally substituted by halogen, oxo, —CN, —OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, or a halogenated C1-C3 alkoxy group; R nis selected from hydrogen, deuterium, a C1-C6 alkyl group, a C3-C10 cycloalkyl group, or a C3-C11 saturated heterocycloalkyl group, wherein said alkyl group, cycloalkyl group, or heterocycloalkyl group is each independently optionally selected from halogen, oxo, -CN, -OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, a halogenated C1-C3 alkoxy group, -OR p or -NR g R h is replaced by R p is selected from hydrogen, deuterium, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group, wherein said alkyl or cycloalkyl group is each independently optionally substituted with halogen, oxo, —CN, OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, or a C1-C3 halogenated alkoxy group; or

[0044] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein in said PTM-15, PTM-15a, PTM-15b, PTM-15c, PTM-15d, PTM-15e, PTM-15f, PTM-15g or PTM-15h: A 1 is CH2 or NH, R 1 is hydrogen or halogen, R 3 represents hydrogen, deuterium, halogen, CN, OH, C1-C3 alkyl group, C2-3 alkenyl group, C3-7 cycloalkyl group, C1-C3 alkyl acyl group, -(C0-3 alkyl)C(O)NR 6 R 7 , -(C2-3 alkenyl)C(O)NR 6 R 7 , -S(O) 1-2 NR 6 R 7, -NR 8 R 9 , -OC1-C3 alkyl group, a 3- to 7-membered monocyclic saturated or partially saturated heterocycloalkyl group, a 5- to 6-membered monocyclic heteroaryl ring, or a 5- to 6-membered monocyclic aryl group, wherein the alkyl, alkylacyl, or alkenyl group is each optionally substituted with a substituent independently selected from halogen, oxo, CN, OH, a C1-C3 alkoxy group, or a C1-C3 halogenated alkoxy group, and the cycloalkyl, heterocycloalkyl, heteroaryl, or aryl group is each optionally substituted with a substituent independently selected from halogen, oxo, CN, OH, a C1-C3 alkyl group, or a C1-C3 halogenated alkyl group; R 4 represents hydrogen, deuterium, halogen, C1-C3 alkyl group, C2-3 alkenyl group, -(C0-3 alkyl)C(O)R 13 , -(C2-3 chain alkenyl)C(O)NR 10 R 11 , -S(O) 1-2 NR 10 R 11 , 3- to 7-membered monocyclic saturated or partially saturated heterocycloalkyl group, —C(O)NR 8 R 9 or -NR 8 R 9 wherein the alkyl, alkenyl or heterocycloalkyl groups are each independently optionally substituted by substituents selected from halogen, oxo, CN, OH, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, or a 3- to 7-membered monocyclic saturated or partially saturated heterocycloalkyl group optionally substituted by oxo; R 5 represents hydrogen, deuterium, -CN, C1-C6 alkyl group, C1-C6 alkoxy group, C3-C10 cycloalkyl group, -NR 8 R 9 , -C(O)NR 8 R 9, -O(C3-7 cycloalkyl), -O(C1-C3 alkyl)-3 to 8-membered cycloalkyl group, -O(C0-3 alkyl)-3 to 8-membered saturated or partially saturated heterocycloalkyl group, -O(C1-C3 alkyl)-phenyl group, -O(C1-C3 alkyl)-5 to 6-membered heteroaryl ring, 3 to 11-membered saturated or partially saturated heterocycloalkyl group or 5 to 6-membered monocyclic heteroaryl ring, and the alkyl group and alkoxy group are each independently halogen, oxo, CN, OH, C1-C3 alkoxy, or a 3- to 11-membered saturated or partially saturated heterocycloalkyl group optionally substituted by substituents such as (i) —C(O)(C1-C3 alkyl) optionally substituted by halogen, (ii) a C1-C3 alkyl group optionally substituted by halogen, wherein the cycloalkyl, heterocycloalkyl, phenyl or heteroaryl group is selected from halogen, oxo, CN, OH, a C1-C6 alkoxy group, —NR 8 R 9 , -C(O)(C1-C3 alkyl), -(C0-3 alkyl)C(O)NR 10 R 11 , -S(O) 1-2 NR 8 R 9 , -OP(O)(OC1-C3 alkyl)2, a C3-C10 cycloalkyl group optionally substituted by OH or halogen, a 3-11 membered saturated or partially saturated heterocycloalkyl group optionally substituted by oxo or a C1-C3 alkyl group, a 5-6 membered monocyclic heteroaryl ring optionally substituted by halogen, oxo, CN, OH, a C1-C3 alkyl group or a C1-C3 halogenated alkyl group, or halogen, oxo, CN, OH, -OC1-C3 alkyl group, -SC1-C3 alkyl group, -SO2C1-C3 alkyl group, -NR 8 R 9 , -C(O)NR 8 R 9optionally substituted by groups such as a C1-C4 alkyl group optionally substituted by a group such as a phenyl group, a C3-C10 cycloalkyl group, a 3-11 membered saturated or partially saturated heterocycloalkyl group optionally substituted by oxo or a C1-C3 alkyl group, or a 5-6 membered monocyclic heteroaryl ring optionally substituted by oxo, halogen, or a C1-C3 alkyl group; A is halogen, oxo, CN, OH, a C1-C6 alkyl group, a -(C0-3 alkyl)-C3-C6 cycloalkyl group, a -(C0-3 alkyl)-3 to 11-membered heterocycloalkyl group, or -NR 8 R 9 , -NR 12 C(O)R 13 , -NR 12 S(O) 1-2 R 13 , -C(O)(C1-C3 alkyl), -C(O)NR 10 R 11 , -C(O)OR 13 , -S(O) 1-2 NR 10 R 11 or a 3- to 11-membered heterocycloalkyl group optionally substituted by a substituent such as -(C0-3 alkyl)-OP(O)(OC1-C3 alkyl)2, wherein the alkyl, cycloalkyl, or heterocycloalkyl group is each independently selected from halogen, oxo, CN, OR 13 , a C1-C3 halogenated alkoxy group, —C(O)(C1-C3 alkyl), —SC1-C3 alkyl group, or a C1-C3 alkyl group optionally substituted by a substituent such as OH, halogen, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group or a 3- to 8-membered heterocycloalkyl group, wherein when A is a 5-membered nitrogen-containing heterocycloalkyl group, the nitrogen atom is substituted; R 6 and R 7each occurrence is independently hydrogen, deuterium, a C1-C3 alkyl group, or a C3-C6 cycloalkyl group, wherein said alkyl or cycloalkyl group is each independently optionally substituted by a substituent such as halogen, oxo, CN, OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, or a C1-C3 halogenated alkoxy group; R 8 , R 9 , R 10 and R 11 each occurrence independently represents hydrogen, deuterium, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a -(C0-3 alkyl)-phenyl group, a 3- to 11-membered saturated heterocycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group, -C(O)R 13 , -C(O)OR 13 , -C(O)NR 6 R 7 or -S(O) 1-2 R 13 or R 10 and R 11 are taken together to form a 5- to 8-membered heterocycloalkyl group, wherein the alkyl group, cycloalkyl group, phenyl group, heterocycloalkyl group, or heteroaryl ring is each independently selected from halogen, oxo, CN, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, -OR 13 , -NR 6 R 7 or a 5- to 6-membered monocyclic heteroaryl group, R 12 each occurrence is independently hydrogen, deuterium, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group, wherein said alkyl or cycloalkyl group is optionally substituted independently by a substituent such as halogen, oxo, CN, OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, or a C1-C3 halogenated alkoxy group; R 13each occurrence is independently hydrogen, deuterium, a C1-C6 alkyl group, a C3-C10 cycloalkyl group, or a 3- to 11-membered saturated heterocycloalkyl group, wherein said alkyl group, cycloalkyl group, or heterocycloalkyl group is each independently optionally selected from halogen, oxo, CN, OH, a C1-C3 alkyl group, a C1-C3 halogenated alkyl group, a C1-C3 alkoxy group, a C1-C3 halogenated alkoxy group, -OR 12 or -NR 6 R 7 and the like, R 16 is hydrogen, deuterium, halogen, CN or a C1-C3 alkyl group optionally substituted by -NH2, halogen or CN, or

[0045] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-16, PTM-16a, PTM-16b, PTM-16c, PTM-16d, PTM-16e or PTM-16f: X, X', Y, and Y' are each independently CH or N, and Z is C or N, with the proviso that no more than three of X, X', Z, Y, and Y' are N; R 1 is a C1-C6 alkyl group or -(C1-C6 alkyl)n-(C1-C6 cycloalkyl), wherein said alkyl or cycloalkyl group is optionally substituted by deuterium, halogen, CN, OH, or a C1-C6 alkoxy group; R 2 is hydrogen or a methyl group or an optionally substituted cycloalkyl group; R 3 is hydrogen, deuterium, heavy hydrogen, halogen, nitrile, -(CH2)tNR 8a R 8b, -(CH2)t(6-10 membered aryl) or -(CH2)t(5-10 membered heteroaryl) having 1-3 heteroatoms selected from N, O or S, wherein the aryl or heteroaryl group is optionally substituted by 1-3 C1-C6 alkyl, deuterium, halogen, CN, OH, hydroxyl C1-C6 alkyl or C1-C6 alkoxy groups, wherein the alkyl group is optionally substituted by hydroxyl, halogen, CN or C1-C3 alkoxy groups; R 4a and R 4b are each independently hydrogen, deuterium, fluorine, OH, a C1-C3 alkoxy group, or CH2OR 7 where R 7 is R 1 and a C1-C4 alkylene group, said C1-C4 alkylene group being optionally substituted by a halogen or an alkyl group; R 5a and R 5b are each independently hydrogen, deuterium, a C1-C3 alkyl group, or a C1-C3 alkoxy group, wherein the alkyl or alkoxy group is optionally substituted with 1 to 3 deuterium, halogen, OH, or CN; or R 5a and R 5b together with the atom to which it is attached form a C3-C7 cycloalkyl group or a C3-C7 heterocycloalkyl group, wherein said cycloalkyl group or heterocycloalkyl group is optionally substituted by 1 to 3 deuterium, halogen, OH, CN, or a C1-C3 alkyl group; R 6 is hydrogen or a C1-C3 alkyl group, or R 5b and R 6 together with the atom to which it is attached form a C3-C7 cycloalkyl group or a C3-C7 heterocycloalkyl group, wherein said cycloalkyl group or heterocycloalkyl group is optionally substituted by 1 to 3 deuterium, halogen, OH, CN, or a C1-C3 alkyl group; R 8aand R 8b are independently hydrogen, deuterium, -S(O)R 9 or -C(O)R 9 and R 9 is a C1-C6 alkyl group, a C1-C6 cycloalkyl group, a 6- to 10-membered aryl group, or a 5- to 10-membered heteroaryl group having 1 to 3 heteroatoms, wherein the alkyl group, cycloalkyl group, aryl group, or heteroaryl group is optionally substituted by 1 to 3 C1-C6 alkyl groups, halogen, CN, OH, C1-C6 alkoxy groups, or C1-C6 hydroxyl groups; n is 0 or 1, t is 0, 1, 2, or 3, or

[0046] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-17, PTM-17a, PTM-17b, PTM-17c, PTM-17d, PTM-17e or PTM-17f: R1 is hydrogen or a C1-C4 alkyl group, wherein the alkyl is further substituted by one or more substituents selected from halogen, hydroxyl, methoxy, amino, CF3, or a C3-C6 cycloalkyl group; R 2 and R 3are each independently hydrogen, deuterium, heavy hydrogen, C1-C6 straight or branched chain alkyl group, C3-C6 cycloalkyl group, C1-C6 straight or branched chain perfluoroalkyl group, C1-C6 straight or branched chain alkoxy group, C1-C6 straight or branched chain perfluoroalkoxy group, halogen, cyano group, hydroxyl group, amino group, carboxyl group, aminocarbonyl group, aryl group, heteroaryl group, (aryl)C1-C6 straight or branched chain alkyl group, (heteroaryl)C1-C6 straight or branched chain alkyl group, straight-chain or branched-chain alkyl group, (heterocycloalkyl)C1-C6 straight-chain or branched-chain alkyl group, (C1-C6 straight-chain or branched-chain alkyl)aryl group, (C1-C6 straight-chain or branched-chain alkyl)heteroaryl group, (C1-C6 straight-chain or branched-chain alkyl)heterocycloalkyl group, (C1-C6 straight-chain or branched-chain alkoxy)carbonyl group, (C1-C6 straight-chain or branched-chain alkyl)aminocarbonylamino group, or (C1-C6 straight-chain or branched-chain alkyl)aminocarbonyl group; R 4 is selected from hydrogen, deuterium, C1-C6 straight or branched chain alkyl groups, C1-C6 straight or branched chain perfluoroalkyl groups, aryl groups or alkaryl groups; X is -NH- or -CR a R b -, wherein (a) R a and R b are independently hydrogen, deuterium, C1-C6 straight or branched chain alkyl group, C3-C6 cycloalkyl group, aryl group, (aryl)C1-C6 straight or branched chain alkyl group, heteroaryl group, (C1-C6 straight or branched chain alkyl)heteroaryl group, (heteroaryl)C1-C6 straight or branched chain alkyl group, (heterocyclic)C1-C6 straight or branched chain alkyl group, or (b) R a and R b Together, -(CR c R d )j-, where R c and R dare independently hydrogen, deuterium, deuterium, a C1-C6 straight or branched chain alkyl group, an aryl group, a (C1-C6 straight or branched chain alkyl)aryl group, a heteroaryl group, a (C1-C6 straight or branched chain alkyl)heteroaryl group, halogen, CN, CF3, a hydroxyl group, CONH2 or SO2CH3; Y is -A-R5, where A is a bond, -(CH2)k-, or -(CD2) k -, and R5 is a C1-C6 straight or branched alkyl group, a C3-C6 cycloalkyl group, an aryl group, or -NR a’ R b’ or an unsaturated, saturated or partially saturated monocyclic or bicyclic ring of a total of 4 to 11 atoms containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulfur, wherein the alkyl group, C3-C6 cycloalkyl group, aryl group or monocyclic or bicyclic ring is optionally substituted with deuterium, halogen, C1-C6 straight or branched chain alkyl group, CN, hydroxyl group, CF3, -OR e , -NR e R f , -S(O) p R e or a C3-C6 cycloalkyl group, wherein the alkyl and cycloalkyl groups can be optionally substituted with one or more substituents selected from halogen, CN, hydroxyl, CONH2, or SO2CH3, wherein (a) R a’ and R b’ are independently hydrogen, deuterium, C1-C6 straight or branched chain alkyl groups, C3-C6 cycloalkyl groups, aryl groups, (C1-C6 straight or branched chain alkyl)aryl groups, heteroaryl groups, or (C1-C6 straight or branched chain alkyl)heteroaryl groups, wherein the alkyl and cycloalkyl groups are optionally selected from the group consisting of one or more R c’ or (b) R a’ and R b’ Together, -(CR c 'R d')j-, where R c’ and R d ' independently represents hydrogen, deuterium, C1-C6 straight or branched chain alkyl, aryl, (C1-C6 straight or branched chain alkyl)aryl, heteroaryl, (C1-C6 straight or branched chain alkyl)heteroaryl, halogen, CN, hydroxyl, CF3, CONH2, -OR e or -NR e R f , or -S(O)pR e where R e and R f are independently hydrogen, deuterium, C1-C6 straight or branched chain alkyl groups, or C3-C6 cycloalkyl groups, wherein said alkyl and cycloalkyl groups can be optionally substituted with one or more substituents selected from halogen, CN, hydroxyl, CF3, and CONH2; j is 2, 3, 4 or 5; k is 1, 2, 3 or 4; p is 0, 1 or 2; n is 1 or 2, or

[0047] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-18, PTM-18a, PTM-18b, PTM-18c, PTM-18d, PTM-18e or PTM-18f: X and X' are each independently CR 6 , N or -N+O-, Y is independently N, —NO—, or CH, with the proviso that at least one of X, X′, or Y is not N or —NO—, and no more than one of X, X′, or Y is —NO—; R 1is a C1-C6 alkyl group or a 3- to 7-membered cycloalkyl group, wherein said alkyl group or cycloalkyl group is optionally halogenated, deuterated, -OR5, -SR5, -NR 11a R 11b , substituted by 1 to 5 substituents selected from a cyano group, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, or a C1-C6 alkoxy group; R 2 is a 3- to 10-membered cycloalkyl group, a 3- to 10-membered heterocycloalkyl group having 1 to 3 heteroatoms, a 5- to 10-membered heteroaryl group having 1 to 3 heteroatoms, or a C aryl group, wherein the cycloalkyl group, heterocycloalkyl group, heteroaryl group, or aryl group optionally has 1 to 5 R 3 and when a heteroatom on said heterocycloalkyl or heteroaryl group is N, said N is optionally substituted by R 4 is replaced by R 3 are independently deuterium, halogen, C1-C6 alkyl group, C3-C6 cycloalkyl group, C1-C6 alkoxy group, oxo, -SR 5 , -NR 11a R 11b , cyano group or -OR 5 wherein the alkyl, cycloalkyl or alkoxy groups are optionally and independently selected from deuterium, halogen, -OR, -SR, -NR 11a R 11b , cyano group, C1-C6 alkyl group, C3-C6 cycloalkyl group or C1-C6 alkoxy group, or two R3 together with the carbon atoms to which they are attached form a 3- to 6-membered cycloalkyl group or a 4- to 6-membered heterocycloalkyl group, wherein the cycloalkyl group or heterocycloalkyl group optionally contains a halogen, deuterium, -OR5, -SR5, -NR 11a R 11b, cyano group, C1-C6 alkyl group or C1-C6 alkoxy group, wherein the alkyl group or alkoxy group is optionally substituted with halogen, deuterium, -OR5, -SR5, -NR 11a R 11b or a cyano group, wherein if a heteroatom on said heterocycloalkyl group is N, said N is optionally substituted by a substituent selected from R 4 is replaced by R 4 represents hydrogen, deuterium, C1-C6 alkyl group, -C(O)R 10 or -S(O)2R 8 wherein the alkyl group is optionally substituted with OH, halogen, deuterium, a C1-C6 alkyl group, a C1-C6 alkoxy group, or a cyano group; R 5 is hydrogen or a C1-C6 alkyl group, wherein said alkyl group is optionally selected from halogen, deuterium, a C1-C6 alkoxy group, a C1-C6 alkylthio group, -NR 11a R 11b , substituted by a cyano group, a C1-C6 alkyl group or a C3-C6 cycloalkyl group; R 6 represents hydrogen, deuterium, halogen, cyano group, -OR5, -SR5, -NR 11a R 11b , a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a 3- to 7-membered heterocycloalkyl group, a 5- to 6-membered heteroaryl group or an aryl group, wherein the alkyl group, cycloalkyl group, heterocycloalkyl group, heteroaryl group or aryl group is optionally selected from the group consisting of halogen, -OR5, -SR5, -NR 11a R 11b , cyano group, C1-C3 alkyl group, -C(O)R 10 or oxo, R 7 are independently hydrogen, deuterium, a methyl group, a cyano group, OCF3, OMe, CF3, or a halogen; R 8are independently a C alkyl group, a 3- to 6-membered cycloalkyl group, a 4- to 6-membered heterocycloalkyl group, a C aryl group, or a 5- to 10-membered heteroaryl group, wherein the alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group, or heteroaryl group is optionally selected from the group consisting of deuterium, halogen, OH, a C-C alkoxy group, and optionally -NR 11a R 11b or a C1-C3 alkyl group substituted with a C1-C6 alkoxy group, a 3- to 6-membered cycloalkyl group, -NR 11a R 11b or a cyano group, R 10 is a C1-C6 alkyl group, a 3- to 6-membered cycloalkyl group, a 4- to 6-membered heterocycloalkyl group, a 6- to 10-membered aryl group, or a 5- to 10-membered heteroaryl group, wherein said alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group, or heteroaryl group is optionally selected from the group consisting of deuterium, halogen, OH, a C1-C6 alkoxy group, and optionally -NR 11a R 11b or a C1-C3 alkyl group substituted with a C1-C6 alkoxy group, a 3- to 6-membered cycloalkyl group, -NR 11a R 11b or a cyano group, R 11a and R 11b are each independently hydrogen, deuterium, a 3- to 6-membered cycloalkyl group, or a C1-C6 alkyl group, wherein the cycloalkyl or alkyl group is optionally substituted with a substituent selected from deuterium, a C1-C6 alkoxy group, or a cyano group, and when the alkyl group is a C2-6 alkyl group, the alkyl group is optionally substituted with deuterium, a C1-C6 alkoxy group, a cyano group, a halogen, or OH; or

[0048] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-19, PTM-19a, PTM-19b, PTM-19c, PTM-19d, PTM-19e, PTM-19f, PTM-19g, PTM-19h, PTM-19i, PTM-19j, PTM-19k, PTM-19l, PTM-19m, PTM-19n, PTM-19o, PTM-19p, PTM-19q, PTM-19r, PTM-19s, PTM-19t, PTM-19u, PTM-19v, PTM-19w, PTM-19x, PTM-19y, PTM-19z, PTM-19a′, PTM-19b′, PTM-19c′, or PTM-19d′, R is an alkyl group, a heteroalkyl group, a heteroaryl group, an aryl group, a halogen, an amide, or CN; R 1 is H, an alkyl group, a heteroalkyl group, or R and R together with the atom to which they are attached form a heterocycloalkyl group; R 2 is H, an aliphatic, alkyl, heteroalkyl, aryl, amido, or heterocycloalkyl group; R 3 are independently H, an alkyl group, a halogen, a heteroalkyl group, an -O-alkyl group, a heterocycloalkyl group, an aryl group, an -O-heterocycloalkyl group, a hydroxyl group, a nitro group, a cyano group, a carboxylic acid, an ester, an acyl group, an amide, an amino group, a sulfonyl group, a sulfonamide, an alkyl-S-, a sulfinyl group, an alkyl halide group, an alkyl phosphate, or an alkyl phosphonate; R 4 , R 5 , R 6 and R 7are each independently H, an alkyl group, a heteroalkyl group, an alkoxy group, a heterocycloalkyl group, an aryl group, an O-heterocycloalkyl group, a hydroxyl group, a halogenated alkyl group, a halogen, a nitro group, a cyano group, a carboxyl group, an ester, an acyl group, an amide, an amino group, a sulfonyl group, a sulfonamide, an alkyl-S-, or a sulfinyl group; R 8 and R 9 are each independently H, an alkyl group, a heteroalkyl group, an aryl group, a heterocycloalkyl group, a sulfonyl group, a nitro group, a halogen, a halogenated alkyl group, an ester, a cyano group, or an amino group; R 10 is H, an alkyl group, a heteroalkyl group, an alkoxy group, an ester, an aryl group, a nitro group, a cyano group, a hydroxyl group, an alkyl halide group, an alkyl phosphate, or an alkyl phosphonate; R 11 , R 12 , R 13 and R 14 are each independently H, an alkyl group, a heteroalkyl group, an aryl group, a heterocycloalkyl group, a sulfonyl group, a nitro group, a halogen, a halogenated alkyl group, an ester, a cyano group, or an amino group; R 15 and R 16 are each independently H, an alkyl group, a heteroalkyl group, an aryl group, a heterocycloalkyl group, or together with the N atom to which they are attached form a heterocycloalkyl group; x, y, and z are each independently an integer of 1 to 6; Het-1 and Het-2 are each independently a heteroaryl group; Het-3 is a heterocycloalkyl group, or

[0049] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-20, PTM-20a, PTM-20b or PTM-20c: R 1 and R 2 At least one of R is aromatic, and the remaining R 1 or R2 is H, an alkyl group, a halogenated alkyl group, a nitro group, a cyano group, an amide group, an amino group, a hydroxyl group, a carboxyl group, a carboxyl ester, or an acyl group; R 3 is H, an alkyl group, a heteroalkyl group, a heterocycloalkyl group, an amide, an aromatic group, or an araliphatic group; R 4 is H, an alkyl group, a heteroalkyl group, or R 1 and R 2 One of the and R 4 together with the atom to which it is attached form a heterocycloalkyl group, R 5 is H or an alkyl group, R 6 , R 7 , R 8 and R 9 is H, an alkyl group, a heteroalkyl group, an alkoxy group, an ester, a sulfonyl group, a halogen, an acyl group, an amino group, an aryl group, a heterocycloalkyl group, a nitro group, a cyano group, a hydroxyl group, a halogenated alkyl group, an alkyl phosphate, or an alkyl phosphonate; Ring A is a heterocycloalkyl group, or

[0050] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide or prodrug thereof, wherein said PTM is PTM-21, PTM-21a or PTM-21b; X is O or S; Y is O or S; Z is N or CR 9 and Het-1 is a heteroaryl group, R 1 and R 2 is independently H, an alkyl group, a cycloalkyl group, a heteroalkyl group, a heterocycloalkyl group, an aryl group, or together with the nitrogen to which it is attached form a heterocycloalkyl group; R 3 , R 4 , R 5 , R 6 and R 9 are independently H, a cycloalkyl group, an alkyl group, a halogen, a heteroalkyl group, an -O-alkyl group, a heterocycloalkyl group, an aryl group, an -O-heterocycloalkyl group, a hydroxyl group, a nitro group, a cyano group, a carboxyl group, an ester, an acyl group, an amide group, an amino group, a sulfonyl group, a sulfonamide group, an alkyl-S-, a sulfinyl group, or a halogenated alkyl group; R 7 is H, an alkyl group, a heteroalkyl group, a heterocycloalkyl group, or an aryl group; R 8 are independently an alkyl group, a halogen, a heteroalkyl group, an -O-alkyl group, a heterocycloalkyl group, an aryl group, an -O-heterocycloalkyl group, a hydroxyl group, a nitro group, a cyano group, a carboxyl group, an ester, an acyl group, an amide, an amino group, a sulfonyl group, a sulfonamide group, an alkyl-S-, a sulfinyl group, or a halogenated alkyl group; and m is the number of possible substituents on Het-1 from 0, or

[0051] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-22, PTM-22a, PTM-22b, PTM-22c, PTM-22d, PTM-22e, PTM-22g or PTM-22h: Ring A is a cycloalkyl group, Ring B is selected from an aryl group or a heteroaryl group; R 1 is selected from a C1-10 alkyl group, a C3-C10 cycloalkyl group, a halogen, an aryl group, or a heteroaryl group; R 2 and R 3 are independently selected from hydrogen or a C1-C6 alkyl group; R 4 is a C1-C6 alkyl group, a cyano group, a halogen, or hydrogen, or

[0052] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt, solvate, hydrate, N-oxide or prodrug thereof, wherein in said PTM-23: Het-1 is a heteroaryl group, R 1 is hydrogen or an alkyl group, R 2 is an alkoxy group or -N(R c )2, R 3 is a C1-C6 alkyl group, a C1-C3 halogenated alkyl group, or a halogen; m is 0, 1 or 2; R 4 is a C1-C6 alkyl group, k is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9; A is N or CR h and R h is hydrogen, deuterium, R 3 ,or [ka] and R 5 is hydrogen, deuterium, an alkyl group, a phosphonooxyalkyl group, a phosphonoalkyl group, or an acyl group; R 6 and R 7 are each independently hydrogen, deuterium, an alkyl group, or a halogen; X is O or NR 9 and R 9 is R a , C(O)C1-C6 alkyl group, C(O)N(R c )2, C(O)OR a and Y is N or CH; Linker is a bond, -(C(R 10 )2) n -O-, -C(O)-(C(R 10 )2) p - or (C(R 10 )2)pN(R a )- and R 10 is R a , or R b and n is 1, 2, 3, 4, 5 or 6; p is 0, 1, or 2; R a is hydrogen, deuterium, D, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group; R b is a hydroxyl group, -OR a , or halogen, R c is R a or two R c taken together with the nitrogen atom to which it is attached form a C heterocycloalkyl group, said heterocycloalkyl group optionally further containing 1 or 2 heteroatoms selected from N, S or O, or

[0053] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-24, PTM-24a, PTM-24b, PTM-24c, PTM-24d, PTM-24e, PTM-24f, PTM-24g, PTM-24h, PTM-24i, PTM-24j, PTM-24k, PTM-24l, PTM-24m, PTM-24n, PTM-24o, PTM-24p, PTM-24q, PTM-24r, PTM-24s, PTM-24t, PTM-24u, PTM-24v, PTM-24w, PTM-24x or PTM-24y, Ring A is a 3- to 7-membered saturated or partially unsaturated carbocyclic ring or a 4- to 7-membered saturated or partially unsaturated heterocycloalkyl group containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; n is an integer from 0 to 4, R 1 are independently -R, halogen, -CN, -NO2, -OR, -CH2OR, -SR, -N(R)2, -S2R, -SO2N(R)2, -SOR, -C(O)R, -C2R, -C(O)N(R)2, -C(O)N(R)-OR, -NR c (O)OR, -NR c (O)N(R)2, Cy or -NRSO2R, or R1 is [ka] is one of the items selected from or two R's 1 together with the atoms to which it is attached form an optionally substituted 4-7 membered fused, spiro-fused or bridged bicyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; each Cy is an optionally substituted ring selected from a 3- to 7-membered saturated or partially unsaturated carbocycle or a 4- to 7-membered saturated or partially unsaturated heterocycle containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R is independently hydrogen or an optionally substituted group selected from a C1-C6 alkyl group, a phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocycle containing 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaryl ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or two R's together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated, partially unsaturated heterocycle or heteroaryl ring containing 0 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, excluding the nitrogen atom; Ring B is a 4- to 8-membered partially unsaturated carbocyclic fused ring, a benzofused ring, or a 4- to 7-membered partially unsaturated heterocyclic fused ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaromatic fused ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said Ring B is optionally substituted with one or more selected from oxo, thiocarbonyl, or imino groups; m is 1 to 4; p is 0 to 2; W is N or -C(R 3 )- and R z is R, CN, NO2, halogen, -C(O)N(R)2, -C(O)OR, -C(O)R, -N(R)2, -NH-[Ar], -N(R)C(O)OR, -NR c (O)N(R)2, -OR or -SO2N(R)2; [Ar] is an optionally substituted phenyl group or heteroaromatic ring; R 3 is hydrogen, deuterium, halogen, —CN, a C1-C4 aliphatic group, a C1-C4 haloaliphatic group, —OR, —C(O)R, or —C(O)N(R), L 1is a bond or a C-C divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -NR-, -N(R)C(O)-, -C(O)N(R)-, -N(R)SO-, -SON(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -SO-, or -SO-; Each L 2 is independently a bond or a C-C divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -NR-, -N(R)C(O)-, -C(O)N(R)-, -N(R)SO-, -SON(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -SO-, or -SO-; Each R 4 are independently halogen, -CN, -NO2, -OR, -SR, -N(R)2, -S02R, -SO2N(R)2, -SOR, -C(O)R, -C02R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -C(O)N(R)OR, -N(R)C(O)OR, -N(R)S(O)2N(R)2, -NRSO2R or an optionally substituted group selected from a C1-C6 aliphatic group, a phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocycle containing 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or two -L 2 (R 4 )pR 4 a group, taken together with the atom to which it is attached, forms an optionally substituted 4-7 membered fused, spirofused or bridged bicyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or

[0054] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-25, PTM-25a, PTM-25b, PTM-25c, PTM-25d, PTM-25e, PTM-25f, PTM-25g or PTM-25h: Q is CH, C-CN or N; X is for CL 2 (R 4 )pR x and Y is N, or X is N and Y is CR x and Ring A is a 3- to 7-membered saturated or partially unsaturated carbocyclic ring or a 4- to 7-membered saturated or partially unsaturated heterocycloalkyl group containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 1 and R 1 ' is independently -R 2 , halogen, -CN, -NO2, -OR, -SR, -N(R)2, -S(O)2R, -S(O)2N(R)2, -S(O)R, -C(O)R, -C(O)OR, -C(O)N(R)2, -C(O)N(R)OR, -N(R)C(O)OR, -N(R)C(O)N(R)2, Cy or -N(R)S(O)2R; or R 1 teeth, [ka] or Two R's 1 a group, taken together with the atom to which it is attached, forms an optionally substituted 4-7 membered fused, spirofused or bridged bicyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; each Cy is an optionally substituted ring selected from a 3- to 7-membered saturated or partially unsaturated carbocycle or a 4- to 10-membered saturated or partially unsaturated heterocycle containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R is independently hydrogen or an optionally substituted group selected from a C1-C6 alkyl group, a phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two R groups, together with the nitrogen atom to which they are attached, form a 4- to 7-membered saturated, partially unsaturated heterocyclic or heteroaromatic ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, excluding nitrogen; Each R 2 are independently optionally substituted groups selected from a C1-C6 alkyl group, a phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocycle containing 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaromatic ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 4 are independently an optionally substituted group selected from halogen, —CN, —NO2, —OR, —SR, —N(R)2, —S(O)2R, —S(O)2N(R)2, —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R)2, —N(R)C(O)R, —N(R)C(O)N(R)2, —C(O)N(R)OR, —N(R)C(O)OR, —N(R)S(O)2N(R)2, —N(R)S(O)2R, or a C1-C6 alkyl group, a phenyl group, a 4-7 membered saturated or partially unsaturated heterocycle containing 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R x is hydrogen, deuterium, -R 2 , -CN, -NO2, halogen, -C(O)N(R)2, -C(O)OR, -C(O)R, -N(R)2, -NH[Ar], -OR or -S(O)2N(R)2; R z is hydrogen, deuterium, -R 2, -CN, -NO2, halogen, -C(O)N(R)2, -C(O)OR, -C(O)R, -N(R)2, -NH[Ar], -OR or -S(O)2N(R)2; [Ar] is m R 1 phenyl or heteroaromatic ring substituted by '; L 1 is a covalent bond or a C-C divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)-, -S(O)N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)-; L 2 is a covalent bond or a C-C divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)-, -S(O)N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)-; m is an integer from 0 to 4; n is an integer from 0 to 4, p is an integer from 0 to 2, or

[0055] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-26, PTM-26a, PTM-26b, PTM-26c, PTM-26d, PTM-26e, PTM-26f, PTM-26g, PTM-26h, PTM-26i, PTM-26g, PTM-26k, PTM-26l, PTM-26m or PTM-26n, Q is CH or N; Ring A is a 3- to 7-membered saturated or partially unsaturated carbocyclic ring or a 4- to 7-membered saturated or partially unsaturated heterocycloalkyl group containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 1 independently, -R 2 , halogen, -CN, -NO2, -OR, -SR, -N(R)2, -S(O)2R, -S(O)2N(R)2, -S(O)R, -C(O)R, -C(O)OR, -C(O)N(R)2, -C(O)N(R)OR, -N(R)C(O)OR, -N(R)C(O)N(R)2, Cy or -N(R)S(O)2R; or R 1 teeth, [ka] or Two R's 1 a group, taken together with the atom to which it is attached, forms an optionally substituted 4-7 membered fused, spirofused or bridged bicyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; each Cy is an optionally substituted ring selected from a 3- to 7-membered saturated or partially unsaturated carbocycle or a 4- to 10-membered saturated or partially unsaturated heterocycle containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R is independently hydrogen or an optionally substituted group selected from a C1-C6 alkyl group, a phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two R groups, together with the nitrogen atom to which they are attached, form a 4- to 7-membered saturated, partially unsaturated heterocyclic or heteroaromatic ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, excluding nitrogen; Each R 2are independently optionally substituted groups selected from a C1-C6 alkyl group, a phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocycle containing 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaromatic ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 5 and R 6 are each independently hydrogen or -L 2 (R 4 )pR x or R 5 and R 6 together with the atom to which it is attached form a 4- to 7-membered partially unsaturated heterocyclic or aromatic ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 4 are independently an optionally substituted group selected from halogen, —CN, —NO2, —OR, —SR, —N(R)2, —S(O)2R, —S(O)2N(R)2, —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R)2, —N(R)C(O)R, —N(R)C(O)N(R)2, —C(O)N(R)OR, —N(R)C(O)OR, —N(R)S(O)2N(R)2, —N(R)S(O)2R, or a C1-C6 aliphatic, phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocycle containing 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R x is hydrogen, deuterium, -R 2 , -CN, -NO2, halogen, -C(O)N(R)2, -C(O)OR, -C(O)R, -N(R)2, -NH[Ar], -OR or -S(O)2N(R)2; R z is hydrogen, deuterium, -R 2 , -CN, -NO2, halogen, -C(O)N(R)2, -C(O)OR, -C(O)R, -N(R)2, -NH[Ar], -OR or -S(O)2N(R)2; [Ar] is an optionally substituted phenyl group or a 5-6 membered heteroaryl ring containing 1-4 heteroatoms independently selected from N, O, or S; L 1 is a covalent bond or a C-C divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)-, -S(O)N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)-; L 2 is a covalent bond or a C-C divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)-, -S(O)N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)-; m is an integer from 0 to 4; n is an integer from 0 to 4, p is an integer from 0 to 2, or

[0056] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-27, PTM-27a, PTM-27b, PTM-27c, PTM-27d, PTM-27e, PTM-27f, PTM-27g or PTM-27h: Ring A is a 3- to 7-membered saturated or partially unsaturated carbocyclic ring or a 4- to 7-membered saturated or partially unsaturated heterocycloalkyl group containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 1are independently -R, halogen, -CN, -NO2, -OR, -SR, -N(R), -S(O)2R, -S(O)2N(R)2, -S(O)R, -C(O)R, -C(O)OR, -C(O)N(R)2, -C(O)N(R)OR, -N(R)C(O)OR, -N(R)C(O)N(R)2, Cy, or -N(R)S(O)2R; or R 1 teeth, [ka] or Two R's 1 a group, taken together with the atom to which it is attached, forms an optionally substituted 4-7 membered fused, spirofused or bridged bicyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; each Cy is an optionally substituted ring selected from a 3- to 7-membered saturated or partially unsaturated carbocycle or a 4- to 10-membered saturated or partially unsaturated heterocycle containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R is independently hydrogen or an optionally substituted group selected from a C1-C6 alkyl group, a phenyl group, a 4-7 membered saturated or partially unsaturated heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two R groups together with the nitrogen atom to which they are attached form a 4-7 membered saturated, partially unsaturated heterocyclic or heteroaromatic ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, excluding nitrogen; R z is -R, -CN, -NO2, halogen, -C(O)N(R)2, -C(O)OR, -C(O)R, -N(R)2, -OR or -S(O)2N(R)2; Ring B is a 4- to 8-membered unsubstituted partially unsaturated carbocyclic fused ring; L is a covalent bond or a C1-C6 divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)2-, -S(O)2N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)2-; n is an integer from 0 to 4, or

[0057] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or an acceptable salt thereof, wherein in said PTM-28, PTM-28a, PTM-28b, PTM-28c, PTM-28d or PTM-28e: Ring A is a 3- to 7-membered saturated or partially unsaturated carbocyclic ring or a 4- to 7-membered saturated or partially unsaturated heterocycloalkyl group containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; n is 0 to 4, R 1 are independently -R, halogen, -CN, -NO2, -OR, -CH2OR, -SR, -N(R)2, -S2R, -SO2N(R)2, -SOR, -C(O)R, -C2R, -C(O)N(R)2, -C(O)N(R)-OR, -NR c (O)OR, -NR c (O)N(R)2, Cy or -NRSO2R, or R 1 teeth, [ka] or one selected from or two R's 1 taken together with the atoms to which it is attached, forms an optionally substituted 4-7 membered fused, spirofused or bridged bicyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; each Cy is an optionally substituted ring selected from a 3- to 7-membered saturated or partially unsaturated carbocycle or a 4- to 7-membered saturated or partially unsaturated heterocycle containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R is independently hydrogen or an optionally substituted group selected from a C1-C6 alkyl group, a phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or two R groups together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated, partially unsaturated heterocyclic or heteroaryl ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, excluding the nitrogen atom; R x and R y are each independently R, CN, NO2, halogen, -SR, -OR, -N(R)2, -S2R, -SO2N(R)2, -SOR, -C(O)R, -C(O)OR, -C(O)N(R)2, -N(R)C(O)R, -NR c (O)N(R)2, or -NRSO2R; R x and R y together with the atoms to which it is bonded, [ka] forming a ring B substituted by ring B is a 4- to 8-membered partially unsaturated carbocyclic fused ring, a benzofused ring, a 4- to 7-membered partially unsaturated heterocyclic fused ring containing 1 to 2 heteroatoms selected from nitrogen, oxygen, and sulfur, or a 5- to 6-membered heteroaromatic fused ring having 1 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein ring B is optionally substituted with one or more selected from oxo, thiocarbonyl, and imino groups; m is an integer from 0 to 4, p is an integer from 0 to 2, W is N or -C(R 3)- and R z is R, CN, NO2, halogen, -C(O)N(R)2, -C(O)OR, -C(O)R, -N(R)2, -N(R)C(O)OR, -NR c (O)N(R)2, -OR or -SO2N(R)2; R 3 is hydrogen, deuterium, halogen, —CN, a C1-C4 aliphatic group, a C1-C4 haloaliphatic group, —OR, —C(O)R, or —C(O)N(R), L 1 is a bond or a C-C divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -NR-, -N(R)C(O)-, -C(O)N(R)-, -N(R)SO-, -SON(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -SO-, or -SO-; Each L 2 are independently a covalent bond or a C-C divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -NR-, -N(R)C(O)-, -C(O)N(R)-, -N(R)SO-, -SON(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -SO-, or -SO-; Each R 4 are independently halogen, -CN, -NO2, -OR, -SR, -N(R)2, -S02R, -SO2N(R)2, -SOR, -C(O)R, -C02R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -C(O)N(R)OR, -N(R)C(O)OR, -N(R)S(O)2N(R)2, -NRSO2R or an optionally substituted group selected from a C1-C6 alkyl group, a phenyl group, a 4-7 membered saturated or partially unsaturated heterocycle containing 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; or two -L 2 (R4 ) p R 4 a group, taken together with the atom to which it is attached, forms an optionally substituted 4-7 membered fused, spirofused or bridged bicyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or

[0058] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-29: Ring A is a 3- to 7-membered saturated or partially unsaturated carbocyclic ring or a 4- to 7-membered saturated or partially unsaturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur; Ring B is [ka] and where: [ka] represents a ring moiety fused to a pyrimidine ring, and # represents -L 2 (R 4 )PR x and R 1 and R 1 ' is independently -R 2 , halogen, -CN, -NO2, -OR, -CH2OR, -SR, -N(R)2, -SO2R, -SO2N(R)2, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -C(O)N(R)-OR, -NR c (O)OR, -NR c (O)N(R)2, Cy or -NRSO2R, or R 1 teeth, [ka] or one selected from or two R's1 taken together with the atoms to which it is attached, forms an optionally substituted 4-7 membered fused, spirofused or bridged bicyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; each Cy is an optionally substituted ring selected from a 3- to 7-membered saturated or partially unsaturated carbocycle or a 4- to 10-membered saturated or partially unsaturated heterocycle containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R is independently hydrogen or an optionally substituted group selected from a C1-C6 alkyl group, a phenyl group, a 4-7 membered saturated or partially unsaturated heterocycle containing 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or: two R groups, together with the nitrogen atom to which they are attached, form a 4- to 7-membered saturated, partially unsaturated heterocyclic or heteroaryl ring containing, excluding said nitrogen atom, 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 2 are independently optionally substituted groups selected from a C1-C6 alkyl group, a phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocycle containing 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaromatic ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 4are independently an optionally substituted group selected from halogen, —CN, —NO2, —OR, —SR, —N(R)2, —S(O)2R, —S(O)2N(R)2, —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R)2, —N(R)C(O)R, —N(R)C(O)N(R)2, —C(O)N(R)OR, —N(R)C(O)OR, —N(R)S(O)2N(R)2, —N(R)S(O)2R, or a C1-C6 aliphatic, phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocycle containing 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R x is hydrogen, deuterium, -R 2 , -CN, -NO2, halogen, -C(O)N(R)2, -C(O)OR, -C(O)R, -N(R)2, -NH[Ar], -OR or -S(O)2N(R)2; R z is hydrogen, deuterium, -R 2 , -CN, -NO2, halogen, -C(O)N(R)2, -C(O)OR, -C(O)R, -N(R)2, -NH[Ar], -OR or -S(O)2N(R)2; [Ar] is m R 1 a phenyl group substituted by ' or a heteroaromatic ring containing 1 to 4 heteroatoms selected from N, O or S, L 1 is a covalent bond or a C-C divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)-, -S(O)N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)-; L 2is a covalent bond or a C-C divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)-, -S(O)N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)-; m is an integer from 0 to 4; n is an integer from 0 to 4, p is an integer from 0 to 2, or

[0059] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-30: Y is N or CR x and Ring A is a 3- to 7-membered saturated or partially unsaturated carbocyclic ring or a 4- to 7-membered saturated or partially unsaturated heterocycloalkyl group containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 1 and R 1 ' is independently -R 2 , halogen, -CN, -NO2, -OR, -CH2OR, -SR, -N(R)2, -SO2R, -SO2N(R)2, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -C(O)N(R)-OR, -NR c (O)OR, -NR c (O)N(R)2, Cy or -NRSO2R, or R 1 teeth, [ka] or one selected from or two R's 1taken together with the atoms to which it is attached, forms an optionally substituted 4-7 membered fused, spirofused or bridged bicyclic ring containing 0-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; each Cy is an optionally substituted ring selected from a 3- to 7-membered saturated or partially unsaturated carbocycle or a 4- to 10-membered saturated or partially unsaturated heterocycle containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R is independently hydrogen or an optionally substituted group selected from a C1-C6 alkyl group, a phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocyclic ring containing 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or two R groups together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated, partially unsaturated heterocyclic or heteroaryl ring containing 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, excluding the nitrogen atom; Each R 2 are independently optionally substituted groups selected from a C1-C6 alkyl group, a phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocycle containing 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaromatic ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 4 are independently an optionally substituted group selected from halogen, —CN, —NO2, —OR, —SR, —N(R)2, —S(O)2R, —S(O)2N(R)2, —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R)2, —N(R)C(O)R, —N(R)C(O)N(R)2, —C(O)N(R)OR, —N(R)C(O)OR, —N(R)S(O)2N(R)2, —N(R)S(O)2R, or a C1-C6 aliphatic, phenyl group, a 4- to 7-membered saturated or partially unsaturated heterocycle containing 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered heteroaryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Rx , R y and R z are independently hydrogen, deuterium, -R 2 , -CN, -NO2, halogen, -C(O)N(R)2, -C(O)OR, -C(O)R, -N(R)2, -NH[Ar], -OR or -S(O)2N(R)2, or R x and R y together with the atom to which it is attached form a 4- to 7-membered partially unsaturated carbocyclic ring or a partially unsaturated heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, or S; [Ar] is m R 1 a phenyl group substituted by ' or a 5-6 membered heteroaryl group containing 1-4 heteroatoms selected from N, O or S, L 1 is a covalent bond or a C-C divalent hydrocarbon chain, wherein one or two methylene group units of said chain are optionally and independently replaced by -N(R)-, -N(R)C(O)-, -C(O)N(R)-, -N(R)S(O)-, -S(O)N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -S-, -S(O)-, or -S(O)-; m is an integer from 0 to 4; n is an integer from 0 to 4, or

[0060] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein PTM-31 is according to the formula: Ring A is a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, said heteroaromatic ring being optionally substituted; X is absent or -O-, -S-, -SO2-, -SO-, -C(O)-, -CO2-, -C(O)N(R)-, -OC(O)N(R)-, -NRc (O)-, -NR c (O)N(R)-, -NRSO2- or -N(R)-, or X is (CR r )mO-, -(CR r )mS-, -(CR r )mSO2-, -(CR r )mSO-, -(CR r )mC(O)-, -(CR r )mCO2-, -(CR r )mC(O)N(R)-, -(CR r )mOC(O)N(R)-, -(CR r )mNR c (O)-, -(CR r )mNR c (O)N(R)-, -(CR r )mNRSO2- or -(CR r )mN(R)-, Y is an optionally substituted C alkyl group; Z is absent, a divalent C3-10 aryl group, a divalent 3-8 membered saturated or partially unsaturated carbocycle, a divalent 3-7 membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a divalent 5-6 membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the foregoing groups being optionally substituted, or Z is -O-, -S-, -SO2-, -SO-, -C(O)-, -CO2-, -C(O)N(R)-, -OC(O)N(R)-, -NR c (O)-, -NR c (O)N(R)-, -NRSO2- or -N(R)-; W is CR or N; each R is independently hydrogen, deuterium, a C1-6 alkyl group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated carbocycle, a 3- to 7-membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; or two R groups on the same atom together with the atom to which they are attached form a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated carbocycle, a 3- to 7-membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; Each R 1 are independently -R, halogen, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -C02R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R or -N(R)2; R 2 are -R, halogen, -OR, -SR, -CN, -NO2, -SO2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R or -N(R)2; R 4 are -R, halogen, -OR, -SR, -CN, -NO2, -SO2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R or -N(R)2; each m is independently 1 or 2, and n is 0, 1, 2, 3, 4 or 5, or

[0061] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein PTM-32, PTM-32a or PTM-32b is according to the formula: Ring A is a 5-membered heterocyclic ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-membered monocyclic heteroaromatic ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said heterocyclic ring or heteroaromatic ring is optionally substituted; Ring B is a 6-membered aryl group or a 6-membered monocyclic heteroaromatic ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein the aryl group or heteroaromatic ring is optionally substituted; Ring C is a 5-membered heterocyclic ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-membered monocyclic heteroaromatic ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said heterocyclic ring or heteroaromatic ring is optionally substituted; X is absent or is -CH=CH-, -O-, -S-, -SO2-, -SO-, -C(O)-, -CO2-, -C(O)N(R)-, -OC(O)N(R)-, -NR c (O)-, -NR c (O)N(R)-, -NRSO2- or -N(R)-; Y is absent or a divalent C3-10 aryl group, a divalent 3-8 membered saturated or partially unsaturated carbocycle, a divalent 3-7 membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a divalent 5-6 membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the foregoing groups being optionally substituted; each R is independently hydrogen, a C1-6 alkyl group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated carbocycle, a 3- to 7-membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the foregoing groups being optionally substituted or Each R is independently -OR c , -SR c , -SO2R c , -SOR c , -C(O)R c , -CO2R c , -C(O)N(R)R c , -OC(O)N(R)R c , -NR c (O)R c , -NR c (O)N(R)R c , -NRSO2R c or -N(R)R c and two R groups on the same atom, together with the atom to which they are attached, form a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated carbocycle, a 3- to 7-membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; R a is H or an optionally substituted C alkyl group; R b is H or an optionally substituted C alkyl group; Each R c are independently H or an optionally substituted C alkyl group; n is 1, 2, 3, 4 or 5; p is 0, 1, 2, 3 or 4, and r is 0, 1 or 2, or

[0062] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or pharmaceutically acceptable tautomers, solvates, salts and stereoisomers thereof, including mixtures in all ratios thereof; wherein in said PTM-33: R1 and R3 are each independently H, (CH2)pCON(R 5 )2, OA, Hal, COOH, COOA, (CH2)pNHCOA, (CH2)pHet1, (CH2)pNR 2 R 5 or OH, R2 is H or a linear or branched alkyl group having 1, 2 or 3 C atoms, where one or two H atoms of said alkyl group are OR 6 , N.R. 5 R 6 , NHCOR 5 ,CONR 5 R 6 can be replaced by R4 is H or A; R5 is H or a linear or branched alkyl group having 1, 2 or 3 C atoms, R6 is H or a linear or branched alkyl group having 1, 2 or 3 C atoms, Z is absent or is Ar-diyl or Het-diyl; L is (CH2)n, where one or two CH2 groups are replaced by O or CH=CH-yl, and / or where one or two H atoms are replaced by OR 2 , N.R. 2 R 5 or can be replaced by Het1, Ar-diyl is a 1,2-, 1,3- or 1,4-phenylene group optionally substituted by 1 to 5 groups independently selected from Hal, CN, -CF3, -OCF3, OH, OA, SO2-A, COOH, COOA, -CO-A, O-phenyl, SO2-phenyl, SO2-CF3, Het2 or A; Het-diyl is an unsaturated, saturated or 5- or 6-membered heteroaryl group having 1 to 2 N, O or S atoms, which can be unsubstituted or mono-, di- or trisubstituted by Hal, CN, -CF3, -OCF3, OA, SO2-A, COOH, COOA, -CO-A, O-phenyl, SO2-phenyl, SO2-CF3, Het2 or A, A is a linear or branched alkyl group having 1 to 10 C atoms, in which 1 to 5 H atoms may be replaced by F or one or two non-adjacent CH groups may be replaced by O, Het1 is a morpholinyl, piperidinyl or pyrrolidinyl group; Het2 is a morpholinyl, piperidinyl or pyrrolidinyl group; Hal is F, Cl, Br, I, n is 1, 2, 3, 4, 5 or 6; p is 0, 1 or 2, or

[0063] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein PTM-34 is according to the formula: [ka] is a 3- to 7-membered nitrogen-containing heterocycloalkyl or heteroaryl group having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R a are independently -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R or -N(R)2; Ring X is a C3-C10 aryl group, a 5-6 membered monocyclic heteroaryl group containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a fused C3-C10 aryl group, a fused 5-10 membered saturated or partially unsaturated cycloalkyl group, a fused 5-10 membered heterocycloalkyl group containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a fused 5-10 membered monocyclic heteroaryl group containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; R 1 is -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R, or -N(R)2; R 2 is -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R or -N(R)2; R 3 is —R or —halogenated alkyl group, R 4 is -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R, or -N(R)2; Z is N or CR; each R is independently hydrogen, deuterium, a C1-C6 alkyl group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated carbocycle, a 3- to 7-membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; or two R groups on the same atom together with the atom to which they are attached form a C3-C10 aryl, a 3- to 8-membered saturated or partially unsaturated carbocycle, a 3- to 7-membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; and p is 0, 1, 2, 3, 4 or 5; where ring X is a phenyl group, Z is N, and R 1 teeth, [ka] and R 2 is H and R 3 is an n-propyl group, and R 4 is H, [ka] teeth, [ka] rather than, or

[0064] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein said PTM-35 or PTM-35a: B is CH, N or S, D is CH or N, E is CH or N, F is CH or N, G is CH or N, and J is C or N, where if B is S then D is CH, E is N, F is CH, G is N, and J is C; X is O, S, CH2 or N; M is 0 or 1, n is 0, 1 or 2, Ring A is a pyridyl group, a pyrazolyl group, a thienyl group, a furyl group, or a phenyl group; R1 is independently selected from a (C1-4)alkyl group, pyrimidine, piperidine, or phenyl group, each of which is optionally a (C1-4)alkyl group, OH, halogen, O(C1-4)alkyl group, methyl-piperidine, S(O)2R c Substitution, C(O)N(R b )2, or C(O)O(C1-C4) alkyl groups, R2 is absent or H; R3 is independently selected from a (C1-C4) alkyl group, a pyranyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a thiopyranyl group, a pyrazolyl group, a piperidinyl group, a morpholinyl group, and a piperazinyl group, each of which is independently selected from halogen, OH, oxo, N(R b )2, oxopyrrolidinyl group or morpholinyl group, or or R2 and R3 together with the nitrogen to which they are attached form a piperazinyl or morpholinyl group, respectively, optionally substituted by oxo; R4 is independently H or a methyl group; R b is independently selected from H and a (C1-4) alkyl group, and R c is a methyl group, or

[0065] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein in said PTM-37: X is NH or O, b is 0 or 1, n is 0, 1, 2, 3 or 4; R 1 and R2 are independently H or a C1-C4 alkyl group, or R 1 and R2 together with the nitrogen to which it is attached form a monocyclic or bicyclic heterocycle containing 3 to 8 carbon atoms, said heterocycle optionally further containing, apart from the nitrogen, one or two heteroatoms selected from N, O or S, said alkyl group and heterocycle optionally being joined by R a and is substituted by one or more substituents selected from R3 is a C1-C4 alkyl group, where two adjacent alkyl groups can be bonded together to form a bridged ring of 3 to 6 carbon atoms; R4 is absent, halogen or an O(C1-C4)alkyl group; R5 is halogen, CN, a C1-C4 alkyl group, an O(C1-C4) alkyl group, a C2-4 alkenyl group, an aryl group, a heteroaryl group, or a non-aromatic ring, and the alkyl group, alkenyl group, aryl group, heteroaryl group, and non-aromatic ring are optionally selected from the group consisting of one or more R b is replaced by R6 is absent, halogen, or an O(C1-C4)alkyl group; R a are independently selected from halogen, oxo, hydroxyl, CF, O(C-C)alkyl, SO(C-C)alkyl, C(O)O(C-C)alkyl, C(O)heterocycloalkyl, or heterocycloalkyl groups, wherein said alkyl groups can be grouped together to form a bridged ring with another alkyl group, and wherein said alkyl and heterocycloalkyl groups are optionally selected from R b is replaced by, and R b are independently OH, halogen, CHF2, (C1-C4) alkyl group, CF3, COOH, SO2(C1-C4) alkyl group, C(O)O(C1-C4) alkyl group, O(C1-C4) alkyl group, aryl group, heterocycloalkyl group, CN, C(O)N(R c )2, N(R c )2, wherein R c and the alkyl group is optionally substituted by OH, O(C1-C4) alkyl groups, alkyl groups and heterocycloalkyl groups, and R c are independently H, SO, a (C-C) alkyl group, or a (C-C) alkyl group; or

[0066] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein in said PTM-38, PTM-38a or PTM-38b: X is CH or N; a is 0 or 1, b is 0 or 1, and m is 0, 1, or 2; Ring A is a C-C cycloalkyl group, a C-C cycloalkenyl group, an aryl group, or a heterocycle, and optionally independently R 1 and is substituted by 1 to 3 substituents selected from R1 is H, oxo, (C=O) a O b (Cl-10) alkyl group, (C=O) a O b -aryl group, (C=O) a O b (C2-10) alkenyl group, (C=O) a O b (C2-10) alkynyl group, CO2H, halogen, OH, O b (Cl-6) Fluoroalkyl group, (C=O) a NR5 R 6 , CN, (C=O) a O b (C3-C8) cycloalkyl group, S(O)mNR 5 R 6 , SH, S(O)m-(C1-10) alkyl group or (C=O) a O b -heterocycloalkyl groups, wherein the alkyl groups, aryl groups, alkenyl groups, alkynyl groups, cycloalkyl groups and heterocycloalkyl groups are optionally selected from R a and is substituted by one or more substituents selected from R2 and R3 are independently H, (C=O) a O b (Cl-10) alkyl group, (C=O) a O b -aryl group, C2-10 alkenyl group, C2-10 alkynyl group, (C=O) a O b Heterocycloalkyl groups, COH, CN, O b (Cl-6) Fluoroalkyl group, Oa(C=O)bNR 5 R 6 , CHO, (N=O)R 5 R 6 , S(O)mNR 5 R 6 , SH, S(O)m(C1-C10) alkyl group, (C=O) a O b -C3-C8 cycloalkyl group, and optionally R 1 or R2 and R3 together with the nitrogen to which they are attached can form a monocyclic or bicyclic heterocycle, each ring having 3 to 7 members, and excluding the nitrogen, the ring optionally further containing one or two heteroatoms selected from N, O, or S, and the monocyclic or bicyclic heterocycle can optionally be formed by R 1 and is substituted by one or more substituents selected from R4 is selected from a C1-C6 alkyl group or a C3-C6 cycloalkyl group, and optionally Ra is replaced by R5 and R6 are independently H, oxo, (C=O) a O b -(C1-10) alkyl group, (C=O) a O b -aryl group, (C=O) a O b (C2-10) alkenyl group, (C=O) a O b -(C2-C10) alkynyl group, CO2H, O b (C1-C6) fluoroalkyl group, (C=O) a N(R a )2, CN, (C=O) a O b -(C3-C8))cycloalkyl group, S(O)mN(R a )2, SH, S(O)m(C1-10) alkyl groups and (C=O) a O b -heterocycloalkyl groups, wherein the alkyl groups, aryl groups, alkenyl groups, alkynyl groups, cycloalkyl groups and heterocycloalkyl groups are optionally selected from R a and is substituted by one or more substituents selected from R a are independently b , OH, C1-C6 alkoxy group, halogen, cyclopropyl group, CO2H, CN, Oa(=O)b(C1-C6) alkyl group, oxo or N(R b )2 is selected, R b are independently selected from H or a C1-C6 alkyl group, or

[0067] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein in said PTM-39 or PTM-39a: X is independently CH or N; Y is H or a methyl group; a is 0 or 1, b is 0 or 1, m is 0, 1 or 2, and n is 0, 1, 2, 3 or 4; Ring A is a C cycloalkenyl group, an aryl group, or a heterocycle, and optionally independently contains R 1 and is substituted by 1 to 3 substituents selected from R1 is H, oxo, (C=O) a O b (Cl-10) alkyl group, (C=O) a O b -aryl group, (C=O) a O b (C2-10) alkenyl group, (C=O) a O b (C2-10) alkynyl group, CO2H, halogen, OH, O b (Cl-6) Fluoroalkyl group, (C=O) a NR 5 R 6 , CN, (C=O) a O b (C3-C8) cycloalkyl group, S(O)mNR 5 R 6 , SH, S(O)m-(C1-10) alkyl group or (C=O) a O b -heterocycloalkyl groups, wherein the alkyl groups, aryl groups, alkenyl groups, alkynyl groups, cycloalkyl groups and heterocycloalkyl groups are optionally selected from R a and is substituted by one or more substituents selected from R2 and R3 are independently H, (C=O) a O b (Cl-10) alkyl group, (C=O) a O b -aryl group, C2-10 alkenyl group, C2-10 alkynyl group, (C=O) a O b Heterocycloalkyl groups, COH, CN, O b (Cl-6) Fluoroalkyl group, Oa(C=O)bNR 5 R 6 , CHO, (N=O)R5 R 6 , S(O)mNR 5 R 6 , SH, S(O)m-(C1-C10) alkyl group, (C=O) a O b -C3-C8 cycloalkyl group, and optionally R 1 or R2 and R3 together with the nitrogen to which they are attached form a monocyclic or bicyclic heterocycle, each ring having 3 to 7 members, and excluding the nitrogen, the ring optionally further containing one or two heteroatoms selected from N, O, or S, and the monocyclic or bicyclic heterocycle optionally includes R 1 and is substituted by one or more substituents selected from R4 is selected from a C1-C6 alkyl group, a hydroxyl group, a methoxy group, CF3, or F, wherein the alkyl group is optionally substituted by a hydroxyl group; R5 and R6 are independently H, (C=O) a O b -(C1-10) alkyl group, (C=O) a O b -aryl group, (C=O) a O b (C2-10) alkenyl group, (C=O) a O b -(C2-C10) alkynyl group, CO2H, O b (C1-6) fluoroalkyl group, (C=O) a N(R a )2, CN, (C=O) a O b -(C3-C8))cycloalkyl group, S(O)mN(R a )2, SH, S(O)m-(C1-10) alkyl groups and (C=O) a O b -heterocycloalkyl groups, wherein the alkyl groups, aryl groups, alkenyl groups, alkynyl groups, cycloalkyl groups and heterocycloalkyl groups are optionally selected from R a and is substituted by one or more substituents selected from R a are independently b , OH, C1-C6)alkoxy group, halogen, cyclopropyl group, CO2H, CN, Oa(C=O)b(C1-C6)alkyl group, oxo or N(R b )2 is selected, R b are independently selected from H or a C1-C6 alkyl group, or

[0068] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-42: X is N or CH; Y is -NR 2 and when Y is -CHR-, R and R, taken together with the carbon to which they are attached, optionally form a 4-6 membered cycloalkyl, cycloalkenyl or heterocycloalkyl group, wherein said 4-6 membered cycloalkyl, cycloalkenyl or heterocycloalkyl group is optionally substituted with 1 to 3 substituents, said substituents being independently selected from C-C alkyl, C-C cycloalkyl, phenyl, CF, heterocycloalkyl, halogen, -COOR 8 , -NHR 8 , -SR 8 , -OR 8 , -SO2R 8 , -COR 8 , -NHCOR 8 or -CONHR 8 or Y is selected from -NR 2 -If R 2 and R 3together with the nitrogen to which it is attached form a 4-6 membered heterocycle, wherein said 4-6 membered heterocycloalkyl group is optionally independently selected from a C1-C3 alkyl group, a C3-6 cycloalkyl group, a phenyl group, CF3, a heterocycloalkyl group, a halogen, -COOR 8 , -NHR 8 , -SR 8 , -OR 8 , -SO2R 8 , -COR 8 , -NHCOR 8 or -CONHR 8 and is substituted by 1 to 3 substituents selected from R 1 represents hydrogen, deuterium, C1-10 alkyl group, C3-C6 cycloalkyl group, aryl group, heterocycloalkyl group, halogen, -COOR 7 , -NHR 7 , -SR 7 , -OR 7 , -SO2R 7 , -COR 7 , -NHCOR 7 or -CONHR 7 wherein the alkyl, cycloalkyl, aryl, and heterocycloalkyl groups are optionally substituted with 1 to 3 substituents, the substituents being independently selected from C1-C4 alkyl, C3-C6 cycloalkyl, CN, phenyl, CF3, heterocycloalkyl, halogen, -COOR 8 , -NHR 8 , -SR 8 , -OR 8 , -SO2R 8 , -COR 8 , -NHCOR 8 or -CONHR 8 wherein said -NHR is selected from 8 is optionally substituted by —N(C1-C4 alkyl)NH2 or —N(C3-C6 cycloalkyl)NH2; R 2 is selected from hydrogen, deuterium, a C1-10 alkyl group, or a C3-C8 cycloalkyl group; R 3is hydrogen, deuterium, a C1-10 alkyl group, a C3-C8 cycloalkyl group, an aryl group, a heterocycloalkyl group, or -COOR 7 wherein the alkyl, cycloalkyl, aryl, and heterocycloalkyl groups are optionally substituted with 1 to 3 substituents, the substituents being independently selected from C1-C4 alkyl, C3-6 cycloalkyl, phenyl, CF3, heterocycloalkyl, halogen, -COOR 8 , -NHR 8 , -SR 8 , -OR 8 , -SO2R 8 , -COR 8 , -NHCOR 8 or -CONHR 8 is selected from R 6 represents a C1-10 alkyl group, a C3-C8 cycloalkyl group, an aryl group, a heterocycloalkyl group, -COOR 7 , -SO2R 7 , -COR 7 wherein the alkyl, cycloalkyl, aryl, and heterocycloalkyl groups are optionally substituted with 1 to 3 substituents, the substituents being independently selected from C1-C4 alkyl groups, C3-C6 cycloalkyl groups, phenyl groups, CF3, heterocycloalkyl groups, halogens, -COOR 8 , -NHR 8 , -SR 8 , -OR 8 , -SO2R 8 , -COR 8 , -NHCOR 8 or -CONHR 8 is selected from R 7 is selected from hydrogen, deuterium, a C1-10 alkyl group, a C3-C8 cycloalkyl group, an aryl group, or a heteroaryl group, wherein the alkyl group, cycloalkyl group, aryl group, and heterocycloalkyl group are optionally substituted with 1 to 3 substituents, the substituents being independently selected from a C1-C4 alkyl group, a C3-C6 cycloalkyl group, a phenyl group, CF3, a heterocycloalkyl group, a halogen, -COOR8 , -NHR 8 , -SR 8 , -OR 8 , -SO2R 8 , -COR 8 , -NHCOR 8 or -CONHR 8 is selected from R 8 is selected from hydrogen, deuterium, a C1-C6 alkyl group or a C3-C6 cycloalkyl group; or

[0069] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-43: A' is C=O, C(R)2 or NR; L is selected from a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated carbocycle, a 3- to 7-membered heterocyclic divalent group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each group being optionally substituted; X is CR or Y is NR or S; Z is CR or N; R1 is a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated carbocycle, a 3- to 7-membered heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted; R2 is -R, halogen, halogenated alkyl group, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R or -N(R)2; each R is independently hydrogen, deuterium, a C1-C6 alkyl group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated carbocycle, a 3- to 7-membered heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each group being optionally substituted; or two R groups on the same atom together with the atom to which they are attached form a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated cycloalkyl group, a 3- to 7-membered heterocycloalkyl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each group being optionally substituted; or

[0070] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-44: X is CR or N; X' is CR or N, where at least one of X or X' is N; Y is CR or N; R 1 is a C1-C6 alkyl group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated cycloalkyl group, a 3- to 7-membered heterocycloalkyl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted; R 2is a C1-C6 alkyl group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated cycloalkyl group, a 3- to 7-membered heterocycloalkyl group having 1-4 heteroatoms independently selected from nitrogen and oxygen, or a 5- to 6-membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each group being optionally substituted; or R 2 is (CR 2 )m-C3-C10 aryl group, (CR 2 )m-3 to 8-membered saturated or partially unsaturated cycloalkyl group, (CR 2 )m-3 to 7-membered heterocycloalkyl group, wherein the heterocycloalkyl group is a 3 to 7-membered heterocycloalkyl group containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or (CR 2 ) m- a 5-6 membered monocyclic heteroaryl group, said heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, each group being optionally substituted; Each R 3 are independently -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, NR c (O)R, -NR c (O)N(R)2, -NRSO2R, or -N(R)2; each R is independently hydrogen, deuterium, a C1-C6 alkyl group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated cycloalkyl group, a 3- to 7-membered heterocycloalkyl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each group being optionally substituted; or two R groups on the same atom together with the atom to which they are attached form a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated cycloalkyl group, a 3- to 7-membered heterocycle having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each group being optionally substituted; m is 1 or 2; n is 0, 1, 2 or 3, or

[0071] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein PTM-45 is according to the formula: X and X' are each independently CR or N; A is O, S, SO2, SO, -NR c (O), -NRSO2, or -N(R), or A is absent; R 3 is -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R, or -N(R)2, or A is -NR c-(O), -NRSO2 or -N(R), R and R3 together with the atoms to which they are attached form a 3- to 7-membered heterocycloalkyl group having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a 5- to 6-membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, each of the foregoing groups being optionally substituted; Ring Z is a 3- to 7-membered heterocycloalkyl group having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl group having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted; R 1 is -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R, or -N(R)2; R a is absent or is -R, halogen, halogenated alkyl group, -OR, -SR, -CN, -NO2, -S2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R, or -N(R)2; Ring Y is an optionally substituted 5-6 membered monocyclic heteroaryl group having 2-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 2 is -R, halogen, halogenated alkyl group, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R, or -N(R)2; R bis absent or is -R, halogen, halogenated alkyl group, -OR, -SR, -CN, -NO2, -S2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R, or -N(R)2; each R is independently hydrogen, deuterium, a C1-C6 alkyl group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated cycloalkyl group, a 3- to 7-membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl group containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; or two R groups on the same atom together with the atom to which they are attached form a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated cycloalkyl group, a 3- to 7-membered heterocycloalkyl group containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; where X is N and A is absent, then R 3 is not H, or

[0072] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or pharmaceutically acceptable derivatives, solvates, tautomers, salts, hydrates, and stereoisomers thereof, including mixtures in all ratios thereof, wherein PTM-46 is described by the formula: R" is H, a C1-C6 alkyl group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated cycloalkyl group, a 3- to 7-membered heterocycloalkyl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; R 1 is absent or is A or QR, R a does not exist OR 3 , CF3, Hal, NO2, R b is absent or is A or COR, R 2 are independently a C1-6 alkyl group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated cycloalkyl group, a 3- to 7-membered heterocycloalkyl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; Each Q is independently a straight or branched chain alkylidene group having 1 to 6 carbon atoms, wherein 1 to 5 hydrogen atoms are independently selected from OR 3 , Hal, N(R 3 and one or two of -CH-yl may be independently selected from CO, SO, SO, or NR 3 or Q represents a 4-8 membered saturated or unsaturated heterocycloalkyl or heteroaryl group having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each A is independently a straight or branched chain alkyl group having 1 to 10 carbon atoms, wherein 1 to 7 hydrogen atoms are independently selected from -OR 3 , Hal, NHSO2A, SO2A, SOA, N(R 3)2, and 1, 2 or 3 non-adjacent -CH-yl groups are independently selected from -CO-, -NR 3 or -O-, each Hal is F, Cl, Br or I; each R is independently hydrogen, a C1-C6 alkyl group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated cycloalkyl group, a 3- to 7-membered heterocycloalkyl group containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaryl group containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the foregoing groups being optionally substituted; Each R 3 is H or a C1-C6 alkyl group, in which one hydrogen atom can be replaced by a group selected from OH, O—(C1-C6 alkyl) or Hal, n is 0 or 1, or

[0073] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-47: Z is [ka] and X is CH or N; Y is CH or N; Ra, Rc, and R1 are each independently H, Hal, or A. 1 and Rb is H or a C alkyl group; A1 is a C1-12 branched or straight chain alkyl group, where 1 to 7 H atoms are optionally selected from Hal, OR b , COOR b , CN or N(R b)2, wherein 1 to 5 -CH2-yl are optionally substituted by O, CO, NR b or substituted by S, SO, SO2, 1,2-, 1,3- or 1,4-phenylene radicals, -CH=CH- or -C≡C-, Hal is F, Cl, Br, I, or

[0074] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-48: R 0 is hydrogen or a C1-C4 alkyl group, wherein the C1-C4 alkyl group is optionally mono- or polysubstituted with the same or different groups selected from hydroxyl groups or halogens; R 1 represents hydrogen, deuterium, halogen, cyano group, C(O)OH, C(O)OR a , C(O)NH2, C(O)N(H)R a , C(O)N(R a )R b , C(O)R d , a hydroxyl group, or a C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally a hydroxyl group, a halogen, a cyano group, C(O)OH, C(O)OR a , S(O)2C1-C6 alkyl group, NH2, NHR a , N(R a )R b a C1-C6 alkoxy group optionally mono- or polysubstituted with the same or different groups selected from halogen; a C3-C8 cycloalkyl-O- optionally mono- or polysubstituted with the same or different groups selected from halogen; cor a C1-C6 alkoxy group, wherein the C1-C6 alkoxy group is optionally selected from a hydroxyl group, a halogen, a cyano group, C(O)OH, C(O)OR a , S(O)2C1-C6 alkyl group, NH2, NHR a , N(R a )R b a C3-C8 cycloalkyl group optionally mono- or polysubstituted with the same or different groups selected from halogen; a C1-C6 alkoxy group optionally mono- or polysubstituted with the same or different groups selected from halogen; a C3-C8 cycloalkyl-O- optionally mono- or polysubstituted with the same or different groups selected from halogen; c heterocycloalkyl groups mono- or polysubstituted with the same or different groups selected from c or optionally R c or C3-C8 cycloalkyl-O- or heterocycloalkyl-O- optionally mono- or polysubstituted by the same or different groups selected from hydroxyl groups, halogens, cyano groups or C1-C6 alkyl groups, or represent aryl-O- or 5- or 6-membered heteroaryl-O-, wherein aryl-O- and 5- or 6-membered heteroaryl-O- are optionally mono- or polysubstituted by the same or different groups selected from hydroxyl groups, halogens, cyano groups, C(O)OH, C(O)OR a, a C3-C8-cycloalkyl or heterocycloalkyl group, which may be mono- or polysubstituted by the same or different groups selected from C1-C6 alkyl groups or C1-C6 alkoxy groups, or which may be mono- or polysubstituted by the same or different groups selected from hydroxyl groups, halogens, cyano groups and C1-C6 alkyl groups, or represents a C2-6 alkenyl or C2-6 alkynyl group, or represents an aryl group, a 5- to 10-membered heteroaryl group, an aryl-C1-C4 alkyl group or a 5- or 6-membered heteroaryl-C1-C4 alkyl group, wherein the aryl and heteroaryl groups are optionally mono- or polysubstituted by the same or different groups selected from halogens, hydroxyl groups, cyano groups, C(O)OH, C(O)OR a , may be mono- or polysubstituted by the same or different groups selected from a C1-C6 alkyl group, a C3-C8 cycloalkyl group or a C1-C6 alkoxy group; R a represents a C1-C6-alkyl group, a C3-C10-cycloalkyl group, a heterocycloalkyl group, an aryl group or a heteroaryl group, in which the alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are optionally mono- or polysubstituted by identical or different groups selected from halogen, hydroxyl, cyano, C1-C3 alkyl groups, C1-C3 alkoxy groups, heterocycloalkyl groups, —C(O)O—C6 alkyl groups or S(O)2C1-C6 alkyl groups, R b represents a C1-C6 alkyl group or a C3-C10 cycloalkyl group, or R a and R b together with the nitrogen atom form a 5- or 6-membered heterocycle, which may optionally be mono- or polysubstituted by identical or different groups selected from hydroxyl groups, halogens, cyano groups or C1-C6-alkyl groups, R c represents a hydroxyl group, a halogen, a cyano group, a C1-C3-alkyl group or a C1-C3-alkoxy group, R d represents hydrogen, deuterium, a C1-C6-alkyl group or a C3-C10 cycloalkyl group, R 2 represents hydrogen, deuterium, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group; R 13 represents hydrogen or a C1-C6 alkyl group, W contains 1 to 3 heteroatoms selected from N, O, or S, and optionally R 3 and optionally monosubstituted by the same or different groups R 4 or W represents a 5-membered heteroaryl group, optionally mono- or polysubstituted by R 3 and optionally monosubstituted by the same or different groups R 4 represents a pyridyl group, a pyrazinyl group, a pyridazinyl group, a 1,2,4-triazinyl group or a 1,3,5-triazinyl group, which is mono- or polysubstituted by R 3 represents hydrogen, deuterium, halogen, cyano group, C(O)R a , NH2, NHR a , N(R a )R b , N(H)C(O)R a or a C1-C6-alkyl group, wherein the C1-C6-alkyl group is optionally hydroxyl, halogen, cyano, C(O)R a , C(O)OH, C(O)OR a , S(O)2-C1-C6 alkyl group, NH2, NHR a , N(R a )R b, C1-C6 alkoxy groups, C3-C8-cycloalkyl-O-, where the C1-C6 alkoxy groups and C3-C8-cycloalkyl-O- can optionally be mono- or polysubstituted by the same or different halogen groups, or the C1-C6-alkyl groups can optionally be mono- or polysubstituted by the same or different groups selected from C3-C6-cycloalkyl groups and heterocycloalkyl groups, where the C3-C6-cycloalkyl groups and heterocycloalkyl groups can optionally be mono- or polysubstituted by the same or different groups selected from halogen groups. or the C1-C6-alkyl groups may be mono-, di- or tri-substituted by the same or different groups selected from halogen, cyano groups, C1-C3-alkyl groups and C1-C3-alkoxy groups, or the C1-C6-alkyl groups may be optionally mono- or polysubstituted by the same or different groups selected from aryl groups and 5- or 6-membered heteroaryl groups, where the aryl groups and 5- or 6-membered heteroaryl groups may be optionally mono-, di- or tri-substituted by the same or different groups selected from halogen, cyano groups, C1-C3-alkyl groups and C1-C3-alkoxy groups, or R 3 represents a C1-C6 alkoxy group, where the C1-C6-alkoxy group is optionally hydroxyl, halogen, cyano, C(O)OR a , S(O)2-C1-C6 alkyl group, N(R a )R b , C3-C8-cycloalkyl groups, C1-C4 alkoxy groups, C3-C8 cycloalkyl-O-, or represent a C3-C6-cycloalkyl group, a heterocycloalkyl group or a C5-C11 spirocycloalkyl group, wherein the cycloalkyl group, heterocycloalkyl group and spirocycloalkyl group may optionally be substituted with a hydroxyl group, a halogen atom, a cyano group, a C(O)R a , C(O)OH, C(O)OR a, which may be mono- or polysubstituted by identical or different groups selected from C1-C6-alkyl groups and C1-C4-alkoxy groups, or represent an aryl group or a 5- to 10-membered heteroaryl group, wherein the aryl and heteroaryl groups are optionally substituted with halogen, hydroxyl groups, cyano groups, C(O)OR a , S(O)2-C1-C6 alkyl group, NO2, NH2, NHR a , N(R a )R b , N(H)C(=O)R a , a C3-C8 cycloalkyl group, a C1-C3 alkoxy group and a C1-C3 alkyl group, wherein the C1-C3 alkyl group can optionally be mono- or polysubstituted with the same or different halogen groups; R 4 represents a halogen, a hydroxyl group, a cyano group or a C1-C6-alkyl group, where the C1-C6-alkyl group is optionally mono- or polysubstituted by the same or different groups selected from the halogens, a C1-C6-alkoxy group, where the C1-C6-alkoxy group is optionally mono- or polysubstituted by the same or different groups selected from the halogens, a C2-6-alkenyl group, a C2-6-alkynyl group, a C3-C10-cycloalkyl group, a 3- to 10-membered heterocycloalkyl group and an aryl group, where the aryl group can optionally be mono- or polysubstituted by the same or different groups R, or R 4 represents an aryl or heteroaryl group which may optionally be mono- or polysubstituted by identical or different groups R, or R 4 is C(O)R a , C(O)NH2, C(O)N(H)R a , C(O)N(R a )R b , C(O)OR a , NH2, NHR a , N(R a )R b , N(H)C(O)R a, N(R a )C(O)R a , N(H)C(O)NH2, N(H)C(O)NHR a , N(H)C(O)N(R a )R b , N(R a )C(O)NH2, N(R a )C(O)NHR a , N(R a )C(O)N(R a )R b , N(H)C(O)OR a , N(R a )C(O)OR a , NO2, N(H)S(O)R a , N(R a )S(=O)R a , N(H)S(O)R a , N(R a )S(O)2R a , N=S(O)(R a )R b ,OC(O)R a , OC(O)NH2, OC(O)NHR a , OC(O)N(R a )R b , S.H., S.R. a , S(O)R a , S(O)2R a , S(O)2NH2, S(O)2NHR a , S(O)2N(R a )R b or S(O)(=NR a )R b represents R is a halogen, a cyano group, a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-C10 cycloalkyl group, a 3- to 10-membered heterocycloalkyl group, an aryl group, a heteroaryl group, or C(O)R a , C(O)NH2, C(O)N(H)R a , C(O)N(R a )R b , C(O)OR a , NH2, NHR a , N(R a )R b , N(H)C(O)R a, N(R a )C(O)R a , N(H)C(O)NH2, N(H)C(O)NHR a , N(H)C(O)N(R a )R b , N(R a )C(O)NH2, N(R a )C(O)NHR a , N(R a )C(O)N(R a )R b , N(H)C(O)OR a , N(R a )C(O)OR a , NO2, N(H)S(O)R a , N(R a )S(O)R a , N(H)S(O)R a , N(R a )S(O)2R a , N=S(O)(R a )R b , OH, C1-C6-alkoxy group, OC(O)R a , OC(O)NH2, OC(O)NHR a , OC(O)N(R a )R b , S.H., S.R. a , S(O)R a , S(O)2R a , S(O)2NH2, S(O)2NHR a , S(O)2N(R a )R b or S(O)(=NR a )R b represents n represents 0 or 1, Y is [ka] represents a group selected from where * represents the point of attachment of the group to the rest of the molecule; R 5represents hydrogen, deuterium, a C1-C6-alkyl group or a C3-C10-cycloalkyl group, where the C1-C6-alkyl group is optionally a hydroxyl group, a halogen, a cyano group, C(O)OH, C(O)OR a , S(O)2-C1-C6 alkyl group, N(R a )R b , can be mono- or polysubstituted by the same or different groups selected from C1-C4 alkoxy groups or C3-C8 cycloalkyl groups, R 6 represents hydrogen or a C1-C6-alkyl group, where the C1-C6-alkyl group is optionally a hydroxyl group, a halogen, a cyano group, a C3-C10-cycloalkyl group, C(O)R a , C(O)OH, C(O)OR a , S(O)2-C1-C6 alkyl group, N(R a )R b , a C1-C4 alkoxy group or a C3-C8 cycloalkyl-O-, which may be mono- or polysubstituted by identical or different groups selected from a hydroxyl group, a halogen, a cyano group or a C1-C6-alkyl group, which may be optionally substituted by a hydroxyl group, or or heterocycloalkyl groups, which may optionally be mono- or polysubstituted by identical or different groups selected from halogen, cyano groups, C1-C3-alkyl groups or C1-C3-alkoxy groups, or represent aryl groups or 5- or 6-membered heteroaryl groups, where aryl groups and 5- or 6-membered heteroaryl groups are optionally mono- or polysubstituted by identical or different groups selected from halogen, cyano groups, C1-C3-alkyl groups, C1-C3-alkoxy groups, S(O)2NH2, S(O)2NHR a and S(O)N(R a )R b and may be mono- or polysubstituted by the same or different groups selected from R7a The table shows hydrogen, deuterium, halogens, N(R a )R b , a C1-C6-alkyl group or a C3-C10 cycloalkyl group, wherein the C1-C6-alkyl group is optionally a hydroxyl group, a halogen, a cyano group, C(O)OH, C(O)OR a , S(O)2-C1-C6 alkyl group, N(R a )R b , can be mono- or polysubstituted by identical or different groups selected from C1-C4-alkoxy groups, C3-C8-cycloalkyl groups and heterocycloalkyl groups, R 7b represents hydrogen, deuterium, halogen or a C1-C6-alkyl group, where the C1-C6-alkyl group is optionally a hydroxyl group, a halogen, a cyano group, C(O)OH, C(O)OR a , S(O)2-C1-C6 alkyl group, N(R a )R b , C1-C4-alkoxy groups, C3-C8-cycloalkyl groups or heterocycloalkyl groups, or R 7a and R 7b together with the carbon atoms form a C3-C6-cycloalkyl group, which can optionally be mono- or polysubstituted by identical or different groups selected from hydroxyl groups, halogens, cyano groups and C1-C6-alkyl groups, or R 7a and R 7b together represent an oxo group, R 7c is hydrogen, deuterium, halogen, N(R a )R b , a C1-C6-alkyl group or a C3-C10-cycloalkyl group, where the C1-C6-alkyl group is optionally a hydroxyl group, a halogen, a cyano group, C(O)OH, C(O)OR a , S(O)2-C1-C6-alkyl group, N(R a )Rb , can be mono- or polysubstituted by the same or different groups selected from C1-C4 alkoxy groups, C3-C8 cycloalkyl groups or heterocycloalkyl groups, R 7d represents hydrogen, deuterium, halogen or a C1-C6-alkyl group, where the C1-C6-alkyl group is optionally a hydroxyl group, a halogen, a cyano group, C(O)OH, C(O)OR a , S(O)2-C1-C6 alkyl group, N(R a )R b , a C1-C4 alkoxy group, a C3-C8 cycloalkyl group or a heterocycloalkyl group, or R 7c and R 7d together with the carbon atoms form a C3-C6-cycloalkyl group, which can optionally be mono- or polysubstituted by identical or different groups selected from hydroxyl groups, halogens, cyano groups or C1-C6-alkyl groups, or R 7c and R 7d together represent an oxo group, R 8a is hydrogen, deuterium, halogen, N(R a )R b , a C1-C6 alkyl group or a C3-C10 cycloalkyl group, wherein the C1-C6-alkyl group is optionally a hydroxyl group, a halogen, a cyano group, C(O)OH, C(O)OR a , S(O)2C1-C6 alkyl group, N(R a )R b , a C1-C4 alkoxy group, a C3-C8 cycloalkyl group or a heterocycloalkyl group, and R 8b represents hydrogen, deuterium, halogen or a C1-C6-alkyl group, where the C1-C6-alkyl group is optionally a hydroxyl group, a halogen, a cyano group, C(O)OH, C(O)ORa , S(O)2C1-C6 alkyl group, N(R a )R b , a C1-C4 alkoxy group, a C3-C8 cycloalkyl group or a heterocycloalkyl group, or R 8a and R 8b together with the carbon atoms form a C3-C6-cycloalkyl group, said C3-C6-cycloalkyl group optionally being mono- or polysubstituted by identical or different groups selected from hydroxyl groups, halogens, cyano groups or C1-C6-alkyl groups, R 8c is hydrogen, deuterium, halogen, N(R a )R b , a C1-C6-alkyl group or a C3-C10 cycloalkyl group, wherein the C1-C6-alkyl group is optionally a hydroxyl group, a halogen, a cyano group, C(O)OH, C(O)OR a , S(O)2C1-C6 alkyl group, N(R a )R b , C1-C4-alkoxy groups, C3-C8-cycloalkyl groups or heterocycloalkyl groups, R 8d represents hydrogen, deuterium, halogen or a C1-C6-alkyl group, where the C1-C6-alkyl group is optionally a hydroxyl group, a halogen, a cyano group, C(O)OH, C(O)OR a , S(O)2-C1-C6 alkyl group, N(R a )R b , a C1-C4 alkoxy group, a C3-C8 cycloalkyl group or a heterocycloalkyl group, or R 8c and R 8dtogether with the carbon atoms form a C3-C6-cycloalkyl group, which can optionally be mono- or polysubstituted by identical or different groups selected from hydroxyl groups, halogens, cyano groups or C1-C6-alkyl groups, or R 8c and R 8d together represent an oxo group, o represents 0, 1 or 2; p represents 0, 1 or 2; q represents 0, 1 or 2; r represents 0, 1 or 2; s represents 0, 1 or 2; where o, p, q, r, and s, if different, represent 0; Z is C(=O), CR 9 R 10 , N.R. 11 , O, S, S(O) or S(O) groups, R 9 represents hydrogen or a C1-C6-alkyl group, R 10 represents hydrogen, deuterium, halogen, cyano group, C(O)R a , C(O)OH, C(O)OR a , C(O)NH2, C(O)N(H)R a , C(O)N(R a )R b , N(H)C(O)R a , N(R b )C(O)R a , S(O)2R a , hydroxyl group, N(R a )R b and a C1-C6 alkyl group, wherein the C1-C6 alkyl group optionally includes a hydroxyl group, a halogen, a cyano group, a C(O)R a , C(O)OH, C(O)OR a , S(O)2C1-C6 alkyl group, N(R a )R b, which may be mono- or polysubstituted by identical or different groups selected from C1-C4 alkoxy groups and C3-C8 cycloalkyl-O-, or represent a C1-C6-alkoxy group, where the C1-C6-alkoxy group is optionally hydroxyl, halogen, cyano, C(O)OH, C(O)OR a , S(O)2C1-C6 alkyl group, N(R a )R b , C3-C8-cycloalkyl groups, C1-C4-alkoxy groups, C3-C8-cycloalkyl-O-, heterocycloalkyl groups, aryl groups or 5- or 6-membered heteroaryl groups, where the aryl groups and the 5- or 6-membered heteroaryl groups can optionally be mono- or polysubstituted by the same or different groups selected from halogens, cyano groups, C1-C3 alkyl groups and C1-C3 alkoxy groups, or represent aryl-O- or 5- or 6-membered heteroaryl-O-, where the aryl-O- and 5- or 6-membered heteroaryl-O- are optionally hydroxyl groups, halogens, cyano groups, C(O)OH, C(O)OR a , which may be mono- or polysubstituted by the same or different groups selected from C1-C3 alkyl groups or C1-C3 alkoxy groups, or represent a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl-C1-C4 alkyl group, a heterocycloalkyl group or a heterocycloalkyl-C1-C4 alkyl group, which may optionally be substituted with a hydroxyl group, a halogen, a cyano group, a C(O)R a , C(O)OH, C(O)OR a, C1-C6-alkyl groups or C1-C6-alkoxy groups, where the C1-C6-alkoxy groups may optionally be mono- or polysubstituted by the same or different halogen groups or oxo groups, or represent a C2-6 alkenyl group or a C2-6 alkynyl group, or represent an aryl group, a 5- to 10-membered heteroaryl group, an aryl-C1-C4 alkyl group or a 5- or 6-membered heteroaryl-C1-C4 alkyl group, where the aryl and heteroaryl groups may optionally be halogen, a hydroxyl group, a cyano group, C(O)OH, C(O)OR a , NHR a , N(R a )R b , C1-C3-alkyl groups, C3-C8-cycloalkyl groups or C1-C3-alkoxy groups, or R 9 and R 10 together with the carbon atoms form a C3-C8 cycloalkyl group or a 4- to 6-membered heterocycloalkyl group, wherein the C3-C8 cycloalkyl group or the 4- to 6-membered heterocycloalkyl group optionally contains a hydroxyl group, a halogen, a cyano group, a C1-C6-alkyl group, a C(O)R a or oxo groups, R 11 is hydrogen, deuterium, C(O)R a , C(O)OR a , C(O)NH2, C(O)N(H)R a , C(O)N(R a )R b , S(O)2R a , S(O)2N(R a )R b or a C1-C6-alkyl group, wherein the C1-C6-alkyl group is optionally hydroxyl, halogen, cyano, C(O)R a , C(O)OR a , C(O)NH2, C(O)N(H)R a, C(O)N(R a )R b , S(O)2C1-C6 alkyl group, N(R a )R b , a C3-C8 cycloalkyl group, a C1-C4 alkoxy group or a C3-C8 cycloalkyl-O-, wherein the C3-C8 cycloalkyl group, the C1-C4 alkoxy group and the C3-C8-cycloalkyl-O- can optionally be mono- or polysubstituted by the same or different groups selected from a hydroxyl group and a halogen, or represent a C3-C8-cycloalkyl group, a heterocycloalkyl group or a heterocycloalkyl-C1-C4 alkyl group, which can optionally be mono- or polysubstituted by the same or different groups selected from a hydroxyl group, a halogen, a cyano group, a C1-C6-alkyl group , C1-C6-alkoxy groups, where the alkyl and alkoxy groups may optionally be mono- or polysubstituted by the same or different groups selected from halogen and oxo groups, or represent a C2-6 alkenyl group or a C2-6 alkynyl group, or represent an aryl group, a 5- to 10-membered heteroaryl group, an aryl-C1-C4 alkyl group or a 5- or 6-membered heteroaryl-C1-C4 alkyl group, where the aryl and heteroaryl groups may optionally be halogen, a hydroxyl group, a cyano group, C(O)OH, C(O)OR a , can be mono- or polysubstituted by the same or different groups selected from C1-C3 alkyl groups, C3-C8 cycloalkyl groups or C1-C3 alkoxy groups, or

[0075] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt or solvate or salt of the solvate thereof, wherein in said PTM-49: Cy is one or more independently selected R 3or containing one or two heteroatoms independently selected from N, S, or O, and independently selected from R 3 is a 4- to 7-membered monocyclic heterocycloalkyl group substituted with one or more groups selected from R 1 is H, SO3H, P(O)(OH), a C1-C4 alkyl group, C(O)-(a 4- to 7-membered monocyclic heterocycloalkyl containing one or two heteroatoms independently selected from N, S, and O), or a C(O)C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally joined to one or more independently selected R 4 is substituted by a group, R 2 is H or a C1-C4 alkyl group, Each R 3 is independently selected from OH, oxo, halogen, or a C1-C4 alkyl group; Each R 4 are independently -NR 5a R 5b , —C(O)OH, a 4- to 7-membered monocyclic heterocycloalkyl group, which contains one or two heteroatoms independently selected from N, S and O, and is optionally substituted by one or more independently selected C1-C4 alkyl groups, or —NHC(O)—C1-C4 alkyl-NH2; R 5a and R 5b are independently H or a C1-C4 alkyl group, or

[0076] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-50, PTM-50, PTM-50 or PTM-50: Ring A is selected from a phenyl group or a 5- or 6-membered heteroaryl group; Ring B is selected from a phenyl group or a 5- or 6-membered heteroaryl group; n is 0, 1 or 2; p is 0, 1 or 2; one of W and X is N and the other of W and X is C; Y is N or CR 2 and R 1 is a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-C6 cycloalkyl group, a 3- to 6-membered saturated heterocycloalkyl group, a halogen, -CN, -C(R 1a )=NR(OR 1a ), -C(R 1a )=N(R 1a ), -C(O)R 1a , -C(O)2R 1a , -C(O)NR 1a , -NO2, -N(R 1a )2, -N(R 1a )C(O)R 1a , -NR 1a C(O)2R 1a , -N(R 1a )C(O)N(R 1a )2, -N(R 1a )S(O)2Rla, -OR 1a , -OC(O)R 1a , -OC(O)N(R 1a )2, -SRla, -S(O)Rla, -S(O)2Rla, -S(O)N(R 1a )2, or -S(O)2N(R 1a )2, wherein the C1-C6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C3-C6 cycloalkyl group, and 3- to 6-membered saturated heterocycloalkyl group are optionally selected from one or more R 10 or two R 1 Substituents, together with the atoms to which they are attached, form a C5-7 cycloalkyl group or a saturated 5- to 7-membered heterocycle, wherein said C5-7 cycloalkyl group or saturated 5- to 7-membered heterocycle optionally contains one or more R 15 is replaced by R appeared every time la are independently selected from H, a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a 3- to 6-membered monocyclic cycloalkyl group, or a 3- to 6-membered monocyclic heterocycloalkyl group, wherein each of said C1-C6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, 3- to 6-membered monocyclic cycloalkyl group, and 3- to 6-membered monocyclic heterocycloalkyl group is each independently optionally selected from one or more R 10 is replaced by R appeared every time 10 are independently a C1-C6 alkyl group, a C2-6 chain alkenyl group, a C2-6 alkynyl group, a 3- to 6-membered cycloalkyl group, a 3- to 6-membered heterocycloalkyl group, a halogen, -CN, -C(R 10a )=NR(OR 10 a), -C(R 10a )=N(R 10a ), -C(O)R 10 a, -C(O)2R 10 a, -C(O)N(R 10a )2, -NO2, -N(R 10a )2, -N(R 10a )C(O)R 10 a, -N(R 10a )C(O)2R 10 a, -N(R 10a )C(O)N(R 10a )2, -N(R 10a )S(O)2Rl0a, -OR 10 a, -OC(O)R 10 a, -OC(O)N(R 10a )2, -SR 10 a, -S(O)Rl0a, -S(O)2Rl0a, -S(O)N(R 10a )2 and -S(O)2N(R 10a )2 is selected, R appeared every time 10 a is independently selected from H and a C1-C6 alkyl group, wherein said C1-C6 alkyl group is optionally substituted by one or more halogens; R appeared every time 15are independently a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a 3- to 6-membered cycloalkyl group, a 3- to 6-membered heterocycloalkyl group, a halogen, -CN, -C(R 15 a)=NR(OR 15 a), -C(R 15 a)=N(R 15 a), -C(O)(R 15 a), -C(O)2(R 15 a), -C(O)N(R 15 a)2, -NO2, -N(R 15 a)2, -N(R 15 a)C(O)(R 15 a), -N(R 15 a)C(O)2(R 15 a), N(R 15 a)C(O)N(R 15 a)2, N(R 15 a)S(O)2(R 15 a), -OR 15 a, -OC(O)R 15 a, -OC(O)N(R 15 a)2,-SR 15 a, -S(O)R 15 a, -S(O)2(R 15 a), -S(O)N(R 15 a)2 and -S(O)2N(R 15 a) selected from 2, R appeared every time 15 a is independently selected from H and a C1-C6 alkyl group, wherein said C1-C6 alkyl group is optionally substituted by one or more halogens; R is H, a C1-C8 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a 3- to 7-membered cycloalkyl group, a 3- to 7-membered heterocycloalkyl group, a halogen, -CN, -C(R 2a )=NR(OR 2a ), -C(R 2a )=N(R 2a ), -C(O)(R 2a ), -C(O)2(R 2a ), -C(O)N(R 2a )2, -NO2, -N(R 2a )2, -N(R 2a )C(O)(R2a ), -N(R 2a )C(O)2(R 2a ), N(R 2a )C(O)N(R 2a )2, N(R 2a )S(O)2(R 2a ), -OR 2a , -OC(O)R 2a , -OC(O)N(R 2a )2, -SR 2a , -S(O)R 2a , -S(O)2(R 2a ), -S(O)N(R 2a )2 and -S(O)2N(R 2a )2, wherein the C1-C6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, 3- to 7-membered cycloalkyl group and 3- to 7-membered heterocycloalkyl group are optionally substituted by one or more R; R appeared every time 2a are independently selected from H and a C1-C6 alkyl group, wherein each occurrence of said C1-C6 alkyl group is optionally and independently selected from one or more R 20 is replaced by R 20 is independently selected from each occurrence of a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-7 cycloalkyl group, a 3- to 7-membered saturated heterocycloalkyl group, halogen, —CN, —C(R 20 a)=NR(OR 20 a), -C(R 20 a)=N(R 20 a), -C(O)(R 20 a), -C(O)2(R 20 a), -C(O)N(R 20 a)2, -NO2, -N(R 20 a)2, -N(R 20 a)C(O)(R 20 a), -N(R 20 a)C(O)2(R 20 a), N(R 20 a)C(O)N(R 20 a)2, N(R 20 a)S(O)2(R 20 a), -OR20 a, -OC(O)R 20 a, -OC(O)N(R 20 a)2,-SR 20 a, -S(O)R 20 a, -S(O)2(R 20 a), -S(O)N(R 20 a)2 and -S(O)2N(R 20 a) 2, wherein each occurrence of C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, and 3- to 7-membered saturated heterocycloalkyl is optionally and independently substituted by one or more R; R appeared every time 20 a is independently selected from H and a C1-C4 alkyl group, wherein said C1-C4 alkyl group is optionally substituted by R; R 25 is halogen and -OR 25 is selected from a R 25a is selected from H and a C1-C6 alkyl group; R is a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-C6 cycloalkyl group, a 3- to 6-membered saturated heterocycloalkyl group, a halogen, -CN, -C(R 3a )=NR(OR 3a ), -C(R 3a )=N(R 3a ), -C(O)(R 3a ), -C(O)2(R 3a ), -C(O)N(R 3a )2, -NO2, -N(R 3a )2, -N(R 3a )C(O)(R 3a ), -N(R 3a )C(O)2(R 3a ), N(R 3a )C(O)N(R 3a )2, N(R 3a )S(O)2(R 3a ), -OR 3a , -OC(O)R 3a , -OC(O)N(R 3a )2, -SR 3a, -S(O)R 3a , -S(O)2(R 3a ), -S(O)N(R 3a )2 and -S(O)2N(R 3a )2, wherein the C1-C6 alkyl group, C2-6 chain alkenyl group, C2-6 alkynyl group, C3-C6 cycloalkyl group and 3- to 6-membered saturated heterocycloalkyl group are optionally substituted by one or more R; R appeared every time 3a are independently selected from H, a C1-C6 alkyl group, a 3- to 6-membered cycloalkyl group, and a 3- to 6-membered heterocycloalkyl group, wherein each occurrence of said C1-C6 alkyl group, 3- to 6-membered cycloalkyl group, and 3- to 6-membered heterocycloalkyl group is optionally and independently substituted by one or more R; Each occurrence of R is independently a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a 3- to 6-membered cycloalkyl group, a 3- to 6-membered heterocycloalkyl group, a halogen, -CN, -C(R 30a )=NR(OR 30 a), -C(R 30a )=N(R 30a ), -C(O)(R 30a ), -C(O)2(R 30a ), -C(O)N(R 30a )2, -NO2, -N(R 30a )2, -N(R 30a )C(O)(R 30a ), -N(R 30a )C(O)2(R 30a ), N(R 30a )C(O)N(R 30a )2, N(R 30a )S(O)2(R 30a ), -OR 30 a, -OC(O)R 30 a, -OC(O)N(R 30a )2, -SR 30 a, -S(O)R 30 a, -S(O)2(R 30a ), -S(O)N(R 30a )2 and -S(O)2N(R 30a)2, wherein each occurrence of said C1-C6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, 3- to 6-membered cycloalkyl group, or 3- to 6-membered heterocycloalkyl group is optionally and independently substituted by one or more R; R appeared every time 30 a is independently selected from H and a C1-C4 alkyl group, where the C1-C4 alkyl group is optionally substituted by one or more R; R appeared every time 35 are independently halogen and -OR 35 is selected from a R appeared every time 35a is independently selected from H and a C1-C6 alkyl group; R 4 is H, halogen, C1-C4 alkyl group, N(R 4a )2 and -OR 4a Selected from, and R appeared every time 4a are independently selected from H and a C1-C6 alkyl group; or

[0077] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-51, PTM-51a, PTM-51b or PTM-51c: Ring A is selected from a phenyl group and a 5- or 6-membered heteroaryl group; Ring B is selected from a phenyl group and a 5- or 6-membered heteroaryl group; Ring C is a 3- to 6-membered cycloalkyl group, N is 1, 2 or 3; P is 0, 1 or 2; one of W and X is N and the other of W and X is C; Y is N or CR 2 and R1 is a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, halogen, -CN, -C(R 1a )=NR(OR 1a ), -C(R 1a )=N(R 1a ), -C(O)(R 1a ), -C(O)2(R 1a ), -C(O)N(R 1a )2, -NO2, -N(R 1a )2, -N(R 1a )C(O)(R 1a ), -N(R 1a )C(O)2(R 1a ), N(R 1a )C(O)N(R 1a )2, N(R 1a )S(O)2(R 1a ), -OR 1a , -OC(O)R 1a , -OC(O)N(R 1a )2, -SR 1a , -S(O)R 1a , -S(O)2(R 1a ), -S(O)N(R 1a )2 or -S(O)2N(R 1a )2, wherein the C1-C6 alkyl group, C2-6 chain alkenyl group, and C2-6 alkynyl group are optionally selected from one or more R 10 is replaced by R appeared every time 1a are independently selected from H or a C1-C6 alkyl group, wherein each occurrence of said C1-C6 alkyl group is optionally and independently selected from one or more R 10 is replaced by R appeared every time 10 are independently halogen, -CN, -C(R 10a )=NR(OR 10 a), -C(R 10a )=N(R 10a ), -C(O)(R 10a ), -C(O)2(R 10a ), -C(O)N(R 10a )2, -NO2, -N(R 10a )2, -N(R10a )C(O)(R 10a ), -N(R 10a )C(O)2(R 10a ), N(R 10a )C(O)N(R 10a )2, N(R 10a )S(O)2(R 10a ), -OR 10 a, -OC(O)R 10 a, -OC(O)N(R 10a )2, -SR 10 a, -S(O)R 10 a, -S(O)2(R 10a ), -S(O)N(R 10a )2 and -S(O)2N(R 10a )2 is selected, R appeared every time 10 a is independently selected from H or a C1-C6 alkyl group, wherein said C1-C6 alkyl group is optionally substituted by one or more halogens; R 2 is H, C1-C6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, 3- to 7-membered cycloalkyl group, 3- to 7-membered heterocycloalkyl group, halogen, -CN, -C(R 2a )=NR(OR 2a ), -C(R 2a )=N(R 2a ), -C(O)(R 2a ), -C(O)2(R 2a ), -C(O)N(R 2a )2, -NO2, -N(R 2a )2, -N(R 2a )C(O)(R 2a ), -N(R 2a )C(O)2(R 2a ), N(R 2a )C(O)N(R 2a )2, N(R 2a )S(O)2(R 2a ), -OR 2a , -OC(O)R 2a , -OC(O)N(R 2a )2, -SR 2a , -S(O)R 2a , -S(O)2(R 2a), -S(O)N(R 2a )2 and -S(O)2N(R 2a )2, wherein the C1-C6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, 3- to 7-membered cycloalkyl group and 3- to 7-membered heterocycloalkyl group are optionally selected from one or more R 20 is replaced by R appeared every time 2a are independently selected from H or a C1-C6 alkyl group, wherein each occurrence of said C1-C6 alkyl group is optionally selected from one or more R 20 is replaced by R appeared every time 20 are independently a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-7 cycloalkyl group, a 3- to 7-membered saturated heterocycloalkyl group, a halogen, —CN, —C(R 20 a)=NR(OR 20 a), -C(R 20 a)=N(R 20 a), -C(O)(R 20 a), -C(O)2(R 20 a), -C(O)N(R 20 a)2, -NO2, -N(R 20 a)2, -N(R 20 a)C(O)(R 20 a), -N(R 20 a)C(O)2(R 20 a), N(R 20 a)C(O)N(R 20 a)2, N(R 20 a)S(O)2(R 20 a), -OR 20 a, -OC(O)R 20 a, -OC(O)N(R 20 a)2,-SR 20 a, -S(O)R 20 a, -S(O)2(R 20 a), -S(O)N(R 20 a)2 and -S(O)2N(R 20a) 2, wherein each occurrence of said C alkyl group, C chain alkenyl group, C alkynyl group, C cycloalkyl group and 3-7 membered saturated heterocycloalkyl group may optionally be followed by one or more R 25 is replaced by R 20a is, at each occurrence, independently selected from H and a C1-C6 alkyl group, wherein said C1-C6 alkyl group is optionally selected from R 25 is replaced by R 25 is halogen and -OR 25 is selected from a R 25a is selected from H and a C1-C6 alkyl group; R is a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-C6 cycloalkyl group, a 3- to 6-membered saturated heterocycloalkyl group, a halogen, -CN, -C(R 3a )=NR(OR 3a ), -C(R 3a )=N(R 3a ), -C(O)(R 3a ), -C(O)2(R 3a ), -C(O)N(R 3a )2, -NO2, -N(R 3a )2, -N(R 3a )C(O)(R 3a ), -N(R 3a )C(O)2(R 3a ), N(R 3a )C(O)N(R 3a )2, N(R 3a )S(O)2(R 3a ), -OR 3a , -OC(O)R 3a , -OC(O)N(R 3a )2, -SR 3a , -S(O)R 3a , -S(O)2(R 3a ), -S(O)N(R 3a )2 and -S(O)2N(R 3a)2, wherein the C1-C6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C3-C6 cycloalkyl group, and 3- to 6-membered saturated heterocycloalkyl group are optionally selected from one or more R 30 is replaced by R appeared every time 3a are independently selected from H, a C1-C6 alkyl group, a 3- to 6-membered cycloalkyl group, and a 3- to 6-membered heterocycloalkyl group, wherein each occurrence of said C1-C6 alkyl group, 3- to 6-membered cycloalkyl group, and 3- to 6-membered heterocycloalkyl group may optionally be accompanied by one or more R 30 is replaced by R appeared every time 30 are independently a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a 3- to 6-membered cycloalkyl group, a 3- to 6-membered heterocycloalkyl group, a halogen, -CN, -C(R 30a )=NR(OR 30 a), -C(R 30a )=N(R 30a ), -C(O)(R 30a ), -C(O)2(R 30a ), -C(O)N(R 30a )2, -NO2, -N(R 30a )2, -N(R 30a )C(O)(R 30a ), -N(R 30a )C(O)2(R 30a ), N(R 30a )C(O)N(R 30a )2, N(R 30a )S(O)2(R 30a ), -OR 30 a, -OC(O)R 30 a, -OC(O)N(R 30a )2, -SR 30 a, -S(O)R 30 a, -S(O)2(R 30a ), -S(O)N(R 30a )2 and -S(O)2N(R 30a)2, wherein the C1-C6 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, 3- to 6-membered cycloalkyl group, and 3- to 6-membered heterocycloalkyl group are optionally selected from one or more R 35 is replaced by R appeared every time 30a are independently selected from H or a C1-C4 alkyl group, where the C1-C4 alkyl group is optionally selected from one or more R 35 is replaced by R appeared every time 35 are independently halogen or -OR 35 is selected from a R appeared every time 35a are independently selected from H or a C1-C6 alkyl group, or

[0078] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-52, PTM-52a, PTM-52b, PTM-52c, PTM-52d, PTM-52e or PTM-52f: Ring A is a phenyl group or a 5-6 membered heteroaryl group containing 1-3 heteroatoms selected from O, S or N, wherein Ring A is optionally further substituted by an optionally substituted alkyl group; Ring B is a phenyl group, a 5-6 membered heterocycloalkyl group containing 1-3 heteroatoms selected from O, S and N, or a 5-6 membered heteroaryl group containing 1-3 heteroatoms selected from O, S and N, wherein Ring B is optionally further substituted by an optionally substituted alkyl group; R 3is selected from hydrogen, deuterium, an alkyl group optionally substituted with an alkoxy group, an amino group, an N-(alkyl)amino group, an N,N-(dialkyl)amino group, a phenyl group, a heterocycloalkyl group, and a heteroaryl group, wherein the phenyl group, the heterocycloalkyl group, and the heteroaryl group are each independently optionally substituted with one or two groups selected from an alkyl group, and the alkoxy group is optionally substituted with a tri(alkyl)silyl group; R 4 are each independently selected from an optionally substituted heteroaryl or aryl group, or R 4 and R3 together with the nitrogen to which it is attached form an optionally substituted 3- to 7-membered heterocycloalkyl group, or R 4 is an alkylene chain having 1 to 3 carbon atoms optionally substituted with one or two groups independently selected from alkyl or cycloalkyl groups, where each group is optionally substituted with a hydroxyl or alkoxy group, or R 4 does not exist, R 5 is C(O)NR 51 , N.R. 52 or O, or R 5 does not exist, and the condition is R 4 If does not exist, R 5 does not exist, R 6 is an alkylene or alkenylene chain having one or two double bonds, wherein the alkylene or alkenylene chain has 2 to 10 carbon atoms, and wherein the alkylene or alkenylene chain is optionally substituted with one or two groups independently selected from alkyl or cycloalkyl groups, wherein each group is optionally substituted with a hydroxyl or alkoxy group, and wherein one or two carbon atoms in the alkylene chain are optionally substituted with O, S, SO, SO2, or NR 61wherein two carbon atoms in the alkylene chain are optionally joined via an alkylene chain of 2 or 3 carbon atoms to form a 5- to 7-membered ring; R 7 is NR 71 or O, or R 7 does not exist, R 51 is selected from hydrogen or an alkyl group; R 52 represents hydrogen, deuterium, alkyl groups and -C(O)OR 81 is selected from R 61 represents hydrogen, deuterium, alkyl groups and -C(O)OR 81 is selected from R 71 represents hydrogen, deuterium, alkyl groups and -C(O)OR 81 is selected from R 81 is an alkyl group, or

[0079] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] wherein, in the PTM-53 or PTM-53a, R1 is selected from CN, a C1-C6 alkyl group, or a 3- to 6-membered heterocycloalkyl group, wherein the C1-C6 alkyl group and the 3- to 6-membered heterocycloalkyl group are optionally joined by 1, 2, or 3 R a is replaced by R2 is selected from a C1-C6 alkyl group and a 3- to 6-membered heterocycloalkyl group, wherein the C1-C6 alkyl group and the 3- to 6-membered heterocycloalkyl group are optionally joined by one, two, or three R b is replaced by R3 is selected from H, F, Cl, Br, I, OH, NH2, CN, a C1-C6 alkyl group, a -C(O)O-C1-C6 alkyl group, a -C(O)C1-C6 alkyl group, a C3-C6 cycloalkyl group, wherein said C1-C6 alkyl group, -C(O)O-C1-C6 alkyl group, -C(O)C1-C6 alkyl group, a C3-C6 cycloalkyl group is optionally followed by 1, 2 or 3 R c is replaced by Ring A is selected from a 3- to 10-membered heterocycloalkyl group, and said 3- to 10-membered heterocycloalkyl group optionally contains one, two, or three R d is replaced by L1 is O and N(R 4 ) and L2 is selected from a single bond, CH2 and CH2CH2; R4 is selected from H and Me; R a are each independently selected from F, Cl, Br, I, OH, NH, CN, and COOH; R b are each independently selected from F, Cl, Br, I, OH, NH, COOH, and Me; R c are each independently selected from F, Cl, Br, I, OH, NH, or CN; R d are each independently selected from F, Cl, Br, I, OH, NH, or CN; the 3- to 6-membered heterocycloalkyl group contains 1, 2, or 3 heteroatoms or heteroatom groups independently selected from -O-, -S-, -NH-, and N; the 3- to 10-membered heterocycloalkyl group contains 1, 2, or 3 heteroatoms or heteroatom groups independently selected from -O-, -S-, -NH-, N, -C(O)NH-, or

[0080] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-54: m is 0, 1, 2 or 3; Ring A is selected from 5- to 6-membered heteroaryl groups; Ring B is selected from a 3- to 7-membered cycloalkyl group and a 4- to 6-membered heterocycloalkyl group; L is selected from O or NH; R1 is selected from H or a C1-C3 alkyl group, a C1-C3 heteroalkyl group optionally substituted with 1, 2 or 3 R; R2 is selected from OH, NH2, CN, halogen, or a C1-C3 alkyl group, a C1-C3 heteroalkyl group, a 4- to 6-membered heterocycloalkyl group, optionally substituted by 1, 2 or 3 R; R is selected from F, Cl, Br, I, OH, NH, CN, a methyl group, an ethyl group, and CF; the "hetero" in the C-C heteroalkyl group, the 4- to 6-membered heterocycloalkyl group, or the 5- to 6-membered heterocycloalkenyl group is independently selected from N, O, S, NH, and -C(O)NH-; and the number of heteroatoms or heteroatom groups is independently selected from 1, 2, 3, or 4; or

[0081] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-55: n is selected from 1 or 2; m is selected from 0, 1, 2 or 3; R1 is selected from H, CN, OH or optionally substituted by R [ka] is selected from R2 is selected from H, F, Cl, Br, and I; R3 is selected from OH, NH2, CN, halogen, or a C1-C3 alkyl group, a C1-C3 heteroalkyl group optionally substituted by 1, 2 or 3 R, or Two R3's together with the atoms to which they are attached form a 3- to 6-membered ring, L is selected from a single bond, -CH2-, and -CH2CH2-; L1 is selected from O or NH; Ring A is selected from 4- to 6-membered heterocycloalkyl groups; R is selected from F, Cl, Br, I, OH, NH, CN, or a C-C alkyl group or a C-C heteroalkyl group optionally substituted by 1, 2 or 3 R', R' is selected from F, Cl, Br, I, OH, NH, CN, CF, the "hetero" in the C-C heteroalkyl group or 4- to 6-membered heterocycloalkyl group is independently selected from N, O, S, NH, the number of heteroatoms or heteroatom groups is independently selected from 1, 2, 3 or 4, or

[0082] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-56 or PTM-56a: R1 is H, X is O or NR a and R a is H or a C1-C6 alkyl group, Y is CR b R c or NR d where R b and R c are each independently H, halogen, a C1-C6 alkyl group, a C1-C6 alkoxy group, or an amino group, and R d is H or a C1-C6 alkyl group, or R b and Ra is R b Carbon atoms bonded to and R a together with the nitrogen atom attached to R to form a C3-C10 heterocycloalkyl group, or d is R a and R d and R a together with the nitrogen atom attached to form a C3-C10 heterocycloalkyl group, R2 is -CH2CH2R e or NR f R g where R e is H, halogen, C1-C6 alkyl group or OR h and R f and R g are each independently a C1-C6 alkyl group or a C3-C8 cycloalkyl group, and R h is H or a C1-C6 alkyl group, or R h , R d is R h Oxygen atoms and R bonded to d together with the nitrogen atom bonded to is a C3-C10 heterocycloalkyl group, R3 and R4 are each independently H, a halogen, a nitro group, a cyano group, an amino group, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C3-C10 cycloalkyl group, a C3-C10 heterocycloalkyl group, an aryl group, or a heteroaryl group; m is 1, 2, 3 or 4; n is 1 or 2, or

[0083] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-57 or PTM-57a: R1 is a C1-C6 alkyl group or a thioalkyl group; X is O or NRa where R a is H or a C1-C6 alkyl group, Y is CR b R c or NR d where R b and R c are each independently H, halogen, a C1-C6 alkyl group, a C1-C6 alkoxy group, an amino group, or R d is H or a C1-C6 alkyl group, where X is NR a and Y is CR b R c If R b and R a is R a Carbon atoms bonded to and R a together with the nitrogen atom attached to NR, an unsubstituted C3-C10 heterocycloalkyl group, or X is NR a and Y is NR d If R d is R a and R d and R a together with the nitrogen atom bonded to is an unsubstituted C3-C10 heterocycloalkyl group, R2 is -CH2CH2R e or NR f R g where R e is H, halogen, or OR h and R f and R g are each independently an unsubstituted C1-C6 alkyl group, and R h is H or an unsubstituted C1-C6 alkyl group, where Y is NR d and R2 is -CH2CH2R e and R e OR h If R h is R d , R h Oxygen atoms and R bonded to d together with the nitrogen atom bonded to is an unsubstituted C3-C10 heterocycloalkyl group, R3 is an unsubstituted 6-membered heteroaryl group containing one or two nitrogen atoms, or

[0084] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-58: R 1 is a 5-6 membered monocyclic aromatic heterocycloalkyl group, an 8-14 membered fused polycyclic aromatic heterocycloalkyl group, or a C aryl group, each of which is optionally substituted with 1 to 3 substituents selected from: (1) a halogen atom, (2) a C1-C6 alkyl group optionally substituted with 1 to 3 selected from halogen or hydroxyl groups; (3) a C6-14 aryl group optionally substituted by 1 to 3 halogens; (4) a 5- to 6-membered monocyclic aromatic heterocycloalkyl group, or an 8- to 14-membered fused polycyclic aromatic heterocycloalkyl group, each of which is optionally substituted with 1 to 3 substituents selected from the following: (i) an amino group optionally mono- or di-substituted with a C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally substituted with 1 to 3 substituents selected from (a) a halogen atom, or (b) a C3-C10 cycloalkyl group; (ii) a halogen atom, (iii) a C1-C6 alkoxy group, (iv) a cyano group, (v) a C1-C6 alkyl group optionally substituted by 1 to 3 substituents selected from the following: (a) an azido group, (b) an amino group optionally mono- or di-substituted by a C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally substituted by 1 to 3 substituents selected from a halogen atom and a C3-C10 cycloalkyl group, (c) a hydroxyl group, (d) a halogen atom, (vi) a formyl group, (vii) a carboxyl group, (viii) an aminoformyl group; (ix) a C3-C10 cycloalkyl group, or (x) a 3- to 8-membered monocyclic non-aromatic heterocycloalkyl group, (5) a 3- to 8-membered monocyclic non-aromatic heterocycloalkyl group, a 9- to 14-membered fused polycyclic non-aromatic heterocycloalkyl group, or a 7- to 14-membered spiroheterocycloalkyl group, each of which is optionally substituted with 1 to 3 substituents selected from the following: (i) a C1-C6 alkyl group optionally substituted with 1 to 3 substituents selected from: (a) a hydroxyl group, (b) an amino group optionally mono- or di-substituted with a C1-C6 alkyl group, (c) a cyano group, or (d) a C6-14 aryl group; (ii) oxo, (iii) a hydroxyl group, (iv) an aminoformyl group, or (v) a thio group, (6) a C3-C10 cycloalkylsulfonyl group, (7) a C1-C6 alkyl-carbonyl group, (8) a 5- to 6-membered monocyclic aromatic heterocyclic sulfonyl group, or (9) halogenated sulfur groups, R 2 teeth, (1) A C1-C6 alkyl group optionally substituted with 1 to 3 substituents selected from the following: (i) a C1-C6 alkoxy-carbonyl group, (ii) a C1-C6 alkylsulfonyl group, (iii) an aminoformyl group, (iv) a cyano group, (v) a 3- to 8-membered monocyclic non-aromatic heterocycloalkyl group optionally substituted by 1 to 3 oxo, or (vi) a halogen atom, (2) a C3-C10 cycloalkyl group optionally substituted with 1 to 3 hydroxyl groups, or (3) a 3- to 8-membered monocyclic non-aromatic heterocycloalkyl group, R3 and R4 are independently (1) a hydrogen atom, or (2) a C1-C6 alkyl group substituted by 1 to 3 substituents selected from an amino group, wherein the amino group is optionally mono- or di-substituted by a C1-C6 alkyl group; R 5 and R 6 is, independently, (1) a hydrogen atom, (2) hydroxyl group, (3) a C1-C6 alkyl group optionally substituted by 1 to 3 substituents selected from the following: (i) a hydroxyl group, (ii) an amino group mono- or di-substituted by substituents selected from the following: (a) a C1-C6 alkyl group optionally substituted by 1 to 3 halogen atoms, (b) a C3-C10 cycloalkyl group optionally substituted by 1 to 3 halogen atoms, (c) a 3- to 8-membered monocyclic non-aromatic heterocycloalkyl group, (d) a C1-C6 alkylsulfonyl group, (e) a C1-C6 alkyl-carbonyl group, or (f) a C3-C10 cycloalkyl-carbonyl group, (iii) a halogen atom, (iv) a C1-C6 alkylsulfur group, (v) a C1-C6 alkylsulfinyl group, or (vi) a C1-C6 alkylsulfonyl group, (4) a C1-C6 alkoxy group, (5) an amino group optionally mono- or di-substituted with a substituent selected from the following: (i) a C1-C6 alkyl group, (ii) a C1-C6 alkyl group, or (iii) a C1-C6 alkylsulfonyl group; (6) a 3- to 8-membered monocyclic non-aromatic heterocycloalkyl group, (7) a carboxyl group, or (8) an aminoformyl group optionally mono- or di-substituted by a C1-C6 alkyl group, or R 5 and R 6 optionally join to form (1) a 3- to 8-membered monocyclic non-aromatic heterocycle, or (2) a C3-C10 cycloalkane; X is CR 7 R 8 , N.R. 9 , O or S; R7 and R 8 are independently (1) a hydrogen atom, (2) a cyano group, (3) a C1-C6 alkyl group optionally substituted with 1 to 3 hydroxyl groups, or (4) a hydroxyl group; R 7 and R 8 combine to form (1) a C3-C10 cycloalkane optionally substituted with 1 to 3 substituents selected from: (i) oxo, or (ii) a hydroxyl group; (2) a 3- to 8-membered monocyclic non-aromatic heterocycle optionally substituted with 1 to 3 C7-16(aryl)alkyl-; R 9 teeth, (1) a hydrogen atom, (2) a C1-C6 alkyl group substituted by 1 to 3 substituents selected from the following: (i) a hydroxyl group, (ii) a C1-C6 alkoxy group optionally substituted by 1 to 3 C6-14 aryl groups, or (iii) an amino group optionally mono- or di-substituted by a C1-C6 alkyl group; (3) a C2-6 alkenyl group, or (4) C7-16(aryl)alkyl- optionally substituted with 1 to 3 C1-C6 alkoxy groups; or

[0085] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein PTM-59 is represented by the formula: R 1 is an optionally substituted heteroaryl group or a C aryl group; R 2 , R 3 , R 4 , R 5 and R 6 are independently hydrogen or a substituent, or

[0086] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable oxide, pharmaceutically acceptable solvate and / or pharmaceutically acceptable salt thereof, wherein in said PTM-60, PTM-60a, PTM-60b, PTM-60c, PTM-60d, PTM-60e, PTM-60f, PTM-60g, PTM-60h, PTM-60i, PTM-60j, PTM-60k, PTM-60l, PTM-60m, PTM-60n, PTM-60o, PTM-60p, PTM-60q, PTM-60r, PTM-60s, PTM-60t, PTM-60u or PTM-60v, Ring A is a substituted or unsubstituted, saturated, unsaturated or partially unsaturated 5-6 membered heterocycloalkyl group, provided that it is a heterocycloalkyl group and is not a thiazolyl group; Cy 1 is a 5-membered heteroaryl group, Cy 2 is a C cycloalkyl group optionally fused to a 5- or 6-membered heteroaryl group or a 5- to 7-membered heteroaryl group; L 1 is a bond or a C1-C3 alkylene group, where one CH2 group is optionally replaced by O or NH, X is N, NR 3 , O or S; Y is CR 4 or N, When X is N, k is 2, ring A is a 6-membered heteroaryl group, and X is NR 3 , when k is S or O, k is 1 and ring A is a 5-membered heteroaryl group; R 1is H, a substituted or unsubstituted C1-C3 alkyl group, a substituted or unsubstituted C1-C4 alkoxy group, a substituted or unsubstituted C3-C6 cycloalkyl group, a substituted or unsubstituted 3- to 7-membered heterocycloalkyl group, a substituted or unsubstituted C6-12 aryl group, a substituted or unsubstituted 5- to 7-membered heteroaryl group, halogen, CN, -NO2, -OR 10 , -SR 10 , -NR 11 R 12 , -C(O)R 14 , -C(O)NR 11 R 12 , -NR 13 C(O)R 14 , -OC(O)R 14 , -C(O)2R 11 , -NR 13 C(O)NR 11 R 12 , -NR 13 S(O)2R 14 , -S(O)NR 11 R 12 , -S(O)R 14 , -S(O)2R 14 are selected from, and the assumption is that R 1 But not -NH2, R 2 is selected from H or a substituted or unsubstituted C1-C3 alkyl group; R 3 is H, a substituted or unsubstituted C1-C4 alkyl group, a substituted or unsubstituted C2-4 alkenyl group, a substituted or unsubstituted C2-4 alkynyl group, a substituted or unsubstituted C3-C6 cycloalkyl group, a substituted or unsubstituted C3-C6 cycloalkenyl group, a substituted or unsubstituted 3- to 7-membered heterocycloalkyl group, a substituted or unsubstituted C5-12 aryl group, a substituted or unsubstituted 5- to 7-membered heteroaryl group, -CN, -C(O)R 6 and -C(O)NR 7a R 7b is selected from R 4is H, a substituted or unsubstituted C1-4 alkyl group, a substituted or unsubstituted C2-4 alkenyl group, a substituted or unsubstituted C2-4 alkynyl group, a substituted or unsubstituted C1-C4 alkoxy group, a substituted or unsubstituted C3-C6 cycloalkyl group, a substituted or unsubstituted C3-C6 cycloalkenyl group, a substituted or unsubstituted 3-7 membered heterocycloalkyl group, a substituted or unsubstituted C5-12 aryl group, a substituted or unsubstituted 5-7 membered heteroaryl group, -OH, -OR 6 , -CN, -C(O)R 6 , -C(O)OR 6 , -C(O)NR 7a R 7b , COOH or halogen; R 6 is selected from a substituted or unsubstituted C1-C4 alkyl group, a substituted or unsubstituted C3-C6 cycloalkyl group, a substituted or unsubstituted 3-7 membered heterocycloalkyl group, a substituted or unsubstituted C6-12 aryl group, and a substituted or unsubstituted 5-7 membered heteroaryl group; R 7a and R 7b are each independently selected from H or a substituted or unsubstituted C1-C3 alkyl group, or R 7a and R 7b together with the N to which it is attached form a substituted or unsubstituted 3- to 7-membered heterocycloalkyl group; Each R 8 is independently selected from a C1-C4 alkyl group, a C1-C4 halogenated alkyl group, halogen, CN, or —NO2; Each R 9 are independently a C1-C4 alkyl group, a C1-C4 halogenated alkyl group, a C3-C8 cycloalkyl group, a 3- to 7-membered heterocycloalkyl group, a phenyl group, a 5- to 7-membered heteroaryl group, a halogen atom, CN, -NO2, -OR 10 , -SR 10 , -NR 11 R 12 , -C(O)R 14 , -C(O)NR 11 R 12 , -NR 13 C(O)R 14 , -OC(O)R 14, -C(O)2R 11 , -NR 13 C(O)NR 11 R 12 , -NR 13 S(O)2R 14 , -S(O)NR 11 R 12 , -S(O)R 14 , -S(O)2R 14 is selected from R 10 is selected from H, a C1-C4 alkyl group, a C2-4 chain alkenyl group, a C2-4 alkynyl group, a C3-C8 cycloalkyl group, a 3- to 7-membered heterocycloalkyl group, a phenyl group, and a 5- to 7-membered heteroaryl group; R 11 and R 12 are independently H, a C1-C4 alkyl group, a C3-C8 cycloalkyl group, a 3- to 7-membered heterocycloalkyl group, a phenyl group, and a 5- to 7-membered heteroaryl group, or R 11 and R 12 together with the nitrogen to which it is attached form a 3- to 7-membered heterocycloalkyl group; R 13 is selected from H or a C1-C4 alkyl group; R 14 is selected from a C1-C4 alkyl group, a C3-C8 cycloalkyl group, a 3- to 7-membered heterocycloalkyl group, a phenyl group, or a 5- to 7-membered heteroaryl group; m is 0, 1 or 2; n is 0, 1 or 2, or

[0087] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] and pharmaceutically acceptable tautomers, salts and stereoisomers thereof (including mixtures thereof in all ratios), wherein in said PTM-61: R 1 is absent or is A or Q-Het, Z is [ka] wherein X is O, S or N, Y is C or N, T is C or N, or Z is pyridine or pyridazine; R a does not exist OR 3 , CF3, Hal, NO2, R b is absent or selected from A or COHet; R 2 represents H, Het, Q-Het, Cyc, A or OA, Het represents a 4-9 membered monocyclic or fused, spiro or bridged bicyclic ring, which is saturated, unsaturated or aromatic, which contains 1-3 group members independently selected from N, O, S, CO, SO or SO2, where one or two H atoms are selected from A, OA, COA, CN, Hal, NO2, OR 3 , can be replaced by SOA or SO2A, Cyc represents a 4-8 membered saturated carbocyclic ring, which optionally contains the groups SO, SO2, CO, and optionally CO(NR 3 )2 and COHet, OR 3 , Het1, A, CH2Het1, NH2, NHCOA, OCH2Cyc1, SO2A or -SA(=NH)(=O), Q represents a straight or branched chain alkylene group having 1 to 6 carbon atoms, wherein 1 to 5 H atoms are independently selected from OR 3 , Hal, N(R 3 )2, wherein one or two CH2 groups are independently selected from CO, SO, SO2, and NR 3 or Q represents a 4-8 membered divalent heterocycle which is saturated, unsaturated or aromatic and which contains 1-3 heteroatoms independently selected from N, O and S; A represents a linear or branched alkyl group having 1 to 10 carbon atoms, wherein 1 to 7 H atoms are independently selected from -OR 3 , Hal, NHSO2A, SO2A, SOA, N(R 3 )2, wherein one, two, or three non-adjacent -CH-yls are independently selected from -CO-, -NR 3 and / or -O-, Hal represents F, Cl, Br or I; R 3 represents H or a C1-C6 alkyl group, where one H atom can be replaced by a group selected from OH, an O—C1-C6 alkyl group or Hal, Het1 represents a 5- or 6-membered saturated monocyclic heterocycle, which has 1 to 3 N- and / or O-atoms, which is optionally substituted by A-, Cyc1 represents a cycloalkyl group having 3 to 7 atoms, or

[0088] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-62: A is a phenyl group or a 5- to 10-membered heteroaryl group, optionally containing one or more R 1 is substituted by a group, L is O or NR 2 is selected from G is a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a 4- to 6-membered heterocycloalkyl group, or a phenyl group, optionally with one or more R 3 is substituted by a group, Z is a phenyl group or a 5- to 10-membered heteroaryl group, optionally containing one or more R 4 is substituted by a group, Each R 1are independently selected from a C1-C6 alkyl group, a 4- to 6-membered heterocycloalkyl group, a hydroxyl group, a halogen, a C1-C6 alkyloxyC1-C6 alkyl group, a C1-C6 alkyloxy group, an amino group, a (C1-C6 alkyl)2 amino group, a carboxyl group, or a C1-C6 alkylsulfonyl group; R 2 is selected from hydrogen or a C1-C6 alkyl group; Each R 3 are independently selected from a hydroxyl group, oxo, a C1-C6 alkyl group, a 4- to 6-membered heterocycloalkyl group, a 5- to 10-membered heteroaryl group, a hydroxyl C1-C6 alkyl group, a C1-C6 alkyloxy group, a C1-C6 alkylacylamino group, a C1-C6 alkylcarbonyl group, or a C1-C6 alkylaminoacyl group; Each R 4 are independently a C1-C6 alkyl group, a cyano group, a C3-C6 cycloalkyl group, a 4- to 6-membered heterocycloalkyl group, a phenyl group, a 5- to 10-membered heteroaryl group, oxo, a halogenated C1-C6 alkyl group, a hydroxyl C1-C6 alkyl group, a 4- to 6-membered heterocycloalkylcarbonyl group, or R 4a R 4b NC(O)-; Each R 4a and R 4b are each independently selected from hydrogen, deuterium, a C1-C6 alkyl group, a halogenated C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C1-C6 alkyloxy C1-C6 alkyl group, a 4- to 6-membered heterocycloalkyl C1-C6 alkyl group, a 5- to 10-membered heteroaryl C1-C6 alkyl group, or a 4- to 6-membered heterocycloalkyl group; where R 1 , R 3 , R 4 , R 4a and R 4bwherein the cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups, independently as groups or parts of groups, are optionally substituted by substituents independently selected from C1-C6 alkyl groups or oxo, and wherein the heterocycloalkyl and heteroaryl groups contain one or more heteroatoms selected from nitrogen, oxygen and sulfur; or

[0089] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-63, PTM-63a or PTM-63b: Ring A is an aromatic ring or an aromatic heterocycle; n is an integer from 0 to 4, X is selected from N or O; R0 is a C1-C4 alkyl group, a heterocycle, -OCH3, -CF3, -CHF2, -CN, -CONH2, a halogen, or -(CH2)mR a , -O-(CH2)mR a is selected from m is an integer from 1 to 4, R a is a nitrogen-containing heterocycle, wherein the nitrogen-containing heterocycle can be optionally substituted with one or more substituents selected from halogen, —OH, —CH, —OCH; R2 and R 3独 The alkyl group is a hydrogen atom, a heterocycle, -CH2CH2-N(R b ) 2, and R2 and R3 are linked through a nitrogen atom to form a heterocycle, wherein said heterocycle is selected from one or more R c can be further replaced by R b is selected from a hydrogen atom, a C1-4 alkyl group, or an acetyl group; R cis selected from -CF3, -CHF2, -OH, -NH2 or a formyl group, or

[0090] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-64: R1 is hydrogen, deuterium, halogen, hydroxyl group, nitro group, trifluoromethyl group, cyano group, NH(CO)R 4 , a C1-C8 alkyl group, a C1-C8 alkoxy group, or a C3-C6 cycloalkyl group; R2 is hydrogen, deuterium, halogen or NR 5 R 6 represents R3 represents hydrogen, deuterium, halogen or an amino group; R4 represents a C1-C8 alkyl group, a C3-C6 cycloalkyl group, a C5-C10 aryl group, or a C5-C10 aromatic heterocycloalkyl group, wherein the aromatic heterocycloalkyl group can optionally contain one or more other heteroatoms selected from O, S, or N, and wherein the aryl group or aromatic heterocycloalkyl group can optionally be mono- to penta-substituted with the following same or different substituents, wherein the substituents are selected from halogen, trifluoromethyl, cyano, nitro, or hydroxyl groups; R5 and R6 may be the same or different and represent hydrogen, deuterium, a C1-C8 alkyl group, or R5 and R6 together with the nitrogen to which they are attached form a 5- to 7-membered heterocycloalkyl group, which may optionally contain one or more other heteroatoms selected from O, S or N, and which may optionally be mono- to penta-substituted with the following same or different substituents, the substituents being selected from carboxamide groups, halogens, hydroxyl groups, nitro groups, cyano groups or amino groups; or

[0091] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-65: V is hydrogen, deuterium, halogen, or a substituted or unsubstituted C1-5 straight or branched chain alkyl group, wherein the substituted alkyl group is substituted by one or more substituents selected from a hydroxyl group, a halogen, a nitro group, or —CN; X is -NHR 1 and R 1 is an unsubstituted or substituted 6- to 10-membered aryl group or an unsubstituted or substituted 5- to 10-membered heteroaryl group containing one or more heteroatoms selected from N, O, or S, wherein the substituted aryl group or substituted heteroaryl group can be substituted by an unsubstituted C1-10 straight or branched chain alkyl group, or a C1-10 straight or branched chain alkyl group substituted with one or more substituents selected from halogen, methoxy, and dimethylamine, or a halogen, or an amino group, or a 5- to 10-membered heterocycloalkyl group containing one or more heteroatoms selected from N, O, or S, or a substituted aryl group or a substituted heteroaryl group, a C3-C10 ring, or a 5- to 10-membered fused ring containing one or more heteroatoms selected from N, O, or S; Y is -(C=O)NHR 2 , -NH(C=O)R 2 , -NH(C=O)NHR 2 and R 2 is an unsubstituted or substituted 6- to 10-membered aryl group or an unsubstituted or substituted 5- to 10-membered heteroaryl group containing one or more heteroatoms selected from N, O and S, wherein the substituted aryl group or substituted heteroaryl group is selected from halogen, —CH—R 3, a C1-10 straight-chain or branched-chain alkyl group substituted or unsubstituted by a halogen, a C1-2 alkoxy group substituted or unsubstituted by a halogen, a C6-C10 cycloalkyl group substituted or unsubstituted by a halogen, a 5-10-membered heterocycloalkyl group containing one or more heteroatoms selected from N, O and S, an unsubstituted or substituted 5-10-membered heteroaryl group containing one or more heteroatoms selected from N, O and S, and an unsubstituted or substituted amino group, wherein the substituted heteroaryl group, substituted heterocycloalkyl group, and substituted amino group may be substituted with a substituted or unsubstituted C1-C3 straight-chain or branched-chain alkyl group, and wherein the substituted C1-C3 straight-chain or branched-chain alkyl group may be substituted with a dimethylamino group; R 3 is a 5-10 membered heterocycloalkyl group containing one or more heteroatoms selected from N, O and S, which heterocycloalkyl group may be substituted or unsubstituted with one or more substituents selected from methyl, ethyl, dimethylamino and halogen; or

[0092] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-66: R 1 and R 2 are each independently: a) optionally Z 1 a C1-10 alkyl group substituted by 1 c) a C3-C10 cycloalkyl group substituted by Z 1 d) a 5- to 10-membered heteroaryl group substituted by Z 1 e) a 6- to 10-membered aryl group substituted by Z 1 f) a 4- to 7-membered monocyclic heterocycloalkyl group substituted by Z 1or g)-N(R 12 )(R 12 ), -S(O)R 12 , -S(O)2N(R 12 )(R 12 ), or -H; R 3 and R 4 are each independently a) H, halogen, -NO2, -CN, -OR 12 , -C(O)-R 12 , -C(O)-N(R 12 )(R 12 ), -N(R 12 )(R 12 ), -N(R 12 )C(O)-R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )S(O)2(R 12 ), -N(R 12 )C(O)-N(R 12 )(R 12 ), -S(O)R 12 or -S(O)N(R 12 )(R 12 ), b) optionally Z 1 a C1-9 alkyl group substituted by c) Optionally, Z 1 a C2-9 alkynyl group substituted by d) optionally Z 1 a C2-9 alkenyl group substituted by e) optionally Z 1 a 5- to 10-membered heteroaryl group substituted by f) Optionally, Z 1 a 6- to 10-membered aryl group substituted by g) Optionally, Z 1 a 4- to 12-membered heterocycloalkyl group substituted by h) optionally Z 1 C3-C10 cycloalkyl groups substituted by R 5 , R6 and R 7 are each independently a) H, halogen, -NO2, -CN, -OR 12 , -C(O)-R 12 , -C(O)-N(R 12 )(R 12 ), -N(R 12 )(R 12 ), -N(R 12 )C(O)-R 12 , -N(R 12 )C(O)OR 12 , or -N(R 12 )S(O)2(R 12 ), b) optionally Z 1 a C1-5 alkyl group substituted by c) Optionally, Z 1 a cyclopropyl group, an oxetanyl group or an azetidine group substituted by Z 1 are independently oxo, halogen, -NO2, -N 3 , -CN, C1-9 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C3-15 cycloalkyl group, C1-C8 halogenated alkyl group, aryl group, heteroaryl group, heterocycloalkyl group, -OR 12 , -C(O)-R 12 , -C(O)OR 12 , -C(O)-N(R 12 )(R 12 ), -N(R 12 )(R 12 ), -N(R 12 )2(R 12 )+, -N(R 12 )C(O)-R 12 , -N(R 12 )C(O)OR 12 , -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12 ), -NR 12 S(O)2N(R 12 )(R 12 ), -NR 12S(O)2O(R 12 ), -OC(O)R 12 , -OC(O)OR 12 , -OC(O)-N(R 12 )(R 12 ), -Si(R 12 )3, -SR 12 , -S(O)R 12 , -S(O)(NH)R 12 , -S(O)2R 12 or -S(O)N(R 12 )(R 12 ) and wherein any alkyl, alkenyl, alkynyl, cycloalkyl, halogenated alkyl, aryl, heteroaryl, or heterocycloalkyl group is optionally joined by Z 1 a, and each Z 1 a independently represents oxo, halogen, -NO2, -CN, -N3, C1-9 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C3-15 cycloalkyl group, C1-C8 halogenated alkyl group, aryl group, heteroaryl group, heterocycloalkyl group, -OR 12 , -C(O)R 12 , -C(O)OR 12 , -C(O)N(R 12 )(R 12 ), -N(R 12 )(R 12 ), -N(R 12 )2(R 12 )+, -N(R 12 )-C(O)R 12 , -N(R 12 )C(O)O(R 12 ), -N(R 12 )C(O)N(R 12 )(R 12 ), -N(R 12 )S(O)2(R 12 ), -N(R 12 )S(O)2-N(R 12 )(R 12 ), -N(R 12 )S(O)2O(R 12 ), -OC(O)R 12 , -OC(O)OR 12, -OC(O)-N(R 12 )(R 12 ), -Si(R 12 )3, -SR 12 , -S(O)R 12 , -S(O)(NH)R 12 , -S(O)2R 12 or -S(O)N(R 12 )(R 12 ) and wherein any alkyl, alkenyl, alkynyl, cycloalkyl, halogenated alkyl, aryl, heteroaryl, or heterocycloalkyl group is optionally joined by Z 1 is replaced by b, Each R 12 are independently H, a C alkyl group, a C alkenyl group, a C alkynyl group, a C cycloalkyl group, an aryl group, a heteroaryl group, or a heterocycloalkyl group; wherein any alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl group is optionally joined by Z 1b and each Z 1bare independently oxo, hydroxyl group, halogen, -NO2, -N3, -CN, C1-9 alkyl group, C2-6 alkenyl group, C2-6 alkynyl group, C3-15 cycloalkyl group, C1-C8 halogenated alkyl group, aryl group, heteroaryl group, heterocycloalkyl group, -O(C1-9 alkyl), -O(C2-6 alkenyl), -O(C2-6 alkynyl), -O(C3-15 cycloalkyl), -O(C1-C8 halogenated alkyl), -O(aryl), -O(heteroaryl), -O(heterocycloalkyl), -NH2, -NH( C1-9 alkyl), -NH(C2-6 alkenyl), -NH(C2-6 alkynyl), -NH(C3-15 cycloalkyl), -NH(C1-C8 alkyl halide), -NH(aryl), -NH(heteroaryl), -NH(heterocycloalkyl), -N(C1-9 alkyl)2, -N(C3-15 cycloalkyl)2, -N(C2-6 alkenyl)2, -N(C2-6 alkynyl)2, -N(C3-15 cycloalkyl)2, -N(C1-C8 alkyl halide)2, -N(aryl)2, -N(heteroaryl)2, -N(heterocycloalkyl) -C(O)(Ci_9 alkyl), -C(O)(C2_6 alkenyl), -N(Ci_9 alkyl)(C2_6 alkynyl), -N(Ci_9 alkyl)(C3_15 cycloalkyl), -N(Ci_9 alkyl)(Ci_9 alkyl)(C3_15 cycloalkyl), -N(Ci_9 alkyl)(Ci-C8 alkyl halide), -N(Ci_9 alkyl)(aryl), -N(Ci_9 alkyl)(heteroaryl), -N(Ci_9 alkyl)(heterocycloalkyl), -C(O)(Ci_9 alkyl), -C(O)(C2_6 alkenyl), -C(O)(C2_6 alkynyl), -C(O)(C3-15 cycloalkyl), -C(O)(C1-C8 alkyl halide), -C(O)(aryl), -C(O)(heteroaryl), -C(O)(heterocycloalkyl), -C(O)O(C1-9 alkyl), -C(O)O(C2-6 alkenyl), -C(O)O(C2-6 alkynyl), -C(O)O(C3-15 cycloalkyl), -C(O)O(C1-C8 alkyl halide), -C(O)O(aryl), -C(O)O(heteroaryl), -C(O)O(heterocycloalkyl), -C(O)NH2,-C(O)NH(C1-9 alkyl), -C(O)NH(C2-6 alkenyl), -C(O)NH(C2-6 alkynyl), -C(O)NH(C3-15 cycloalkyl), -C(O)NH(C1-C8 alkyl halide), -C(O)NH(aryl), -C(O)NH(heteroaryl), -C(O)NH(heterocycloalkyl), -C(O)N(C1-9 alkyl), -C(O)N(C3-15 cycloalkyl), -C(O)N(C2-6 alkenyl), -C(O)N(C2-6 alkynyl), -C(O)N(C3-15 cycloalkenyl) alkyl), -C(O)N(C1-C8 alkyl halide), -C(O)N(aryl), -C(O)N(heteroaryl), -C(O)N(heterocycloalkyl), -NHC(O)(C1-9 alkyl), -NHC(O)(C2-6 alkenyl), -NHC(O)(C2-6 alkynyl), -NHC(O)(C3-15 cycloalkyl), -NHC(O)(C1-C8 alkyl halide), -NHC(O)(aryl), -NHC(O)(heteroaryl), -NHC(O)(heterocycloalkyl), -NHC(O)O(C1-9 alkenyl) alkyl), -NHC(O)O(C2-6 alkenyl), -NHC(O)O(C2-6 alkynyl), -NHC(O)O(C3-15 cycloalkyl), -NHC(O)O(C1-C8 alkyl halide), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)O(heterocycloalkyl), -NHC(O)NH(C1-9 alkyl), -NHC(O)NH(C2-6 alkenyl), -NHC(O)NH(C2-6 alkynyl), -NHC(O)NH(C3-15 cycloalkyl), -NHC(O)NH(C1-C8 halide). -C1-C8 alkyl halide), -NHC(O)NH(aryl), -NHC(O)NH(heteroaryl), -NHC(O)NH(heterocycloalkyl), -SH, -S(C1-9 alkyl), -S(C2-6 alkenyl), -S(C2-6 alkynyl), -S(C3-15 cycloalkyl), -S(C1-C8 alkyl halide), -S(aryl), -S(heteroaryl), -S(heterocycloalkyl), -NHS(O)(C1-9 alkyl), -N(C1-9 alkyl)(S(O)(C1-9 alkyl), -S(O)N(C1-9 alkyl)2,-S(O)(C1-9 alkyl), -S(O)(NH)(C1-9 alkyl), -S(O)(C2-6 alkenyl), -S(O)(C2-6 alkynyl), -S(O)(C3-15 cycloalkyl), -S(O)(C1-C8 alkyl halide), -S(O)(aryl), -S(O)(heteroaryl), -S(O)(heterocycloalkyl), -S(O)2(C1-9 alkyl) , —S(O)2(C2-6 alkenyl), —S(O)2(C2-6 alkynyl), —S(O)2(C3-15 cycloalkyl), —S(O)2(C1-C8 halogenated alkyl), —S(O)2(aryl), —S(O)2(heteroaryl), —S(O)2(heterocycloalkyl), —S(O)2NH(C1-9 alkyl), or —S(O)2N(C1-9 alkyl)2; wherein any alkyl, cycloalkyl, aryl, heteroaryl or heterocycloalkyl group optionally comprises one or more halogens, C alkyl group, C-C halogenated alkyl group, —OH, —NH, —NH(C alkyl), —NH(C cycloalkyl), —NH(C-C halogenated alkyl), —NH(aryl), —NH(heteroaryl), —NH(heterocycloalkyl), —N(C alkyl), —N(C cycloalkyl), —NHC(O)(C cycloalkyl), —NHC(O)(C-C halogenated alkyl), —NHC(O)(aryl), —NHC(O)(heteroaryl), —NHC(O)(heterocycloalkyl), —NHC(O)O(C alkyl), —NHC(O)O(C alkynyl), —NHC(O)O(C -15 cycloalkyl), -NHC(O)O(C1-C8 alkyl halide), -NHC(O)O(aryl), -NHC(O)O(heteroaryl), -NHC(O)O(heterocycloalkyl), -NHC(O)NH(C1-9 alkyl), -S(O)(NH)(C1-9 alkyl), S(O)2(C1-9 alkyl), -S(O)2(C3-15 cycloalkyl), -S(O)2(C1-C8 alkyl halide) ), -S(O)2(aryl), -S(O)2(heteroaryl), -S(O)2(heterocycloalkyl), -S(O)2NH(C1-9 alkyl), -S(O)2N(C1-9 alkyl)2, -O(C3-15 cycloalkyl), -O(C1-C8 alkyl halide), -O(aryl), -O(heteroaryl), -O(heterocycloalkyl), or -O(C1-9 alkyl), provided that R 1 is a C3 alkyl group, and R 2 is F or a hydroxyl group-substituted C5 alkyl group, and R 3 , R 5 , R 6 , R 7 is H and R 4 If is CN, then R 1 is Z 1 is replaced by, or

[0093] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] wherein, in the PTM-67, PTM-67a, PTM-67b or PTM-67c, Ring A is a monocyclic heteroaryl group; R1 is hydrogen or optionally 1 to 3 R 10 is a monocyclic or bicyclic heteroaryl group substituted by R2 is hydrogen, deuterium, R0, cyano group, [ka] Halogenated alkyl groups, -C(O)NH2, -C(O)NHR0, -C(O)NH-R0-OH, -C(O)NH-R0-N(alkyl) 1-2 , -C(O)NH-R 00 -OR, -C(O)N(R), -C(O)NH-cycloalkyl group, -C(O)NH-heterocycloalkyl group, -C(O)NH-(pyrazolyl optionally substituted by R), -C(O)-R, -C(O)-cycloalkyl group, -S(O)NH, -S(O)NH-R, -S(O)NH-cycloalkyl group, -R-NH, -R 00 -OH, -R 00 -OR0, -R 00 -(morpholin-4-yl)phenyl, phenyl, oxadiazolyl or tetrazolyl optionally substituted by R, wherein said oxadiazole is optionally substituted by R, R 00 is substituted by -OH or R0-OR0, R3 is hydrogen, deuterium, R0, halogenated alkyl group, cycloalkyl group, heterocycloalkyl group, phenyl group, pyridyl group, pyrimidinyl group, pyrazinyl group, -C(O)N(R0)2, -R 00 -cycloalkyl group, -R 00 -heterocycloalkyl group, -R 00 -phenyl group, -R 00 -OH, -R 00-OR, wherein the cycloalkyl, heterocycloalkyl, phenyl and pyridyl groups are optionally selected from R, halogen, -C(O)-OR, -C(O)-R, -OH, -OR, -S(O)-R, -O-halogenated alkyl, -OR 00 -(morpholin-4-yl), -R0-OH, -R 00 -OR, morpholin-4-yl or -R 00 -(morpholin-4-yl), R 10 is hydrogen, deuterium, R0, halogen, cyano group, halogenated alkyl group, cycloalkyl group, -OR0, optionally substituted amino group, -O-halogenated alkyl group, -R0-OH, -R 00 -OR0 or -R optionally substituted by an amino group 00 and R0 is an alkyl group, R 00 is an alkyl or alkene group, or

[0094] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] Here, in the PTM-68, Z1 is none, a substituted or unsubstituted C1-C6 alkylene group, a substituted or unsubstituted C3-C6 cycloalkylene group, a substituted or unsubstituted C2-C6 alkenylene group, or a substituted or unsubstituted C2-C6 alkynylene group; Z2 is a carbonyl group, [ka] and R1 is [ka] and Each R2 and each R3 independently represent none, a substituted or unsubstituted C1-C10 alkyl group, a substituted C3-C10 cycloalkyl group, a halogen, a substituted or unsubstituted C1-C10 halogenated alkyl group, a substituted or unsubstituted C1-C12 hydroxyalkyl group, a substituted or unsubstituted C1-C12 mercaptoalkyl group, a substituted or unsubstituted C3-C12 hydroxycycloalkyl group, a substituted or unsubstituted C3-C12 mercaptocycloalkyl group, a cyano group, a nitro group, a substituted or unsubstituted 3- to 12-membered heterocycloalkyl group, -AR 10 , or -N(R 11 )R 12 and R4 is a substituted or unsubstituted C6-C20 aryl group or a substituted or unsubstituted 5- to 20-membered heteroaryl group; R5 is a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C3-C10 cycloalkyl group; R6 is a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C3-C10 cycloalkyl group; R7 is hydrogen, deuterium, a substituted or unsubstituted C1-C10 alkyl group, a substituted or unsubstituted C3-C10 cycloalkyl group, or R 13 -C(O)-, R and R are each independently a substituted or unsubstituted C-C alkyl group, or R 8 and R 9 forms a 3- to 12-membered heteroalkane ring together with the S atom to which it is commonly attached, R 10 is hydrogen, deuterium, a substituted or unsubstituted C1-C10 alkyl group, a substituted or unsubstituted C3-C8 cycloalkyl group, a substituted or unsubstituted 3- to 12-membered heterocycloalkyl group, or -R 14 -R 15 and R 11 and R 12 are each independently hydrogen, deuterium, a substituted or unsubstituted C1-C10 alkyl group, or a substituted or unsubstituted C3-C8 cycloalkyl group; R 13is a substituted or unsubstituted C1-C10 alkyl group or a substituted or unsubstituted C3-C10 cycloalkyl group, R 14 is a substituted or unsubstituted C1-C6 alkylene group, R 15 is a substituted or unsubstituted C3-C12 cycloalkyl group or a substituted or unsubstituted C3-C12 heterocycloalkyl group, Here, the optional "substitution" refers to the replacement of one or more (preferably 1, 2, 3, or 4) hydrogen atoms on the group with a C2-C8 acyl group, a C3-C8 cycloalkyl group, a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1-C6 alkylthio group, a hydroxyl group, a mercapto group, an amino group, a nitro group, a halogen, a 3- to 12-membered heterocycloalkyl group, a cyano group, a C1-C10 halogenated alkyl group, a C3-C8 halogenated cycloalkyl group, a C2-C4 ester group, a C2-C4 amido group, a C1-C4 carboxyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C6-C12 aryl group, a 5- to 12-membered heteroaryl group, -N(R 16 )R 1 7, wherein the substituent is selected from the group consisting of R 16 and R 17 are each independently hydrogen, deuterium, a C1-C6 alkyl group, a C3-C8 cycloalkyl group, or a 3- to 10-membered heterocycloalkyl group; the heterocycloalkyl group, heteroaryl group, and heteroalkane ring each independently have 1 to 3 (preferably 1, 2, or 3) heteroatoms selected from N, O, and S; A is S or O; a is 0 or 1, b is 0, 1, 2 or 3, or

[0095] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-69, PTM-69a, PTM-69b, PTM-69c, PTM-69d, PTM-69e, PTM-69f, PTM-69g, PTM-69h, PTM-69i: X and X' are each independently CR 8 , N, or -N+-O-, and Y is independently N, -N+-O-, or CR 8 ', with the proviso that at least one of X, X', or Y is not N or -N+-O-, and at most one of X, X', or Y is -N+-O-; R1 is a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, -(CR 3a R 3b ) m -(3- to 7-membered cycloalkyl), -(CR 3a R 3b ) m -(3- to 7-membered heterocycloalkyl), -(CR 3a R 3b ) m -(5- to 10-membered heteroaryl), or -(CR 3a R 3b ) m -C6-C12 aryl group, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl group is optionally selected from the group consisting of halogen, deuterium, -OR5, -SR5, -NR 11a R 11b , substituted by 1 to 5 substituents selected from a cyano group, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, or a -C1-C6 alkoxy group; R2 is -(CR 3a R 3b ) m -(3- to 10-membered cycloalkyl), -(CR 3a R 3b ) m -(3- to 10-membered heterocycloalkyl), -(CR 3a R 3b )m -(5- to 10-membered heteroaryl), or -(CR 3a R 3b ) m -C6-C12 aryl group, wherein the cycloalkyl group, heterocycloalkyl group, heteroaryl group, or aryl group optionally has 1 to 5 R 4 wherein when the heteroatom on said heterocycloalkyl and heteroaryl groups is N, said N is optionally substituted by R 4 or R2 is a C1-C6 alkyl group, wherein said alkyl group is optionally substituted by an NH2, OH or cyano group; R 3a and R 3b is independently in each occurrence hydrogen or a C1-C3 alkyl group; R4, at each occurrence, independently represents a bond, deuterium, halogen, cyano, C1-C6 alkyl, C2-6 alkenyl, oxo, -OR 5 , -SR 5 , -S(O)R 9 , -S(O)2R 9 , -NR 11a R 11b , -C(O)R 10 , -(CR 3a R 3b ) n -(3- to 7-membered cycloalkyl), -(CR 3a R 3b ) n -(4- to 10-membered heterocycloalkyl), -(CR 3a R 3b ) n -(5-10 membered heteroaryl) or -(CR 3a R 3b ) n -C6-C12 aryl group, wherein said alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or aryl group are each optionally and independently selected from deuterium, halogen, OR, -SR, -NR 11a R 11b, a cyano group, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, or a -C1-C6 alkoxy group, or two R 4 together with the carbon atom to which it is attached form a 3- to 6-membered cycloalkyl group or a 4- to 6-membered heterocycloalkyl group, wherein said cycloalkyl group or heterocycloalkyl group optionally contains a halogen, deuterium, OR, -SR, -NR 11a R 11b , cyano group, C1-C6 alkyl group or C1-C6 alkoxy group, wherein the alkyl group or alkoxy group is optionally substituted with halogen, deuterium, -OR5, -SR5, -NR 11a R 11b or a cyano group, wherein if a heteroatom on said heterocycloalkyl group is N, said N is optionally substituted by a substituent selected from R 4 ' is replaced by R 4’ are independently a C1-C6 alkyl group, a C2-6 alkenyl group, or —C(O)R 10 , -S(O)2R9, -(CR 3a R 3b ) n -(3- to 7-membered cycloalkyl), -(CR 3a R 3b ) n -(4-10 membered heterocycloalkyl) or C(O)(CH)CN, wherein the alkyl, alkenyl, cycloalkyl or heterocycloalkyl group is each optionally and independently substituted with 1 to 5 substituents selected from deuterium, halogen, OH, cyano or C-C alkoxy, or R 4 and R 4’ together with the corresponding atom to which it is attached form a 3- to 6-membered cycloalkyl group or a 4- to 6-membered heterocycloalkyl group, wherein said cycloalkyl group or heterocycloalkyl group optionally contains halogen, deuterium, OR, -SR, -NR 11a R 11b, cyano group, C1-C6 alkyl group or C1-C6 alkoxy group, wherein the alkyl group or alkoxy group is optionally substituted with halogen, deuterium, -OR5, -SR5, -NR 11a R 11b or substituted by a cyano group, R 4a and R 4b are each independently hydrogen, deuterium, F, OH, —OR5, methyl, ethyl, vinyl, cyclopropyl, or propyl, optionally substituted with 1 to 5 deuterium, fluorine, methoxy, or OH; R 4c and R 4d Each occurrence independently represents a halogen, OH, deuterium, a C1-C6 alkyl group, a C2-6 alkenyl group, -OR5, -(CR 3a R 3b ) n -(3- to 6-membered cycloalkyl), -(CR 3a R 3b ) n -(4- to 6-membered heterocycloalkyl), NH, wherein the alkyl group, cycloalkyl group, and heterocycloalkyl group are each optionally and independently substituted with 1 to 5 substituents selected from deuterium, halogen, OH, cyano, or C-C alkoxy; or R 4c and R 4d together with the carbon atom to which it is attached form a 4- to 7-membered heterocycloalkyl group or a 3- to 7-membered cycloalkyl group, wherein said heterocycloalkyl group and cycloalkyl group are each independently optionally substituted with 1 to 3 fluorines, C1-C3 alkyl groups, or C1-C3 fluoroalkyl groups; or R 4c and R 4atogether with the atom to which it is attached form a 4- to 7-membered heterocycloalkyl group or a 3- to 7-membered cycloalkyl group, wherein said heterocycloalkyl group and cycloalkyl group are each independently optionally substituted with 1 to 3 fluorines, C1-C3 alkyl groups, or C1-C3 fluoroalkyl groups; R5 is independently hydrogen or a C1-C6 alkyl group, wherein said alkyl group is optionally selected from halogen, deuterium, a C1-C6 alkoxy group, a C1-C6 alkylthio group, -NR 11a R 11b , cyano group, C1-C6 alkyl group, or C3-C6 cycloalkyl group, or two R 5 together with the oxygen atom to which it is attached form a 5- or 6-membered heterocycloalkyl group, R6 is hydrogen, deuterium, —C(O)NHR7, CO2R7 or a cyano group; R7 is hydrogen or a C1-C6 alkyl group; R8 is independently hydrogen, deuterium, halogen, cyano group, OR5, -SR5, -NR 11a R 11b , a C1-C6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a C3-C6 cycloalkyl group, a 3- to 10-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl or aryl group, wherein the alkyl group, alkenyl group, alkynyl group, cycloalkyl group, heterocycloalkyl group, heteroaryl group, or aryl group optionally contains 1 to 3 halogen atoms, a C3-C6 cycloalkyl group, a C3-C6 heterocycloalkyl group containing one or two N heteroatoms, OR5, -SR5, -NR 11a R 11b , cyano group, C1-C3 alkyl group, -C(O)R 10 or substituted by oxo, R 8’ is hydrogen, deuterium, halogen, cyano group, OR5, -SR5, or -NR 11a R 11b and R9 is -(CR 3a R 3b)p-(C1-C3 alkyl), -(CR 3a R 3b )p-(4- to 6-membered cycloalkyl), -(CR 3a R 3b )p-(4- to 6-membered heterocycloalkyl) or -(CR 3a R 3b )p-(C5-C9 aryl), wherein the alkyl, cycloalkyl, heterocycloalkyl or aryl group is each optionally substituted by fluorine or a C1-C3 alkyl group; R 10 is a C1-C6 alkyl group, wherein said alkyl group is optionally substituted with deuterium, halogen, OH, a C1-C6 alkoxy group, or a cyano group; R 11a and R 11b are each independently hydrogen or a C1-C6 alkyl group, wherein said alkyl group is optionally substituted with deuterium, a C1-C6 alkoxy group, or a cyano group, and when a C2-6 alkyl group, said alkyl group is optionally substituted with deuterium, a C1-C6 alkoxy group, a cyano group, a halogen, or OH; m is independently 0, 1, 2, or 3; n is independently 0, 1, 2, or 3; p is independently 0 or 1, and t is 1, 2, or 3, or

[0096] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-70, PTM-70a, PTM-70b or PTM-70c: X1 and X3 are each independently CH or N, and X2 is CR 2 or N, with the condition that at most one of X1, X2, or X3 is N; A is O, N or S; Y is N, CH or O; Ring Z is an aryl group, a heteroaryl group, or a heterocycloalkyl group; R1 in each occurrence is independently a halogen, an optionally substituted heterocycloalkyl group, or an optionally substituted heteroaryl group, wherein said substituents are alkyl, alkoxy, aminoalkyl, halogen, hydroxyl, hydroxyalkyl, or -NR a R b and R2 is hydrogen, deuterium, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocycloalkyl group, an optionally substituted heteroaryl group, or -NR a R b wherein the substituents are alkyl groups, amino groups, halogens, or hydroxyl groups; R3, in each occurrence, is an alkyl group or a hydroxyl group; R a and R b are independently hydrogen, deuterium, an alkyl group, an acyl group, a heteroaryl group, or a heterocycloalkyl group; m and n are each independently 0, 1, or 2; p is 0 or 1, or

[0097] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] Here, in the PTM-71, Ring A is a 6- to 10-membered aryl group or a 5- to 10-membered heteroaryl group; R dare each independently hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, C3-C6 cycloalkyl, or 5-10 membered heteroaryl, and the alkyl, cycloalkyl, or heteroaryl group is optionally substituted with one or more groups selected from halogen, hydroxyl, and amino; n is 1, 2, 3 or 4; R e is hydrogen or a C1-C6 alkyl group, R c is hydrogen, deuterium, -O-(C1-C6 alkyl), -O-(C3-C8 cycloalkyl), -O-(3- to 8-membered heterocycloalkyl), -O-(6- to 10-membered aryl), -O-(5- to 10-membered heteroaryl), -N(C1-C6 alkyl), -NH(C3-C8 cycloalkyl), -NH(C3-C8 heterocycloalkyl), -NH(6- to 10-membered aryl), -NH(5- to 10-membered heteroaryl), C1-C6 alkyl group, C2-C6 aryl a C2-C6 alkynyl group, a C3-C8 cycloalkyl group, a C3-C8 heterocycloalkyl group, a C6-C10 aryl group, or a 5- to 10-membered heteroaryl group, wherein the alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group, or heteroaryl group is optionally substituted with one or more groups independently selected from a hydroxyl group, an amino group, a halogen atom, an —O—(C1-C6 alkyl), and a cyano group; R b is hydrogen, deuterium, -O-(C1-C6 alkyl), -O-(C3-C8 cycloalkyl), -O-(C3-C8 heterocycloalkyl), -O-(6- to 10-membered aryl), -O-(5- to 10-membered heteroaryl), -N(C1-C6 alkyl) 1-2, -NH(C3-C8 cycloalkyl), -NH(C3-C8 heterocycloalkyl), -NH(6- to 10-membered aryl), -NH(5- to 10-membered heteroaryl), C1-C6 alkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, C3-C8 cycloalkyl group, C3-C8 heterocycloalkyl group, C6-C10 aryl group, or 5- to 10-membered heteroaryl group, wherein the alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group, or heteroaryl group is optionally substituted with one or more groups independently selected from a hydroxyl group, an amino group, a halogen atom, and a cyano group; R a represents hydrogen, deuterium, a 3- to 8-membered heterocycloalkyl group, a C3-C8 cycloalkyl group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group, a C1-C6 alkyl group, [ka] wherein the alkyl group is optionally selected from halogen, hydroxyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, S(O) 1-2 (C1-C6 alkyl), S(O) 1-2 (C3-C6 cycloalkyl), unsubstituted or mono- or polyhalogen-substituted C3-C6 cycloalkyl groups, monocyclic saturated heterocycloalkyl groups having 4 to 6 ring atoms and containing a heteroatom or heterogroup selected from O, S, SO, SO2, unsubstituted or substituted by mono- or dimethyl groups, wherein the cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally substituted by one or more groups selected from hydroxyl, halogen, amino, cyano, C1-C6 alkyl group, —O(C1-C6 alkyl), halogenated C1-C6 alkyl group, hydroxyl C1-C6 alkyl group, amino C1-C6 alkyl group, where * represents the bond site where the group is attached to the remainder of the molecule, or

[0098] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein in said PTM-72: R 1 (a) 0 to 4 R 1a a C2-C3 hydroxyalkyl group substituted by 1a is selected from F, Cl, —OH, —CHF2, —CN, —CF3, —OCH3 and a cyclopropyl group; (b) an —O(C1-C3) alkyl group and 0 to 4 R 1a a C1-C3 alkyl group substituted by 1a is selected from F, Cl, —OH, —CHF2, —CN, —CF3 and a cyclopropyl group; (c) 0 to 7 R 1a a C4-8 alkyl group substituted by 1a is selected from F, Cl, —OH, —CHF2, —CN, —CF3, —OCH3, a cyclopropyl group or —OP(O)(OH)2, (d) -(CH2)2-4NHC(O)(C1-C6 alkyl), -(CH2)2CH(CH3)NHC(O)(C1-C6 alkyl), -(CH2)2CH(CH3)NHC(O)O(C1-C6 alkyl), -(CH2)2CH(CH3)NHC(O)(CH2)0-1NH(C1-C6 alkyl) or -(CH2)2CH(CH3)NHC(O)(CH2)0-1N(C1-C6 alkyl)2, -(CH2)2CH(CH3)NHC(O)(CH2)0-1(C3-C6 cyclo -(C-C alkyl), -(CH2)2CH(CH3)NHC(O)(CH2)0-1(C3-C6 fluorocycloalkyl), -(CH2)2CH(CH3)NHC(O)(C1-C6 hydroxyalkyl), -(CH2)2CH(CH3)NHC(O)N(C1-C6 alkyl)(phenyl) or -(CH2)2CH(CH3)NHC(O)(CH2)0-1R, where R is a phenyl group, a morpholinyl group, a pyrrolidinyl group, a triazolyl group, or a tetrahydropyranyl group; (e) -OH, -OCH3, oxo, -NH2, nitro group, C1-C6 alkyl group, C1-C6 hydroxyalkyl group, -C(O)NH2, -C(O)NH(C1-C3 alkyl), -C(O)NH(C1-C6 hydroxyalkyl), -C(O)NH(C3-C6 cycloalkyl), -C(O)NH(C3-C6 fluorocycloalkyl), -C(O)NH(C3-C6 cyanocycloalkyl), -NHC(O)(C1-C3 alkyl), -NHC(O)(pyridyl), -NHC(O)(morpholinyl), -NHC(O)( hydroxybicyclo[2.2.2]heptyl), -NHC(O)NH(C1-C4 alkyl), -NHC(O)O(C1-C3 alkyl), -NHS(O)2CH3, -NHS(O)2NH2, -NHS(O)2(C1-C3 alkyl), -S(C1-C3 alkyl), thiazolyl group, methylpyrazolyl group, or -OH, a cyclohexyl group, cyclopentyl group, cyclopropyl group, or cyclobutyl group substituted by 0 to 2 substituents independently selected from a C1-C3 alkyl group substituted by a cyclopropyl group; (f) a —(CH) phenyl group, wherein the phenyl group is substituted by —C(O)NH, —C(O)NH(C-C alkyl), or —S(O)NH; (g) a piperidinyl group, an azetidinyl group, an azacyclopentanyl group, a piperazinyl group optionally substituted by —C(O)(C1-C3 alkyl), or [ka] and R 2is a phenyl group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazolyl group, a thiazolyl group, a triazolyl group, a benzoxazolyl group, a pyrazolopyridyl group, a pyrrolopyridyl group, a benzothiazolyl group, a thiazolopyridyl group, a pyrazolopyrimidinyl group, a benzoxadiazolyl group, a benzoxadiazolyl group, a quinolinyl group, a cinnolinyl group, a quinazolinyl group, a quinoxalinyl group, a 1,5-diazanaphthyl group, a 1,6-diazanaphthyl group, a pyridopyrazinyl group or a pyridopyrazinyl group. -pyrimidinyl groups, each independently substituted by 0 to 2 substituents selected from F, Cl, -OH, -CN, a C1-C3 alkyl group, -CH2C(O)OCH3, -O(C1-C3 alkyl), -NH2, -NH(C1-C3 alkyl), -NH(cyclopropyl), -C(O)NH2, -NHC(O)(C1-C3 alkyl), -NH(tetrahydropyranyl), a hydroxypyrrolidinyl group, oxo, -O(piperidinyl), or a pyridyl group; R 3 (a) a C1-C6 alkyl group substituted by 0 to 4 substituents independently selected from F, —CH3, —CF3, a phenyl group, a tetrahydrofuranyl group, a morpholinyl group, or a C3-C6 cycloalkyl group; (b) a C1-C6 hydroxyalkyl group substituted with 0 to 3 groups selected from F, a phenyl group, a fluorophenyl group, a difluorophenyl group, or a dichlorophenyl group; (c) -(CH)(C-C cycloalkyl) substituted by 0 to 2 substituents independently selected from F, Cl, -OH, C-C hydroxyalkyl group, C-C alkyl group, -O(C-C alkyl), -OCF, -C(O)NH, -C(O)NH(C-C alkyl), -C(O)NH(C-C fluoroalkyl), -C(O)NH(C-C hydroxyalkyl), -C(O)NH(C-C cycloalkyl), -C(O)N(C-C alkyl), -S(O)CH, -CFH, -NH, -C(O)CHCH, or a pyrazolyl group; (d) an oxetanyl group, a tetrahydropyranyl group, or a fluorotetrahydropyranyl group; (e) a thiazolyl group substituted with 0 to 2 C1-C3 hydroxyalkyl groups; (f) a phenyl group substituted by 0 to 2 substituents independently selected from -OH, -CN, -O(C1-C3 alkyl), a C1-C3 hydroxyalkyl group, -C(O)NH2, -S(O)2NH2, -NHS(O)2(C1-C3 alkyl), a pyrazolyl group, an imidazolyl group, or a methyltetrazolyl group; or [ka] or

[0099] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-73: HET is a heteroaryl group selected from pyrazolyl, indolyl, pyrrolo[2,3-b]pyridyl, pyrrolo[2,3-b]pyrimidinyl, pyrazolo[3,4-b]pyridyl, pyrazolo[3,4-b]pyrimidinyl, 2,3-dihydro-1H-pyrrolo[2,3-b]pyridyl, imidazo[4,5-b]pyridyl, or purinyl, wherein the heteroaryl group is optionally selected from R a or R b is replaced by R arepresents hydrogen, deuterium, F, Cl, Br, -CN, -OH, C1-C4 alkyl group, C1-C4 hydroxyalkyl group, C1-C4 fluoroalkyl group, C1-C4 alkoxy group, -NH2, -NH(C1-C4 alkyl), -N(C1-C4 alkyl)2, -NH(C1-C4 hydroxyalkyl), -NH(C1-C4 fluoroalkyl), -NH(C1-C6 hydroxyl-fluoroalkyl), -C(O)NH2, -CH2NHC(O)(C1-C6 alkyl), -CH2NHC(O)(C1-C6 hydroxyalkyl), -CH2NHC(O)NH(C1 -C6 alkyl), -CH2NHC(O)NHCH2(phenyl), -CH2NHC(O)N(C1-C4 alkyl), -CH2NHC(O)O(C1-C4 alkyl), -CH2NHC(O)(C3-C6 cycloalkyl), -CH2NHC(O)(tetrahydrofuranyl), -CH2NHC(O)CH2(C3-C6 cycloalkyl), -CH2NHC(O)CH2(tetrahydropyranyl), -CH2NHC(O)CH2(phenyl), -NHC(O)(C1-C4 alkyl), pyrrolidinyl group, hydroxylpyrrolyl group or pyridazinyl group; R b is hydrogen or -NH2, R1 is (i) a C1-C6 alkyl group, a C1-C6 fluoroalkyl group, a C1-C6 hydroxyalkyl group, a C1-C8 hydroxyl-fluoroalkyl group, -(C1-C6 alkylene)O(C1-C4 alkyl), -(C1-C6 alkylene)O(C1-C4 fluoroalkyl), -(C1-C6 fluoroalkylene)O(C1-C4 alkyl), -(C1-C6 fluoroalkylene)O(C1-C4 deuterated alkyl), -(C1-C6 fluoroalkylene)O(C1-C4 fluoroalkyl), -(C1-C6 fluoroalkylene)C(C3-C6 cycloalkyl)2(OH), -(C1-C4 alkylene)nHC(O)(C1-C4 alkylene)OC(O)(C1-C3 alkyl), -(C1-C6 alkylene)nHS(O)2(C1-C4 alkyl), -(C1-C6 alkylene)P(O)(C1-C4 alkoxy)2, -(C1-C6 fluoroalkylene)nH(C1-C4 alkyl), -(C1-C6 alkylene)C(O)NH(C1-C4 alkyl), -(C1-C6 fluoroalkylene)C(O)NH(C1-C4 alkyl), -(C1-C6 fluoroalkylene)C(O)NH(C1-C4 hydroxyalkyl) or -(C1-C6 fluoroalkylene)OP(O)(OH)2, (ii) -(C1-C3 alkylene)R x , -(C1-C3 fluoroalkylene)R x , -(C1-C3 alkylene)C(O)R x , -(C1-C3 alkylene)C(O)NHR x , -(C1-C3 fluoroalkylene)C(O)NHR x or -CHCF=(tetrahydropyranyl), where R xis a cyclic group selected from a C3-C6 cycloalkyl group, a tetrazolyl group, a 1,1-dioxidetetrahydrothienyl group, a 1,1-sulfur dioxidemorpholinyl group, an oxadiazolyl group, a piperidinyl group, a piperazinyl group, a pyrrolidinyl group, an oxetane group, a tetrahydrofuranyl group, a tetrahydropyranyl group, a pyridyl group, an imidazolyl group, a morpholinyl group, a phenyl group, and a triazinyl group, wherein each cyclic group is optionally and is substituted by 0 to 3 substituents independently selected from F, -OH, -CH3, -(CH2)2OH, -OCH3, -C(O)CH2CN, -S(O)2CH3, -S(O)2NH2, -NHC(O)CH3, -N(S(O)2CH3)2, -CH2CH2(acetamidophenyl), -CH2CH2(methoxyphenyl), -CH2CH2(sulfamoylphenyl), oxetane, phenyl, or morpholinyl; (iii) each independently represents F, -OH, -CN, a C1-C3 alkyl group, a C1-C3 alkoxy group, S(C1-C3 alkyl), a nitro group, S(O)2(C1-C3 alkyl), a C1-C4 hydroxyalkyl group, -C(C1-C3 alkyl)(OH)(C3-C6 cycloalkyl), -CH2C(O)NH(C1-C3 alkyl), -NHC(O)(C1-C3 alkyl), -NHC(O)(C1-C4 hydroxyalkyl), -C(O)NH a C3-C6 cycloalkyl group or a C4-C6 cycloalkenyl group substituted by 0 to 3 substituents selected from (C1-C3 alkyl), -C(O)NH(C1-C3 deuterated alkyl), -C(O)NH(C3-C6 cycloalkyl), -NHC(O)O(C1-C3 alkyl), -NHS(O)2(C1-C3 alkyl), a pyridyl group, an imidazolyl group, a pyrazolyl group, a methylimidazolyl group, a methylpyrazolyl group, or a thiazolyl group; (iv) -OH, C1-C3 alkyl group, C1-C3 fluoroalkyl group, C1-C4 hydroxyalkyl group, C1-C3 alkoxy group, -C(O)(C1-C4 alkyl), -S(O)2(C1-C4 alkyl), -S(O)2NH(C1-C4 alkyl), -NH(C1-C3 alkyl), -O(C1-C3 alkylene)n(C1-C3 alkyl)2, -CH2(morpholinyl), azetidine, tetrahydrofuran, a tetrahydrofuranyl group, piperidinyl group, pyrazolyl group, phenyl group, pyridyl group, or pyrimidinyl group substituted by 0 to 1 substituents selected from tetrahydropyranyl group, morpholinyl group, oxetane, piperazinyl group, piperidinyl group, methylpiperazinyl group, methoxypiperidinyl group, pyridyl group, pyrimidinyl group, methylsulfonylazetidine, or —C(O)(methylsulfonylazetidine), or (v) a pyrrolo[2,3-c]pyridyl group, bicyclo[2.2.1]heptan-1-ol, tetrahydrobenzo[d]thiazol-2-amine, or 1,3-diazaspiro[4.5]deca-2,4-dione; R2 is (i) a C1-C7 alkyl group or a C2-6 alkenyl group, each independently substituted by 0-3 substituents independently selected from F, -OH, or -CN, -(C1-C4 alkylene)O(C1-C4 alkyl), -(C1-C4 alkylene)O(C1-C4 fluoroalkyl), -(C1-C6 alkylene)NH2, -(C1-C6 alkylene)S(O)2(C1-C3 alkyl), -(C1-C6 fluoroalkylene)nH(C1-C3 alkyl), or -(C1-C6 alkylene)nHC(O)(C1-C4 fluoroalkyl); (ii) -(C1-C4 alkylene)R y , where R yare a C3-C6 alkyl group, azetidine, oxetane, oxazolyl group, pyridyl group, and tetrahydropyranyl group, each of which independently represents F, —OH, a C1-C3 alkyl group, a C1-C3 hydroxyalkyl group, —C(O)(C1-C3 alkyl), —C(O)(C1-C3 fluoroalkyl), —C(O)(C1-C3 cyanoalkyl), —C(O)O(C1-C3 alkyl), —C(O)NH2, —C(O)NH(C1-C3 alkyl), —C(O)(difluorophenyl), —NH2, — substituted by 0 to 3 substituents selected from NH(C1-C3 alkyl), -NH(C1-C3 fluoroalkyl), -NH(oxetane), -NHC(O)(C1-C3 alkyl), -NHC(O)(C1-C3 fluoroalkyl), -NHC(O)(C3-C6 cycloalkyl), -NHC(O)(fluorophenyl), -S(O)2(C1-C3 alkyl), imidazolyl group, phenyl group, pyrimidinyl group, fluoropyrimidinyl group, chloropyrimidinyl group, or methoxypyrimidinyl group; (iv) an adamantyl group, a hydroxyadamantyl group, a benzo[d]imidazolyl group, a benzo[d]oxazolyl group, a benzo[d]triazolyl group, a benzo[d]thiazolyl group, a bicyclo[1.1.1]pentyl group, or a hydroxyl-bicyclo[2.2.1]heptyl group, or (v) each independently represents F, -Cl, -OH, -CN, C1-C4 alkyl group, C1-C4 hydroxyalkyl group, C1-C4 fluoroalkyl group, C1-cyanoalkyl group, C1-C3 alkoxy group, C3-C6 cycloalkyl group, -(C1-C3 alkylene)O(C1-C3 alkyl), -(C1-C3 alkylene)O(C1-C3 fluoroalkyl), -C(O)NH2, -C(O)NH(C1-C3 alkyl), -NHC(O)(C1-C3 alkyl), -NHC (O) is a phenyl, pyrazolyl, thiazolyl, oxadiazolyl or indazolyl group substituted by 0 to 2 substituents selected from (O)S(O)2(C1-C3 alkyl), -S(O)2NH2, -S(O)2(C1-C3 alkyl), pyrazolyl, methylpyrazolyl, imidazolyl, triazolyl, methyltetrazolyl, ethyltetrazolyl, phenyl, pyrimidinyl, fluoropyrimidinyl or tetrahydropyranyl, or

[0100] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-74: Ring A is an aryl group or a heterocycloalkyl group; R 1 is H, an alkyl group, or a heteroalkyl group, R 2 is H, an alkyl group, a heteroalkyl group, or a heterocycloalkyl group; each Z 1 , Z 2 , Z 3 and Z 4 are independently N or CR 3 where Z 1 , Z 2 , Z 3 and Z 4 at least one of is N, R 4is a halogen, a heterocycloalkyl group, an aryl group, an -O-aryl group, or an -NH-aryl group; or

[0101] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-75: [ka] is C 3-10 an aryl group, a 3- to 8-membered saturated or partially unsaturated carbocyclic ring, a 3- to 7-membered heterocyclic ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaromatic ring containing 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R a are independently -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R or -N(R)2; R b is -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R or -N(R)2, or R b does not exist, Ring X is a C3-10 aryl group, a 5-6 membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a fused C3-10 aryl group, a fused 5-10 membered saturated or partially unsaturated carbocycle, a fused 5-10 membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a fused 5-10 membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; R 1 is -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R, or -N(R)2; R 2 is -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R, or -N(R)2, where R 3 is —R or —halogenated alkyl group, R 4 is -R, halogen, -halogenated alkyl group, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NR c (O)R, -NR c (O)N(R)2, -NRSO2R, or -N(R)2; each R is independently hydrogen, deuterium, a C1-6 aliphatic group, a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated carbocycle, a 3- to 7-membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the foregoing groups being optionally substituted or two R groups on the same atom, together with the atom to which they are attached, form a C3-C10 aryl group, a 3- to 8-membered saturated or partially unsaturated carbocycle, a 3- to 7-membered heterocycle containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5- to 6-membered monocyclic heteroaromatic ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of the above groups being optionally substituted; and p is 0, 1, 2, 3, 4 or 5, or

[0102] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a stereoisomer, tautomer, solvate, or a pharmaceutically acceptable salt thereof, wherein in said PTM-76: Y is O, S, SO, SO2 or NR 1 is selected from Z is S, O or NR 2 is selected from A is a substituted or unsubstituted aryl or heteroaryl group; B is a cycloalkyl group, said cycloalkyl group optionally containing one or more R 3 is substituted by a group, R 1 is selected from hydrogen or an alkyl group; R 2 is selected from hydrogen, deuterium, an alkyl group, a hydroxyalkyl group, a cyanoalkyl group, an alkoxyalkyl group, an alkoxycarbonylalkyl group, an aminoacylalkyl group, an alkylaminoacylalkyl group, a dialkylaminoacylalkyl group, a (heterocycloalkyl)alkyl-, (aryl)alkyl- or a (heteroaryl)alkyl-; Each R 3 are independently an alkyl group, a heterocycloalkyl group, a halogen atom, a hydroxyl group, R 3a R 3bN-, carboxyl group, halogenated alkyl group, hydroxyalkyl group, alkoxy group, heterocycloalkyloxy group, (heterocycloalkyl)alkyl-oxy group, hydroxyalkyloxy group, or R 3a R 3b NC(O)—, wherein the heterocycloalkyl group at each occurrence is optionally substituted by one or more substituents selected from halogen, alkyl, halogenated alkyl, hydroxyl, alkoxy, amino, alkylamino, and dialkylamino groups; Each R 3a and R 3b are each independently selected from hydrogen, deuterium, an alkyl group, a cycloalkyl group, a hydroxyalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, wherein the cycloalkyl group, heterocycloalkyl group, aryl group, or heteroaryl group is optionally substituted with one or more substituents selected from halogen, an alkyl group, a halogenated alkyl group, a hydroxyl group, an alkoxy group, an amino group, an alkylamino group, and a dialkylamino group; or

[0103] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a stereoisomer, tautomer, solvate, or pharmaceutically acceptable salt thereof, wherein in said PTM-77, PTM-77a, PTM-77b, PTM-77c, PTM-77d, PTM-77e, PTM-77f, PTM-77g, PTM-77h, or PTM-77i: R 1is selected from H, a (C1-C8) alkyl group, a C1-C4 halogenated alkyl group, a C1-C4 hydroxyalkyl group, a C1-C4 aminoalkyl group, a -C1-C4 alkyl-O-C1-C4 alkyl group, a -O-C1-C4 alkyl group, a C3-C8 cycloalkyl group, a C3-C8 cycloalkyl(C1-C8)alkyl group, a heterocycloalkyl(C1-C8)alkyl group, a 6- to 10-membered aryl group, an aryl(C1-C8)alkyl group, a heteroaryl(C1-C8)alkyl group or a heteroaryl group, wherein said alkyl group, cycloalkyl group, aryl group or heteroaryl group is optionally substituted; R 2 is selected from a (C1-C8) alkyl group, a C1-C4 halogenated alkyl group, a C1-C4 hydroxyalkyl group, a C1-C4 aminoalkyl group, a -C1-C4 alkyl-O-C1-C4 alkyl group, an -O-C1-C4 alkyl group, a 6- to 10-membered aryl group, or a heteroaryl group, wherein the alkyl group, cycloalkyl group, aryl group, or heteroaryl group is optionally substituted; R 5 , R 6 , R 7 and R 8 are each independently selected from H, halogen, a C-C alkyl group, a C-C halogenated alkyl group, a C-C hydroxyalkyl group, a C-C aminoalkyl group, —C-C alkyl-O—C-C alkyl group, —O—C-C alkyl group, an aryl group, an aryl(C-C) alkyl group, a heteroaryl group, CN, COR′, CONR′R″, NR′R″, NO, OR′, SR′, C(O)R′, OC(O)R′, N(R″)C(O)R′, N(R″)COR′, N(R″)C(O)NR′R″, S(O)NR′R″, S(O)R and N(R″)S(O)R′, wherein said alkyl group, cycloalkyl group, aryl group, and heteroaryl group are optionally substituted, and wherein the subscript m is an integer of 1 or 2; R 9 , R 10 , R 11 , R 12 and R 13are each independently selected from H, halogen, a C-C alkyl group, a C-C halogenated alkyl group, a C-C hydroxyalkyl group, a C-C aminoalkyl group, —C-C alkyl-O—C-C alkyl group, —O—C-C alkyl group, an aryl group, an aryl(C-C) alkyl group, a heteroaryl group, CN, COR′, CONR′R″, NR′R″, NO, OR′, SR′, C(O)R′, OC(O)R′, N(R″)C(O)R′, N(R″)COR′, N(R″)C(O)NR′R″, S(O)NR′R″, S(O)R and N(R″)S(O)R′, wherein said alkyl group, cycloalkyl group, aryl group, and heteroaryl group are optionally substituted, and wherein the subscript m is an integer of 1 or 2; X is selected from H, OR', NR'R'', OC(O)R', CO2R', CONR'R'', OCONR'R'', N(R'')C(O)R', C(O)R', N(R'')COR', N(R'')C(O)NR'R'', Y is C(O), S(O), S(O)2, -CH2-; R' and R'' are each independently selected from H, a C1-C4 alkyl group, a C1-C4 halogenated alkyl group, a C1-C4 hydroxyalkyl group, a C1-C4 aminoalkyl group, a -C1-C4 alkyl-O-C1-C4 alkyl group, an -O-C1-C4 alkyl group, an aryl group, and an aryl(C1-C4)alkyl group, wherein said alkyl group, cycloalkyl group, aryl group, and heteroaryl group are optionally substituted; or R' and R'' together with the N atom to which they are attached form a 5-, 6-, or 7-membered ring.

[0104] Preferably, in some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-70, PTM-70a, PTM-70b or PTM-70c: X1 and X3 are each independently CH or N, and X2 is CR2 or N, with the proviso that not more than one of X1, X2, or X3 is N; A is O or S; Y is N, CH or O; Ring Z is a 6- to 10-membered aryl group, a 5- to 6-membered heteroaryl group, or a 3- to 8-membered heterocycloalkyl group; R1 in each occurrence is independently a halogen, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrrolidinyl group, or an optionally substituted piperidinyl group, wherein said substituents are alkyl groups, alkoxy groups, aminoalkyl groups, halogens, hydroxyl groups, hydroxyalkyl groups, or -NR a R b and R2 is hydrogen, deuterium, an optionally substituted piperidinyl group, an optionally substituted pyrrolidinyl group, an optionally substituted morpholinyl group, an optionally substituted piperazinyl group, an optionally substituted azetidine group, an optionally substituted pyrazolyl group, an optionally substituted furyl group, an optionally substituted azabicyclo[3.2.1]octyl group, or a cyclopropyl group, wherein the substituents are alkyl groups, amino groups, halogens, or hydroxyl groups; R3, in each occurrence, is an alkyl group or a hydroxyl group; R a and R b are independently hydrogen, deuterium, an alkyl group, an acyl group, a heteroaryl group, or a heterocycloalkyl group; m and n are each independently 0, 1, or 2; p is 0 or 1.

[0105] Preferably, in some embodiments of the present invention, the PTM is [ka] [ka] [ka] [ka] [ka] is selected from.

[0106] Preferably, in some embodiments of the present invention, the PTM has a structure of the following formula: [ka]

[0107] Preferably, in some embodiments of the present invention, the compound of formula I, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, is a compound of formula IA, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, [ka] Here, X1, X2, X3, A, Y, p, R 1 , R 3 , m, Z, n are as defined in PTM-70, and L, ULM are as defined herein.

[0108] Preferably, in some embodiments of the present invention, the compound of formula I, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, is a compound of formula IA-1, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, [ka] Here, A, Y, p, and R 1 , R 2 , R 3 , m, and n are as defined in PTM-70a, and L and ULM are as defined herein.

[0109] Preferably, in some embodiments of the present invention, the compound of formula I, and / or a stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug, and / or a pharmaceutically acceptable salt thereof, is a compound of formula IA-2, and / or a stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug, and / or a pharmaceutically acceptable salt thereof, [ka] Here, A, Y, R1, and R 2、 n is as defined in PTM-70b, and L, ULM are as defined herein. Preferably, in some embodiments of the present invention, the compound of formula I, and / or a stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug, and / or a pharmaceutically acceptable salt thereof, is a compound of formula IA-3, and / or a stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug, and / or a pharmaceutically acceptable salt thereof, [ka] wherein A, Y, R1, R2, and n are as defined in PTM-70c, and L and ULM are as defined herein. Preferably, in some embodiments of the invention, the PTM has a structure of the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein in said PTM-69h or PTM-69i: X and X' are each independently CR 8 or N, and Y is independently N or CR 8 ', and the condition is that at least one of X, X', or Y is not N, R1 is a C1-C6 alkyl group or a C3-C6 cycloalkyl group, wherein the alkyl group, cycloalkyl group is optionally substituted by a substituent selected from halogen, deuterium, —OH, cyano group, C1-C3 alkyl group, C3-C6 cycloalkyl group, or C1-C6 alkylthio group; R 3a and R 3b is independently in each occurrence hydrogen or a C1-C3 alkyl group; R4, at each occurrence, is independently selected from halogen, C1-C6 alkyl, C2-6 alkenyl, -OR5, -(CR 3a R 3b ) n -(3- to 6-membered cycloalkyl), -(CR 3a R 3b ) n -(4- to 6-membered heterocycloalkyl), -NR 11a R 11b wherein the alkyl, cycloalkyl, and heterocycloalkyl groups are each optionally and independently substituted with 1 to 5 substituents selected from halogen, OH, cyano, C(O)(CH)CN, or C-C alkoxy, or two R 4 together with the carbon atom to which it is attached form a cyclopropyl, cyclopentyl or cyclobutyl group, wherein said cyclopropyl, cyclopentyl or cyclobutyl group is optionally substituted by 1 to 3 substituents selected from F, Cl, OH, methyl, ethyl, propyl, C1-C3 fluoroalkyl, C1-C3 difluoroalkyl, C1-C3 hydroxyalkyl, methoxy and ethoxy; R 4a and R 4bare each independently hydrogen, deuterium, F, OH, —OR5, methyl, ethyl, vinyl, cyclopropyl, or propyl, optionally substituted with 1 to 5 deuterium, fluorine, methoxy, or OH; R 4c and R 4d Each occurrence independently represents a halogen, OH, deuterium, a C1-C6 alkyl group, a C2-6 alkenyl group, -OR5, -(CR 3a R 3b ) n -(3- to 6-membered cycloalkyl), -(CR 3a R 3b ) n -(4- to 6-membered heterocycloalkyl), NH, wherein the alkyl group, cycloalkyl group, and heterocycloalkyl group are each optionally and independently substituted with 1 to 5 substituents selected from deuterium, halogen, OH, cyano, or C-C alkoxy; or R 4c and R 4d together with the carbon atom to which it is attached form a 4- to 7-membered heterocycloalkyl group or a 3- to 7-membered cycloalkyl group, wherein said heterocycloalkyl group and cycloalkyl group are each independently optionally substituted with 1 to 3 fluorines, C1-C3 alkyl groups, or C1-C3 fluoroalkyl groups; or R 4c and R 4a together with the atom to which it is attached form a 4- to 7-membered heterocycloalkyl group or a 3- to 7-membered cycloalkyl group, wherein said heterocycloalkyl group and cycloalkyl group are each independently optionally substituted with 1 to 3 fluorines, C1-C3 alkyl groups, or C1-C3 fluoroalkyl groups; R5 is independently hydrogen or a C1-C6 alkyl group, wherein said alkyl group is optionally substituted by F; R8 is, independently at each occurrence, hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, C2-6 alkenyl, C2-6 alkynyl, 5- to 6-membered heteroaryl or aryl, wherein said alkyl, alkenyl, alkynyl, heteroaryl or aryl group optionally contains one, two or three halogens, -NR 11a R 11 b , substituted by a C3-C6 cycloalkyl group, a C3-C6 heterocycloalkyl group containing one or two N heteroatoms, a C1-C3 alkyl group or oxo; R 8’ is hydrogen, deuterium, heavy hydrogen, halogen or cyano group; R 10 is a C1-C6 alkyl group, wherein said alkyl group is optionally substituted by deuterium, F or a cyano group; R 11a and R 11b are each independently hydrogen or a C1-C6 alkyl group, wherein said alkyl group is optionally substituted by OH; n is independently 0 or 1; p is independently 0 or 1, and t is 1, 2, or 3.

[0110] In some embodiments of the present invention, in the PTM69h or PTM-69i, R1 is a C1-C6 alkyl group, optionally substituted with 1 to 3 deuterium, fluorine, chlorine, or C1-C3 alkoxy groups, preferably R1 is a methyl group, ethyl group, propyl group, or isopropyl group, wherein each R1 is optionally substituted with deuterium, fluorine, or methoxy group.

[0111] In some embodiments of the present invention, in the PTM69h or PTM-69i, R 3a and R 3b Each occurrence of is independently hydrogen or a methyl group.

[0112] In some embodiments of the present invention, in said PTM69h or PTM-69i, R4 in each occurrence is independently fluorine, chlorine, hydroxyl, or a C1-C3 alkyl group optionally substituted by 1 to 5 deuterated, fluorine, chlorine, hydroxyl, or C1-C3 alkoxy groups; or two R4 together with the carbon atoms to which they are attached form a cyclopropyl, cyclobutyl, or cyclopentyl group, said cyclopropyl, cyclobutyl, and cyclopentyl groups optionally substituted by 1 to 3 fluorine, chlorine, hydroxyl, methyl, ethyl, propyl, C1-C3 hydroxyalkyl, C1-C3 fluoroalkyl, C1-C3 difluoroalkyl, C1-C3 trifluoroalkyl, methoxy, or ethoxy group, preferably R 4 is independently in each occurrence a fluorine, a hydroxyl group, a methyl group, an ethyl group, or a propyl group, wherein said methyl group, ethyl group, or propyl group is optionally substituted by one, two, or three fluorines, hydroxyl groups, or methoxy groups, or two R 4 together with the carbon atom to which it is attached form a cyclopropyl, cyclobutyl or cyclopentyl group, the cyclopropyl, cyclobutyl and cyclopentyl groups optionally being substituted by one to three fluorine, chlorine, hydroxyl, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, ethyl, propyl, C1-C3 hydroxyalkyl, methoxy or ethoxy groups.

[0113] In some embodiments of the present invention, in the PTM69h or PTM-69i, each R8 is independently hydrogen, deuterium, halogen, or a C1-C6 alkyl group, wherein the alkyl group is optionally substituted with fluorine, and preferably, each R8 is independently hydrogen, deuterium, fluorine, or a methyl group.

[0114] In some embodiments of the present invention, in PTM69h or PTM-69i, each R is independently a C2-6 alkenyl group or a C2-6 alkynyl group, wherein the alkenyl group or alkynyl group is optionally substituted by a C3-C6 cycloalkyl group or a C3-C6 heterocycloalkyl group containing one or two N heteroatoms, and preferably R 8 are each independently a vinyl group, an ethynyl group, optionally substituted with a cyclohexane group, a piperidinyl group, or a piperazinyl group.

[0115] In some embodiments of the present invention, in the PTM-69i, R 4a is hydrogen, deuterium, a methyl group, an ethyl group or a propyl group optionally substituted by fluorine, deuterium or a methoxy group. In some embodiments of the present invention, in the PTM-69i, R 4b is hydrogen or fluorine.

[0116] In some embodiments of the present invention, in the PTM-69i, R 4c is a hydroxyl group. In some embodiments of the present invention, in the PTM-69i, R 4d is a fluorine, a methoxy group or a hydroxyl group, or a methyl group optionally substituted by one, two or three fluorines, or an ethyl group optionally substituted by one, two or three fluorines.

[0117] In some embodiments of the present invention, in the PTM-69i, R 4c and R 4a or R 4c and R 4d together with the carbon atom to which it is attached form a cyclopropyl group optionally substituted with 1 to 3 fluorines, C1-C3 alkyl groups, or C1-C3 fluoroalkyl groups.

[0118] Preferably, in some embodiments of the present invention, the PTM is selected from the following: [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka]

[0119] Preferably, in some embodiments of the present invention, the PTM is [ka] is selected from.

[0120] More preferably, in some embodiments of the invention, the PTM is: [ka] is selected from.

[0121] Preferably, in some embodiments of the present invention, the compound of formula I, and / or a stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug, and / or a pharmaceutically acceptable salt thereof, is a compound of formula IB, and / or a stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug, and / or a pharmaceutically acceptable salt thereof, [ka] Here, X, X', Y, and R 1 , R 4 , R 3a , R 3b , R 8 , n is as defined in PTM-69h, and L, ULM are as defined herein.

[0122] Preferably, in some embodiments of the present invention, the compound of formula I, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, is a compound of formula IB-1, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, [ka] Here, X, X', Y, R1, and R 4a , R 4b , R 4c , R 4d, R 3a , R 3b , R8, n are as defined in PTM-69i, and L, ULM are as defined herein.

[0123] Preferably, in some embodiments of the invention, the PTM has a structure of the following formula: [ka] Here, in the PTM-71, Ring A is a 6- to 10-membered aryl group or a 5- to 10-membered heteroaryl group; R d are each independently hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, C3-C6 cycloalkyl, or 5-10 membered heteroaryl, and the alkyl, cycloalkyl, or heteroaryl group is optionally substituted with one or more groups selected from halogen, hydroxyl, and amino; n is 1, 2, 3 or 4; R e is hydrogen or a C1-C6 alkyl group, R c is hydrogen, deuterium, -O-(C1-C6 alkyl), -O-(C3-C8 cycloalkyl), -O-(3- to 8-membered heterocycloalkyl), -O-aryl group, -O-heteroaryl group, -N(C1-C6 alkyl) 1-2 , -NH(C3-C8 cycloalkyl), -NH(3- to 8-membered heterocycloalkyl), -NH-aryl group, -NH-heteroaryl group, C1-C6 alkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, C3-C8 cycloalkyl group, 3- to 8-membered heterocycloalkyl group, 6- to 10-membered aryl group, 5- to 10-membered heteroaryl group, wherein the alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group, and heteroaryl group are optionally substituted by one or more groups independently selected from hydroxyl group, amino group, halogen, cyano group, and -O-(C1-C6 alkyl); R bis hydrogen, deuterium, -O-(C1-C6 alkyl), -O-(C3-C8 cycloalkyl), -O-(3- to 8-membered heterocycloalkyl), -O-aryl group, -O-heteroaryl group, -N(C1-C6 alkyl) 1-2 , -NH(C3-C8 cycloalkyl), -NH(3- to 8-membered heterocycloalkyl), -NH-aryl group, -NH-heteroaryl group, C1-C6 alkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, C3-C8 cycloalkyl group, 3- to 8-membered heterocycloalkyl group, 6- to 10-membered aryl group, 5- to 10-membered heteroaryl group, wherein the alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group, and heteroaryl group are optionally substituted with one or more groups independently selected from a hydroxyl group, an amino group, a halogen atom, and a cyano group; R a represents hydrogen, deuterium, a 3- to 8-membered heterocycloalkyl group, a C3-C8 cycloalkyl group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group, a C1-C6 alkyl group, [ka] wherein the alkyl group is optionally selected from halogen, hydroxyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, S(O) 1-2 (C1-C6 alkyl), S(O) 1-2 (C3-C6 cycloalkyl), unsubstituted or mono- or polyhalogen-substituted C3-C6 cycloalkyl groups, and monocyclic saturated heterocycloalkyl groups having 4 to 6 ring atoms and containing a heteroatom or heterogroup selected from O, S, SO, and SO2, which are unsubstituted or substituted by mono- or dimethyl groups, and the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted by one or more groups selected from hydroxyl, halogen, amino, cyano, C1-C6 alkyl groups, —O(C1-C6 alkyl), halogenated C1-C6 alkyl groups, hydroxyl C1-C6 alkyl groups, and amino C1-C6 alkyl groups.

[0124] More preferably, in some embodiments of the invention, the PTM has a structure of the following formula: [ka] Here, in the PTM-71, Ring A is a phenyl group or a pyridyl group; R d are each independently hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, or C3-C6 cycloalkyl, and the alkyl and cycloalkyl groups are optionally substituted with one or more groups selected from halogen, hydroxyl, and amino; n is 1 or 2, R e is hydrogen, R c represents hydrogen, deuterium, -O(C1-C6 alkyl), -N(C1-C6 alkyl) 1-2 , a C1-C6 alkyl group, -O(C3-C6 cycloalkyl), -N(C3-C6 cycloalkyl), -O(3- to 6-membered heterocycloalkyl), -N(3- to 6-membered heterocycloalkyl), wherein the alkyl group, cycloalkyl group, or heterocycloalkyl group is optionally substituted with one or more groups independently selected from a hydroxyl group, an amino group, a halogen atom, a cyano group, or -O-(C1-C6 alkyl); R b is hydrogen or a C1-C6 alkyl group, said alkyl group being optionally substituted with one or more groups independently selected from a hydroxyl group, an amino group, a halogen, and a cyano group; R a represents hydrogen, deuterium, a 3- to 8-membered heterocycloalkyl group, a C3-C8 cycloalkyl group, a C1-C6 alkyl group, [ka] wherein the alkyl group is optionally selected from halogen, hydroxyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, S(O) 1-2(C1-C6 alkyl), S(O) 1-2 (C3-C6 cycloalkyl), unsubstituted or mono- or polyhalogen-substituted C3-C6 cycloalkyl groups, and monocyclic saturated heterocycloalkyl groups having 4 to 6 ring atoms and containing a heteroatom or heterogroup selected from O, S, SO, and SO2, which are unsubstituted or substituted by mono- or dimethyl groups, and the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally substituted by one or more groups selected from hydroxyl, halogen, amino, cyano, C1-C6 alkyl groups, —O(C1-C6 alkyl), halogenated C1-C6 alkyl groups, hydroxyl C1-C6 alkyl groups, and amino C1-C6 alkyl groups.

[0125] In some embodiments of the present invention, in PTM-71, ring A is a pyridyl group. In some embodiments of the present invention, in the PTM-71, R d are each independently hydrogen, deuterium, halogen, or a C1-C6 alkyl group, said alkyl group being optionally substituted with one or more groups selected from halogen or hydroxyl groups, preferably R d is hydrogen, deuterium, F, methyl, difluoromethyl, trifluoromethyl, or 2-hydroxypropyl.

[0126] In some embodiments of the present invention, in the PTM-71, R e is hydrogen. In some embodiments of the present invention, in the PTM-71, R c is a C1-C6 alkyl group, said alkyl group being optionally substituted with one or more groups independently selected from hydroxyl group, halogen, preferably R c is a difluoromethyl group or a 2-hydroxypropyl group.

[0127] In some embodiments of the present invention, in the PTM-71, R c is —O(C1-C6 alkyl), wherein the alkyl group is optionally substituted with one or more groups independently selected from hydroxyl groups, halogens, or —OCH3, and preferably R c is a methoxy group, an ethoxy group, an isopropoxy group, —OCH2CH2OCH3, a difluoromethoxy group, or a trifluoromethoxy group.

[0128] In some embodiments of the present invention, in the PTM-71, R c is —O— (a 3- to 6-membered heterocycloalkyl group containing one or two heteroatoms selected from N or O), and preferably [ka] is.

[0129] In some embodiments of the present invention, in the PTM-71, R b is hydrogen or a methyl group. In some embodiments of the present invention, in the PTM-71, R a is hydrogen.

[0130] In some embodiments of the present invention, in the PTM-71, R a is a 3-8 membered heterocycloalkyl group containing one or two heteroatoms selected from N, O or S, and the heterocycloalkyl group is optionally substituted by one or more groups selected from hydroxyl, halogen, amino, cyano, C1-C6 alkyl group, —O(C1-C6 alkyl), halogenated C1-C6 alkyl group, hydroxyl C1-C6 alkyl group, amino C1-C6 alkyl group, preferably R ais a 3-8 membered heterocycloalkyl group containing one or two heteroatoms selected from N or O, and the heterocycloalkyl group is optionally substituted by one or more groups selected from a hydroxyl group, a halogen group, an amino group, a cyano group, a C1-C6 alkyl group, —O(C1-C6 alkyl), a halogenated C1-C6 alkyl group, a hydroxyl C1-C6 alkyl group, and an amino C1-C6 alkyl group, more preferably R a is a piperidinyl group or a piperazinyl group, the piperidinyl group and the piperazinyl group being optionally substituted by one or more groups selected from a hydroxyl group, a halogen, an amino group, a cyano group, a C1-C6 alkyl group, —O(C1-C6 alkyl), a halogenated C1-C6 alkyl group, a hydroxyl C1-C6 alkyl group, and an amino C1-C6 alkyl group, and most preferably a piperidinyl group, the piperidinyl group being optionally substituted by one or more groups selected from a hydroxyl group, an amino group, a methyl group, a methoxy group, a hydroxymethyl group, and a trifluoromethyl group.

[0131] In some embodiments of the present invention, in the PTM-71, R a is cyclohexane, optionally substituted with one or more groups selected from hydroxyl, halogen, amino, cyano, C-C alkyl, —O(C-C alkyl), halogenated C-C alkyl, hydroxyl C-C alkyl, amino C-C alkyl, preferably optionally substituted with one or more groups selected from hydroxyl, amino, methyl, methoxy, hydroxymethyl, trifluoromethyl.

[0132] In some embodiments of the present invention, in the PTM-71, R ais hydrogen or a C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally one or more alkyl groups selected from F, a hydroxyl group, a methoxy group, a fluoromethoxy group, —S(O)2CH3, —S(O)2-cyclopropyl group, a cyclopropyl group, and an oxetanyl group.

[0133] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] Here, the R a , R b , R c , R d , R e is as defined in PTM-71 above.

[0134] In some embodiments of the invention, the PTM has a structure of the following formula: [ka] Here, the R a , R b , R c , R d , R e , n is as defined above in PTM-71.

[0135] Preferably, in some embodiments of the invention, the PTM has a structure of the following formula: [ka] Here, the R b , R c , R d , R e is as defined in PTM-71 above.

[0136] Preferably, in some embodiments of the invention, the PTM has a structure of the following formula: [ka] Here, the R b , R c , R d , R e is as defined in PTM-71 above.

[0137] Preferably, in some embodiments of the invention, the PTM has a structure of the following formula: [ka] Here, the R b , R c , R d , R e is as defined in PTM-71 above.

[0138] Preferably, in some embodiments of the invention, the PTM has a structure of the following formula: [ka] Here, the R b , R c , R d , R e is as defined in PTM-71 above.

[0139] Preferably, in some embodiments of the present invention, the PTM is [ka] [ka] [ka] is selected from.

[0140] More preferably, in some embodiments of the invention, the PTM is: [ka] is selected from.

[0141] Preferably, in some embodiments of the present invention, the PTM is [ka] is selected from.

[0142] Preferably, in some embodiments of the present invention, the compound of formula I, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, is a compound of formula IC, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, [ka] wherein the rings A and R a , R b , R c , R d , R e , n is as defined in PTM-71, and L, ULM are as defined herein.

[0143] Preferably, in some embodiments of the present invention, the compound of formula I, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, is a compound of formula IC-1, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, [ka] Here, the R a , R b , R c , R d , R e is as defined in PTM-71, and the L, ULM are as defined herein. Preferably, in some embodiments of the present invention, the compound of formula I, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, is a compound of formula IC-2, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, [ka] Here, the R b , R c , R d , R e is as defined in PTM-71, and the L, ULM are as defined herein. Preferably, in some embodiments of the present invention, the compound of formula I, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, is a compound of formula IC-3, and / or its stereoisomer, enantiomer, diastereomer, deuterated form, metabolite, hydrate, solvate, prodrug and / or pharmaceutically acceptable salt thereof, [ka] Here, the R b , R c , R d , R e is as defined in PTM-71, and the L, ULM are as defined herein.

[0144] In some embodiments of the present invention, L is a bond. In some embodiments of the present invention, L is -(CH2) j- and the -(CH2) j- One or more methylene groups in the 3 '-, -O-, -S-, -S(O)-, -S(O)NR 3 '-, -NR3 'S(O)-, -S(O)2-, -S(O)2NR 3 '-, -NR 3 'S(O)2-, -NR 4 'S(O)2NR 3 '-,-CR 1 'R 2 '-, -C(O)-, -C(O)O-, -OC(O)-, -NR 3 'C(O)O-, -OC(O)NR 3 '-, -C(O)NR 3 '-, -NR 3 'C(O)-, -NR 4 'C(O)NR 3 '-, -P(O)-, -P(O)O-, -OP(O)-, -OP(O)O-, a vinylidene group, an ethynylene group, a C3-C12 cycloalkylene group, a 3- to 12-membered heterocycloalkylene group containing one or more heteroatoms selected from N, O, and S, a 6- to 10-membered arylene group, or a 5- to 10-membered heteroarylene group, wherein the vinylidene group, cycloalkylene group, heterocycloalkylene group, arylene group, and heteroarylene group each independently optionally include a halogen, -OR 3 ', -NR 3 'R 4 ', oxo, nitro group, cyano group, C1-C6 alkyl group, -S(C1-C6 alkyl), C3-C10 cycloalkyl group, 3-10 membered heterocycloalkyl group, 6-10 membered aryl group, 5-10 membered heteroaryl group, -C(O)R 1 ', -C(O)OR 3 ', -OC(O)R 1 ', -C(O)NR 3 ', -NR 3 'C(O)R 1 ', -S(O)R 1 ', -S(O)NR 3 ', -S(O)2R 1 ', -S(O)2NR 3 ', -NR 3 'S(O)2R 1 ', -NR 4 'S(O)2NR 3 ', -OC(O)NR 3 ', -NR4 'C(O)NR 3 ', wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl groups are each independently optionally substituted with one or more substituents selected from halogen, -OH, -NR 3 'R 4 ', oxo, nitro, cyano, C1-C6 alkyl, C3-C10 cycloalkyl, 3- to 10-membered heterocycloalkyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; 1 ', R 2 ' are each independently a halogen, -OH, or -NR 3 'R 4 ', a C1-C6 alkyl group, a chloro C1-C6 alkyl group, a hydroxyl C1-C6 alkyl group, -O(C1-C6 alkyl), -NH(C1-C6 alkyl), -NH(C1-C6 alkyl)2, a C3-C10 cycloalkyl group, -O(C3-C10 cycloalkyl), -NH(C3-C10 cycloalkyl), a 3-10 membered heterocycloalkyl group, -O(3-10 membered heterocycloalkyl), -NH(3-10 membered heterocycloalkyl), a 6-10 membered aryl group, -O(6-10 membered aryl), -NH(6-10 membered aryl), a 5-10 membered heteroaryl group, -O(5-10 membered heteroaryl), -NH(5-10 membered heteroaryl); and R 3 ', R 4 Each ' is independently hydrogen, deuterium, a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a 3- to 10-membered heterocycloalkyl group, a 6- to 10-membered aryl group, or a 5- to 10-membered heteroaryl group; and j is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.

[0145] Preferably, in some embodiments of the present invention, L is -(CH) j- and the -(CH2) j- One or more methylene groups in the 3 '-, -O-, -CR1 'R 2 '-, -C(O)-, -S(O)-, -S(O)2-, -C(O)O-, -OC(O)-, -C(O)NR 3 '-, -NR 3 'C(O)-, -S(O)2NR 3 '-, -NR 3 'S(O)2-, vinylidene group, ethynylene group, phenyl group, 8- to 10-membered bicyclic arylene group, 3- to 7-membered saturated or partially unsaturated cycloalkylene group, 4- to 11-membered saturated or partially unsaturated spirocycloalkylene group, 4- to 11-membered saturated or partially unsaturated fused cycloalkylidene group, 8- to 10-membered bicyclic saturated or partially unsaturated cycloalkylene group, 4- to 7-membered saturated or partially unsaturated heterocycloalkylene group having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur, 4- to 11-membered saturated or partially unsaturated spiroheterocycloalkylene group having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur, 4- to 11-membered saturated or partially unsaturated fused heterocycloalkylidene group having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur. a 8- to 10-membered bicyclic saturated or partially unsaturated heterocycloalkylene group having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; a 5- to 6-membered heteroarylene group having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8- to 10-membered bicyclic heteroaryl group having 1 to 5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and the vinylidene group, ethynylene group, cycloalkylene group, heterocycloalkylene group, phenyl group, spiroheterocycloalkylene group, fused heterocycloalkylene group, spirocycloalkylene group, fused cycloalkylidene group, and heteroarylene group each independently optionally contain one or more of halogen, oxo, -NR 3 'R 4 ', -OR 3', a nitro group, -CN, a C1-C6 alkyl group, a C3-C10 cycloalkyl group, and a 3- to 10-membered heterocycloalkyl group, wherein the alkyl group, cycloalkyl group, and heterocycloalkyl group are optionally substituted by one or more substituents selected from a halogen, -OH, -NH2, -CN, a C1-C4 alkyl group, and a C3-C6 cycloalkyl group; R 1 ', R 2 Each ' is independently a halogen, -OH, -NH, a C1-C4 alkyl group, a C1-C4 chloroalkyl group, a C1-C4 hydroxyalkyl group, -O(C1-C4 alkyl), -NH(C1-C4 alkyl), -NH(C1-C4 alkyl), a C3-C6 cycloalkyl group, -O(C3-C6 cycloalkyl), -NH(C3-C6 cycloalkyl), a 3- to 6-membered heterocycloalkyl group, -O(3- to 6-membered heterocycloalkyl), or -NH(C3-C6 cycloalkyl); R 3 ', R 4 Each ' is independently hydrogen, deuterium, a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or a 3- to 6-membered heterocycloalkyl group; and j is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12.

[0146] Preferably, in some embodiments of the present invention, L is -(CH) j- and the -(CH2) j- One or more methylene groups in the 3 '-, -O-, -CR 1 'R 2 '-, -C(O)-, -S(O)-, -S(O)2-, -C(O)O-, -OC(O)-, -C(O)NR 3 '-, -NR 3 'C(O)-, -S(O)2NR 3 '-, -NR 3'S(O)2-, vinylidene group, ethynylene group, phenyl group, 8- to 10-membered bicyclic arylene group, 3- to 7-membered saturated or partially unsaturated monocyclic cycloalkylene group, 4- to 11-membered saturated or partially unsaturated spirocycloalkylene group, 4- to 11-membered saturated or partially unsaturated fused cycloalkylidene group, 8- to 10-membered bicyclic saturated or partially unsaturated cycloalkylene group, 4- to 7-membered saturated or partially unsaturated heterocycloalkylene group having 1 to 2 heteroatoms independently selected from nitrogen or oxygen, 4- to 11-membered saturated or partially unsaturated spiroheterocycloalkylene group having 1 to 2 heteroatoms independently selected from nitrogen or oxygen, 4- to 11-membered saturated or partially unsaturated fused heterocycloalkylidene group having 1 to 2 het...

Claims

1. A compound of formula I, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate, or pharma- ceutically acceptable salt thereof, Formula I: PTM-L-ULM Where: L is a linker chain that connects the PTM and the ULM by a covalent bond, and the ULM has the structure of the following formula: 【Chemistry 1】 Here, in the ULM-1e and ULM-1ee, Q 1 , Q 2 , Q 3 , and Q 5 are each independently 3 '' or N, R 3 Each of "" independently represents hydrogen, deuterium, a hydroxyl group, an amino group, a cyano group, a halogen, a C1-C6 alkyl group, a C3-C8 cycloalkyl group, a 3- to 8-membered heterocycloalkyl group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group, -O(C1-C6 alkyl), -O-(C3-C8 cycloalkyl), -O-(3- to 8-membered heterocycloalkyl), -N(C1-C6 alkyl). 2 , -NH(C3-C8 cycloalkyl), -NH(3-8 membered heterocycloalkyl), -O-(6-10 membered aryl), or -O-(5-10 membered heteroaryl), wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally substituted with 1-3 groups independently selected from hydroxyl, halogen, cyano, and amino groups; m″ is 1, 2 or 3; R 1 each independently represents hydrogen, deuterium, hydroxyl, amino, cyano, halogen, C1-C6 alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, or -O(C1-C6 alkyl), wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally substituted with 1 to 3 groups independently selected from hydroxyl, halogen, cyano, and amino; R 2 '' is none, hydrogen, deuterium, a C1-C6 alkyl group, or a C3-C6 cycloalkyl group, wherein said C1-C6 alkyl group and C3-C6 cycloalkyl group are optionally substituted with 1 to 3 groups independently selected from a hydroxyl group, a halogen, or -O-(C=O)-(C1-C6 alkyl); The PTM is 【Chemistry 2】 and Here, in the PTM-71', Ring A is a 6- to 10-membered aryl group or a 5- to 10-membered heteroaryl group; R d are each independently hydrogen, deuterium, halogen, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, said alkyl group, cycloalkyl group being optionally substituted with one or more groups selected from a halogen or a hydroxyl group; n is 1, 2, 3 or 4; R e is hydrogen or a C1-C6 alkyl group, R c is hydrogen, deuterium, -O-(C1-C6 alkyl), -O-(C3-C8 cycloalkyl), -O-(3- to 8-membered heterocycloalkyl), a C1-C6 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C3-C8 cycloalkyl group, a 3- to 8-membered heterocycloalkyl group, said alkyl group, cycloalkyl group, heterocycloalkyl group being optionally substituted by one or more groups independently selected from hydroxyl groups, amino groups, halogens, or -O-(C1-C6 alkyl); R b is hydrogen, deuterium, —O—(C1-C6 alkyl), or a C1-C6 alkyl group, said alkyl group being optionally substituted by one or more groups independently selected from a hydroxyl group, or a halogen; R a is none, a 3- to 8-membered heterocycloalkylene group, or a C3-C8 cycloalkylene group; The L is -(CH 2 ) j -, and the -(CH 2 ) j One or more methylene groups in - are optionally represented by -NR 3 '-, -O-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NR 3 'C(O)O-, -OC(O)NR 3 '-, -C(O)NR 3 '-, -NR 3 'C(O)-, -NR 4 'C(O)NR 3 '-, a C3-C12 cycloalkylene group, or a 3- to 12-membered heterocycloalkylene group containing one or more heteroatoms selected from N, O or S; The R 3 ', R 4 each ' is independently hydrogen, deuterium, or a C1-C6 alkyl group; The j is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15; A compound of formula I above, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

2. Q in ULM-1e and ULM-1ee 1 , Q 2 , Q 3 , and Q 5 are each independently 3 '' 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

3. R in ULM-1e and ULM-1ee 1 Each " is independently hydrogen, deuterium, -F, -Cl, or a C1-C6 alkyl group, said alkyl group being optionally substituted with 1 to 3 halogens, preferably R 1 '' is hydrogen; 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

4. R in ULM-1e and ULM-1ee 2 '' is hydrogen or a C1-C6 alkyl group, said alkyl group being optionally substituted with 1 to 3 halogens, preferably R 2 '' is hydrogen; 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

5. R in ULM-1e and ULM-1ee 3 Each independently is hydrogen, deuterium, halogen, —O(C1-C6 alkyl), or a C1-C6 alkyl group, said alkyl group being optionally substituted with 1 to 3 halogens, preferably R 3 " are each independently hydrogen, deuterium, F, Cl, a methyl group, a methoxy group, an ethoxy group, a trifluoromethoxy group, a 2-hydroxyprop-2yl group, or a trifluoromethyl group; 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

6. The ULM is 【Chemistry 3】 is selected from the group consisting of R 1 '', R 2 '', R 3 , m'' are as defined in claim 1, 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

7. The ULM is 【Chemistry 4】 is selected from the group consisting of R 1 '', R 2 '', R 3 '' and m'' are as defined in claim 1, 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

8. The ULM is 【Chemistry 5】 Characterized in that it is selected from 7. A compound of formula I according to claim 6, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

9. The ULM is 【Chemistry 6】 Characterized in that it is selected from 8. A compound of formula I according to claim 7, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

10. The PTM is 【Chemistry 7】 and Here, in the PTM-71', Ring A is a phenyl group or a pyridyl group; R d are each independently hydrogen, deuterium, halogen, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, said alkyl group, cycloalkyl group being optionally substituted with one or more groups selected from a halogen or a hydroxyl group; n is 1 or 2; R e is hydrogen, R c is hydrogen, deuterium, -O(C1-C6 alkyl), C1-C6 alkyl group, -O(C3-C6 cycloalkyl), -O(3- to 6-membered heterocycloalkyl), wherein said alkyl, cycloalkyl, heterocycloalkyl group is optionally substituted with one or more groups independently selected from hydroxyl, amino, halogen, or -O-(C1-C6 alkyl); R b is hydrogen or a C1-C6 alkyl group, said alkyl group being optionally substituted by one or more groups independently selected from a hydroxyl group, or a halogen; R a is none, a 3- to 8-membered heterocycloalkylene group, or a C3-C8 cycloalkylene group; 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

11. R in the PTM-71′ d are each independently hydrogen, deuterium, halogen, or a C1-C6 alkyl group, the alkyl group being optionally substituted with one or more groups selected from halogen or hydroxyl groups, preferably R d is hydrogen, deuterium, F, a methyl group, a difluoromethyl group, a trifluoromethyl group, or a 2-hydroxypropyl group; 11. A compound of formula I according to claim 10, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

12. R in the PTM-71′ c is a C1-C6 alkyl group, the alkyl group being optionally substituted with one or more groups independently selected from a hydroxyl group, a halogen, and preferably R c is a difluoromethyl group or a 2-hydroxypropyl group; 11. A compound of formula I according to claim 10, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

13. R in the PTM-71′ c is a C1-C6 alkyl group, the alkyl group being substituted by a hydroxyl group; 13. A compound of formula I according to claim 12, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

14. R in the PTM-71′ c is —O(C1-C6 alkyl), wherein the alkyl group is optionally independently a hydroxyl group, a halogen, or —OCH 3 and preferably, R c is a methoxy group, an ethoxy group, an isopropoxy group, -OCH 2 CH 2 OCH 3 , a difluoromethoxy group or a trifluoromethoxy group, 11. A compound of formula I according to claim 10, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

15. R in the PTM-71′ c is -O- (a 3- to 6-membered heterocycloalkyl group containing one or two heteroatoms selected from N or O), preferably 【Chemistry 8】 Characterized in that 11. A compound of formula I according to claim 10, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

16. R in the PTM-71′ b is hydrogen or a methyl group; 11. A compound of formula I according to claim 10, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

17. R in the PTM-71′ a is a piperidinediyl group or a piperazinylene group.

11. A compound of formula I according to claim 10, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

18. R in the PTM-71′ a is cyclohexylene 11. A compound of formula I according to claim 10, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

19. The PTM is 【Chemistry 9】 Characterized in that 11. A compound of formula I according to claim 10, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

20. The L is -(CH 2 ) j -, and the -(CH 2 ) j One, two, three or four methylene groups in - are optionally -NH-, -NCH 3 --, --NCH 2 CH 3 -, -O-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)NH-, -C(O)NCH 3 -, -NHC(O)-, -NCH 3 C(O)-, a cyclopropylene group, a cyclobutylene group, a cyclopentylene group, a cyclohexylene group, an oxiranylene group, an oxetanylene group, an oxolane group, an oxane group, an azidopropyl group, a nitridene group, a nitrosyl group, a piperidinylene group, a piperazinylene group, a morpholinylene group, a homomorpholinylene group, 【Chemistry 10】 and j is 2, 3, 4, 5, 6, 7 or 8; 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

21. The L is -(CH 2 ) j -, and the -(CH 2 ) j One, two or three methylene groups in - are optionally -O-, -NH-, -NCH 3 --, --NCH 2 CH 3 -, -C(O)-, -C(O)NH-, -NHC(O)-, -NCH 3 C(O)-, -C(O)NCH 3 -, azidopropyl group, nitridene group, nitrosyl group, piperidinylene group, piperazinylene group, 【Chemistry 11】 and j is 2, 3, 4, 5, 6, 7, or 8; 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

22. The L is -(CH 2 ) j-1-C(O)-, wherein the -(CH 2 ) The methylene group in j-1-C(O)- is optionally represented by -NR 3 '-, -O-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NR 3 'C(O)O-, -OC(O)NR 3 '-, -C(O)NR 3 '-, -NR 3 'C(O)-, -NR 4 'C(O)NR 3 '-, a C3-C12 cycloalkylene group, a 3- to 12-membered heterocycloalkylene group containing one or more heteroatoms selected from N, O or S; The R 3 ', R 4 each ' is independently hydrogen, deuterium, or a C1-C6 alkyl group; The j is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15; 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

23. The L is LA, 【Chemistry 12】 Here, in the LA, Ring D is a 3-12 membered heterocycloalkylene group containing none or 1-2 heteroatoms selected from N, O or S heteroatoms; Ring B is absent or is a 3- to 12-membered heterocycloalkylene group containing 1 to 2 heteroatoms selected from N, O, or S; Ring C is absent or is a 3- to 12-membered heterocycloalkylene group containing 1 to 2 heteroatoms selected from N, O, or S; X'''' is -C(O)-, -NHC(O)- or -NCH 3 C(O)—, L 3 is -(CH 2 ) k, and said L 3 wherein one or two methylene groups are optionally replaced by a substituent selected from -O-, -NH-, or -N(C1-C6 alkyl)-; and k is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

24. The L is LA, 【Chemistry 13】 Here, in the LA, Ring D and ring B are absent, ring C is a 4- to 7-membered saturated monocyclic heterocycloalkylene group containing one or two nitrogen heteroatoms, or a 7- to 11-membered spiroheterocycloalkylene group containing one or two nitrogen heteroatoms, X″″ is —C(O)—, L 3 is -(CH 2 ) k, and said L 3 One methylene group is optionally -O-, -NH-, -NCH 3 -or-NCH 2 CH 3 -, wherein k is 2, 3 or 4; 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

25. The L is 【Chemistry 14】 Characterized in that 2. A compound of formula I according to claim 1, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof.

26. The compound is 【Chemistry 15】 【Chemistry 16】 【Chemistry 17】 【Chemistry 18】 【Chemistry 19】 【Chemistry 20】 【Chemistry 21】 【Chemical 22】 Characterized in that The compound, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate, or a pharma- ceutically acceptable salt thereof.

27. 1. A pharmaceutical composition comprising:

27. A pharmaceutical composition comprising a compound according to any one of claims 1 to 26, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable carrier, diluent or excipient.

28. 27. Use of a compound according to any one of claims 1 to 26, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof, in the preparation of a medicament for the treatment and / or prevention of an IRAK4 mediated disease or condition, or a TLR (excluding TLR3R), IL-1α or IL-1β receptor family mediated disease or condition.

29. 27. Use of a compound according to any one of claims 1 to 26, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharma- ceutically acceptable salt thereof, in the preparation of a medicament for the treatment and / or prevention of cancer, a neurodegenerative disease, a viral disease, an autoimmune disease, an inflammatory disease, a genetic disease, a hormone-related disease, a metabolic disease, an organ transplant-related disease, an immunodeficiency disease, a bone destructive disease, a proliferative disease, an infectious disease, a disease associated with cell death, blood platelet aggregation by thrombin, a liver disease, a pathological immune condition involving activation of T cells, a cardiovascular disease or a CNS disease.

30. Brain cancer, kidney cancer, liver cancer, adrenal gland cancer, bladder cancer, breast cancer, stomach cancer, ovarian cancer, colon cancer, rectal cancer, prostate cancer, pancreatic cancer, lung cancer, vaginal cancer, cervical cancer, testicular cancer, genitourinary cancer, esophageal cancer, throat cancer, skin cancer, bone cancer, thyroid cancer, sarcoma, glioblastoma, neuroblastoma, multiple myeloma, gastrointestinal cancer, neck or head tumors, epidermal hyperplasia, psoriasis, benign prostatic hyperplasia, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small cell lung cancer, lymphoma, Hodgkin and non-Hodgkin, breast cancer, follicular carcinoma, undifferentiated tumor, papillary tumor, seminoma, melanoma, ABC DLBCL, Hodgkin's lymphoma, primary cutaneous T-cell lymphoma, chronic lymphocytic leukemia, smoldering indolent multiple myeloma, leukemia, diffuse large B-cell lymphoma DLBCL, chronic lymphocytic leukemia CLL, chronic lymphocytic lymphoma, primary pleural effusion lymphoma, Burkitt lymphoma / leukemia, acute lymphoblastic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia macroglobulinemia, WM), splenic marginal zone lymphoma, multiple myeloma, or plasmacytoma or intravascular large B-cell lymphoma, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, neurodegenerative diseases due to cerebral ischemia or trauma, glutamate neurotoxicity, hypoxia, epilepsy, diabetes treatment, metabolic syndrome, obesity, organ transplantation or graft versus host disease, eye diseases such as ocular allergy, conjunctivitis, dry eye or vernal conjunctivitis, diseases affecting the nose including, for example, allergic rhinitis, for example, hemolytic anemia, aplastic anemia, pure red cell anemia and idiopathic hemoplegia, Autoimmune blood diseases such as thrombocytopenia, systemic lupus erythematosus, rheumatoid arthritis, polychondritis, scleroderma, dermatomyositis, polymyositis, chronic active hepatitis, myasthenia gravis, Stevens-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease, easy bowel syndrome, celiac disease, periodontitis, hyaline membrane disease, kidney disease, glomerular disease, alcoholic liver disease, multiple sclerosis, endocrine eye disease, Grave's diseasedisease), sarcoidosis, dry eye, vernal conjunctival keratitis, interstitial pulmonary fibrosis, psoriatic arthritis, systemic juvenile idiopathic arthritis, nephritis, vasculitis, interstitial cystitis, diverticulitis, glomerulonephritis, chronic granulomatous disease, endometriosis, leptospirosis nephropathy, glaucoma, retinal disease, aging, headache, pain, complex regional pain syndrome, cardiac hypertrophy, muscle atrophy, catabolism, obesity, fetal growth retardation, hypercholesterolemia, heart disease, chronic heart failure, mesothelioma, anhidrotic ectodermal dysplasia, Behcet's disease, incontinence of pigment, Paget's disease disease), pancreatitis, hereditary periodic fever syndromes, asthma, acute lung injury, acute respiratory distress syndrome, eosinophilia, allergic reactions, anaphylaxis, sinusitis, eye allergies, silica-induced disease, COPD, lung disease, cystic fibrosis, acid-induced lung injury, pulmonary hypertension, polyneuropathy, cataracts, inflammation of the muscles associated with systemic sclerosis, including inclusion body myositis, myasthenia gravis, thyroiditis, Addison's disease disease), lichen planus, type 1 diabetes, type 2 diabetes, appendicitis, atopic dermatitis, asthma, allergy, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, chronic transplant rejection, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatitis, dermatomyositis, polymyositis, encephalitis, endocarditis, endometritis, enteritis, enteritis, epicondylitis, epididymitis, fasciitis, fibromyositis, gastritis, gastroenteritis, Henoch-Schönlein purpurapurpura), hepatitis, hidradenitis suppurativa, immunoglobulin A nephropathy, interstitial lung disease, laryngitis, mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, hepatic fibrosis, renal fibrosis, alcoholic fatty liver, nonalcoholic fatty liver, cardiac fibrosis, psoriasis, Crohn's disease, inflammatory bowel disease, oophoritis, orchitis, osteitis, otitis media, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, localized pneumonia, pneumonia, polymyositis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, ulcerative colitis, uveitis, vaginitis, vasculitis, vulvitis, alopecia areata 27. Use of a compound according to any one of claims 1 to 26, or a stereoisomer, enantiomer, diastereomer, deuterated form, hydrate, solvate or a pharmacologic agent thereof, in the preparation of a medicament for the treatment and / or prevention of erythema multiforme, dermatitis herpetiformis, sclerosis, vitiligo, hypersensitivity vasculitis, urticaria, bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, epidermolysis bullosa acquisita, acute and chronic gout, chronic gouty arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, latent fever associated peripheral syndrome or osteoarthritis.

Citation Information

Patent Citations

  • Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides

    US20200129627A1

  • Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides

    WO2019099926A1

  • IRAK degraders and uses thereof

    WO2019133531A1